

CITATION REPORT

List of articles citing

The epigenomics of cancer

DOI: 10.1016/j.cell.2007.01.029
Cell, 2007, 128, 683-92.

Source: <https://exaly.com/paper-pdf/42031570/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2291	Inhibition of histone deacetylases. 2004 , 287, 87-97		4
2290	Major and essential role for the DNA methylation mark in mouse embryogenesis and stable association of DNMT1 with newly replicated regions. 2007 , 27, 8243-58		57
2289	Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. 2007 , 104, 8023-8		252
2288	Mammalian ASH1L is a histone methyltransferase that occupies the transcribed region of active genes. 2007 , 27, 8466-79		151
2287	Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. 2007 , 6, 2010-8		93
2286	Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. 2007 , 7, 1439-49		35
2285	CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. 2007 , 3, 1757-69		34
2284	Cancer immunomics and application of 'omics' for cancer management. 2007 , 3, 807-12		
2283	Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. 2007 , 13, 6834-41		43
2282	Modifying the epigenome as a therapeutic strategy in myelodysplasia. 2007 , 2007, 405-11		18
2281	Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation?. 2007 , 6, 1040-3		92
2280	Phosphorylation of serine-515 activates the Mammalian maintenance methyltransferase Dnmt1. 2007 , 2, 155-60		32
2279	Circadian clock and breast cancer: a molecular link. 2007 , 6, 1329-31		84
2278	Emerging therapies for malignant glioma. 2007 , 7, S29-36		13
2277	Methylation of human microRNA genes in normal and neoplastic cells. 2007 , 6, 1001-5		229
2276	CpG islands: their potential as biomarkers for cancer. 2007 , 7, 519-31		50
2275	Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. 2007 , 21, 3110-22		221

2274	Epigenetics--a science of heritable biological adaptation. 2007 , 61, 1R-4R	36
2273	Genome-epigenome interactions in cancer. 2007 , 16 Spec No 1, R96-105	50
2272	Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. 2007 , 13, 7237-42	90
2271	RNA sequence analysis defines Dicer's role in mouse embryonic stem cells. 2007 , 104, 18097-102	261
2270	MethyCancer: the database of human DNA methylation and cancer. 2008 , 36, D836-41	102
2269	The role of circadian regulation in cancer. 2007 , 72, 459-64	55
2268	ATM phosphorylates ZBP-89 at Ser202 to potentiate p21waf1 induction by butyrate. 2007 , 359, 817-21	19
2267	PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. 2007 , 25, 801-12	387
2266	Chromatin remodeling and cancer, Part I: Covalent histone modifications. 2007 , 13, 363-72	324
2265	Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. 2007 , 13, 373-80	178
2264	A role for epigenetics in hearing: Establishment and maintenance of auditory specific gene expression patterns. 2007 , 233, 1-13	33
2263	A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. 2007 , 581, 5904-10	42
2262	CpG Islands and DNA Methylation. 2007 ,	2
2261	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. 2007 , 104, 15805-10	1385
2260	Identification of methylation-associated gene expression in neuroendocrine pancreatic tumor cells. 2007 , 7, 352-9	10
2259	Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective. 2007 , 25, 2498-510	164
2258	Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. 2007 , 46, 8058-65	183
2257	Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. 2007 , 117, 2713-22	300

2256	Metastasis as a faulty recapitulation of ontogeny. 2007,	
2255	Epigenetic "bivalently marked" process of cancer stem cell-driven tumorigenesis. 2007, 29, 842-5	37
2254	Fluorous-based small-molecule microarrays for the discovery of histone deacetylase inhibitors. 2007, 46, 7960-4	80
2253	Fluorous-Based Small-Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors. 2007, 119, 8106-8110	12
2252	DNA methylation: the nuts and bolts of repression. 2007, 213, 384-90	504
2251	Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. 2007, 17, 6142-6	15
2250	Origin of diplochromosomal polyploidy in near-senescent fibroblast cultures: heterochromatin, telomeres and chromosomal instability (CIN). 2007, 31, 1447-55	16
2249	Sirtuins: critical regulators at the crossroads between cancer and aging. 2007, 26, 5489-504	503
2248	The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers. 2007, 13, 1060-9	105
2247	Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. 2007, 2, 1931-6	61
2246	DNA methylation analysis by pyrosequencing. 2007, 2, 2265-75	522
2245	Chromatin-modifying proteins in cancer. 2007, 115, 1060-89	29
2244	The Ras-association domain family (RASSF) members and their role in human tumourigenesis. 2007, 1776, 58-85	149
2243	Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 2007, 12, 457-66	334
2242	Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. 2007, 12, 432-44	168
2241	Genomic patterns of DNA methylation: targets and function of an epigenetic mark. 2007, 19, 273-80	291
2240	A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation. 2007, 24, 20-30	62
2239	Dietary histone deacetylase inhibitors: from cells to mice to man. 2007, 17, 363-9	229

2238	Epigenetic stability of embryonic stem cells and developmental potential. 2007 , 25, 556-62	35
2237	New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. 2007 , 24, 707-15	52
2236	Subclassification of microsatellite-unstable tumors in colorectal cancer. 2007 , 3, 212-219	2
2235	Effects of long-term low-dose cadmium exposure on genomic DNA methylation in human embryo lung fibroblast cells. 2008 , 244, 49-55	184
2234	Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development. 2008 , 27, 315-34	82
2233	Current status of epigenetic treatment in myelodysplastic syndromes. 2008 , 87, 601-11	82
2232	[Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer]. 2008 , 29 Suppl 2, 319-27	5
2231	Rapid analysis of heterogeneously methylated DNA using digital methylation-sensitive high resolution melting: application to the CDKN2B (p15) gene. 2008 , 1, 7	60
2230	Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. 2008 , 1, 8	27
2229	Genome wide transcriptional profiling in breast cancer cells reveals distinct changes in hormone receptor target genes and chromatin modifying enzymes after proteasome inhibition. 2008 , 47, 845-85	26
2228	Chemical biology approaches to probe the proteome. 2008 , 9, 2913-9	11
2227	Synthesis of benzamides related to anacardic acid and their histone acetyltransferase (HAT) inhibitory activities. 2008 , 3, 1435-42	47
2226	Systemic cancer therapy: evolution over the last 60 years. 2008 , 113, 1857-87	42
2225	Loss of Drop1 expression already at early tumor stages in a wide range of human carcinomas. 2008 , 123, 2048-56	29
2224	Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps. 2008 , 123, 2587-93	108
2223	Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer. 2008 , 123, 2798-807	35
2222	Single-molecule analysis of chromatin: changing the view of genomes one molecule at a time. 2008 , 105, 330-7	17
2221	Epigenetic aspects of genotoxic and non-genotoxic hepatocarcinogenesis: studies in rodents. 2008 , 49, 9-15	44

2220	Tandem repeat mutation, global DNA methylation, and regulation of DNA methyltransferases in cultured mouse embryonic fibroblast cells chronically exposed to chemicals with different modes of action. 2008 , 49, 26-35	30
2219	Intersection of nuclear receptors and the proteasome on the epigenetic landscape. 2008 , 49, 83-95	16
2218	Methylation pattern analysis using high-throughput microarray of solid-phase hyperbranched rolling circle amplification products. 2008 , 29, 626-33	9
2217	Nanowire-transistor based ultra-sensitive DNA methylation detection. 2008 , 23, 780-7	67
2216	A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression. 2008 , 375, 237-48	30
2215	Characterization of acetylation of <i>Saccharomyces cerevisiae</i> H2B by mass spectrometry. 2008 , 278, 89-94	2
2214	Tumor cell dormancy: implications for the biology and treatment of breast cancer. 2008 , 116, 742-53	37
2213	Chromatin - a new, old drug target?. 2008 , 72, 165-70	11
2212	DNA methylation-mediated nucleosome dynamics and oncogenic Ras signaling: insights from FAS, FAS ligand and RASSF1A. 2008 , 275, 5217-35	32
2211	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. 2008 , 22, 1503-18	49
2210	A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. 2008 , 22, 965-70	104
2209	Genome-scale DNA methylation maps of pluripotent and differentiated cells. 2008 , 454, 766-70	1999
2208	Small RNAs and cancerogenesis. 2008 , 73, 514-27	8
2207	Transforming pathways unleashed by a HDAC2 mutation in human cancer. 2008 , 27, 4008-12	27
2206	Nucleoside analogs: molecular mechanisms signaling cell death. 2008 , 27, 6522-37	163
2205	Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis. 2008 , 27, 4488-96	37
2204	Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. 2008 , 99, 2083-7	61
2203	DNA methylation landscapes: provocative insights from epigenomics. 2008 , 9, 465-76	2183

2202	DNA polymerases and human disease. 2008 , 9, 594-604	219
2201	Epigenome dynamics: a quantitative genetics perspective. 2008 , 9, 883-90	158
2200	Mediators of reprogramming: transcription factors and transitions through mitosis. 2008 , 9, 505-16	178
2199	Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. 2008 , 15, 136-42	68
2198	Introduction: diet, epigenetic events and cancer prevention. 2008 , 66 Suppl 1, S1-6	28
2197	Recent updates on genetics: teaching old dogmas new tricks. 2008 , 25, 99-108	2
2196	Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. 2008 , 99, 376-84	70
2195	Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. 2008 , 53, 588-98	36
2194	Ras regulation of DNA-methylation and cancer. 2008 , 314, 1193-201	56
2193	All and only CpG containing sequences are enriched in promoters abundantly bound by RNA polymerase II in multiple tissues. 2008 , 9, 67	44
2192	Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. 2008 , 8, 154	67
2191	Final checkup of neoplastic DNA replication: evidence for failure in decision-making at the mitotic cell cycle checkpoint G(1)/S. 2008 , 36, 1403-16	8
2190	Genome organization: balancing stability and plasticity. 2008 , 1783, 2061-79	74
2189	Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. 2008 , 13, 69-80	355
2188	Theories of carcinogenesis: an emerging perspective. 2008 , 18, 372-7	154
2187	New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. 2008 , 119, 74-82	33
2186	Epigenetic drivers and genetic passengers on the road to cancer. 2008 , 642, 1-13	114
2185	Mechanisms of peroxisome proliferator-induced DNA hypomethylation in rat liver. 2008 , 644, 17-23	45

2184	PHD fingers in human diseases: disorders arising from misinterpreting epigenetic marks. 2008 , 647, 3-12	157
2183	Chromatin, cancer and drug therapies. 2008 , 647, 44-51	55
2182	Histone deacetylase inhibitors: a novel class of anti-cancer agents on its way to the market. 2008 , 46, 205-80	9
2181	Epigenomics and breast cancer. 2008 , 9, 1879-902	135
2180	Mechanisms of Disease: cancer stem cells--targeting the evil twin. 2008 , 5, 337-47	160
2179	Systems biotechnology of mammalian cell factories. 2008 , 7, 95-110	67
2178	Role of epigenetic therapy in myelodysplastic syndrome. 2008 , 1, 161-74	
2177	DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. 2008 , 36, 4689-98	118
2176	Germline epimutation in humans. 2008 , 9, 1861-8	15
2175	Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. 2008 , 135, 2128-40, 2140.e1-8	294
2174	Epigenetic reprogramming of the male genome during gametogenesis and in the zygote. 2008 , 16, 492-503	74
2173	Metilaci3 y c3ncer. 2008 , 7, 20-22	
2172	Methods of Cancer Diagnosis, Therapy and Prognosis. 2008 ,	13
2171	Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection?. 2008 , 9, 405	8
2170	Chemical probes for histone-modifying enzymes. 2008 , 4, 590-7	220
2169	Epigenetics in Cancer Stem Cell Development. 197-215	
2168	Epigenetics of cutaneous melanoma. 2008 , 24, 59-70	9
2167	High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. 2008 , 105, 252-7	284

2166	The use of diversity profiling to characterize chemical modulators of the histone deacetylases. 2008 , 82, 1050-8		67
2165	Cancer: shift of the paradigm. 2008 , 71, 839-50		8
2164	The next innovation cycle in toxicogenomics: environmental epigenetics. 2008 , 659, 158-65		77
2163	Chromatin-remodelling mechanisms in cancer. 2008 , 658, 191-214		58
2162	Decoding the epigenetic language of neuronal plasticity. 2008 , 60, 961-74		408
2161	Comprehensive profiling of histone modifications using a label-free approach and its applications in determining structure-function relationships. 2008 , 80, 6698-707		37
2160	Molecular alterations in prostate cancer. 2008 , 271, 13-24		32
2159	Analysis of <i>Saccharomyces cerevisiae</i> histone H3 mutants reveals the role of the alphaN helix in nucleosome function. 2008 , 374, 543-8		4
2158	Population epigenetics. 2008 , 18, 221-6		137
2157	Functional genomics of cancer. 2008 , 18, 251-6		17
2156	The impact of Arabidopsis on human health: diversifying our portfolio. <i>Cell</i> , 2008 , 133, 939-43	56.2	79
2155	SnapShot: the human DNA methylome in health and disease. <i>Cell</i> , 2008 , 135, 1144-1144.e1	56.2	11
2154	[Epigenetics of cancer]. 2008 , 31, 37-45		4
2153	Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. 2008 , 15, 1274-87		35
2152	Epigenetics in cancer. 2008 , 358, 1148-59		2783
2151	Do DNA-methylation changes also occur in blood?. 2008 , 9, 312-3		4
2150	Second-hand smoke and human lung cancer. 2008 , 9, 657-66		102
2149	Regulation of DNA methylation activity through Dnmt3L promoter methylation by Dnmt3 enzymes in embryonic development. 2008 , 17, 2654-64		51

2148	Computational epigenetics. 2008 , 24, 1-10	147
2147	Primer: strategies for identifying genes involved in renal disease. 2008 , 4, 265-76	18
2146	Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. 2008 , 68, 8094-103	141
2145	Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine. 2008 , 51, 7593-601	23
2144	A new 1'-methylenedisulfide deoxyribose that forms an efficient cross-link to DNA cytosine-5 methyltransferase (DNMT). 2008 , 130, 17634-5	11
2143	Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. 2008 , 68, 10280-9	172
2142	Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. 2008 , 22, 3403-8	204
2141	Microplate-based chromatin immunoprecipitation method, Matrix CHIP: a platform to study signaling of complex genomic events. 2008 , 36, e17	68
2140	Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. 2008 , 105, 12979-84	289
2139	Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. 2008 , 68, 5753-9	100
2138	Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. 2008 , 105, 19809-14	89
2137	The long road to a cure for acute myelocytic leukemia: from intensity to specificity. 2008 , 26, 3475-7	3
2136	Formation of nucleoprotein filaments by mammalian DNA methyltransferase Dnmt3a in complex with regulator Dnmt3L. 2008 , 36, 6656-63	99
2135	Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. 2008 , 28, 6223-33	103
2134	Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. 2008 , 28, 3219-35	104
2133	LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. 2008 , 17, 2555-64	56
2132	Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. 2008 , 29, 638-46	64
2131	p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. 2008 , 68, 9358-66	44

2130	A mouse gene that coordinates epigenetic controls and transcriptional interference to achieve tissue-specific expression. 2008 , 28, 836-48	8
2129	A simple algorithm for quantifying DNA methylation levels on multiple independent CpG sites in bisulfite genomic sequencing electropherograms. 2008 , 36, e64	31
2128	Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes. 2008 , 83, 439-46	48
2127	Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma. 2008 , 7, 1146-56	151
2126	Genome-wide profiling of methylated promoters in pancreatic adenocarcinoma: defining the pancreatic cancer [corrected] epigenome. 2008 , 7, 1157-9	4
2125	Epigenetic changes in gliomas. 2008 , 7, 1326-34	23
2124	Genetic and epigenetic alterations of familial pancreatic cancers. 2008 , 17, 3536-42	72
2123	Epigenetics and the uremic phenotype: a matter of balance. 2008 , 161, 55-62	11
2122	Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. 2008 , 69, 938-45	19
2121	Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. 2008 , 14, 2918-26	43
2120	GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. 2008 , 68, 5562-71	41
2119	SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. 2008 , 28, 3457-64	216
2118	Rational design, selection and specificity of artificial transcription factors (ATFs): the influence of chromatin in target gene regulation. 2008 , 11, 146-58	16
2117	RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. 2008 , 68, 6208-14	52
2116	The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. 2009 , 19, 438-51	201
2115	Oncogene-induced plasticity and cancer stem cells. 2008 , 7, 45-51	74
2114	Cancer prevention: epigenetics steps up to the plate. 2008 , 1, 219-22	42
2113	MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determination. 2008 , 79, 553-61	102

2112	Agglomerative epigenetic aberrations are a common event in human breast cancer. 2008 , 68, 8616-25	120
2111	DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients. 2008 , 17, 645-54	128
2110	QUMA: quantification tool for methylation analysis. 2008 , 36, W170-5	430
2109	Defining a candidate lung cancer gene. 2008 , 100, 1564-5	3
2108	An analytical pipeline for genomic representations used for cytosine methylation studies. 2008 , 24, 1161-7	47
2107	Epigenetic inactivation of the Groucho homologue gene TLE1 in hematologic malignancies. 2008 , 68, 4116-22	46
2106	Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. 2008 , 68, 2498-506	67
2105	A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. 2008 , 100, 1734-8	290
2104	Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance. 2008 , 14, 2664-72	33
2103	Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. 2008 , 7, 1080-90	55
2102	Transcriptome sequencing of malignant pleural mesothelioma tumors. 2008 , 105, 3521-6	126
2101	Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. 2008 , 4, 229-39	13
2100	Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. 2008 , 68, 2112-21	43
2099	miR-148 targets human DNMT3b protein coding region. 2008 , 14, 872-7	461
2098	Breast cancer-associated fibroblasts confer AKT1-mediated epigenetic silencing of Cystatin M in epithelial cells. 2008 , 68, 10257-66	60
2097	Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. 2008 , 14, 3283-90	78
2096	Methylation of Tip30 promoter is associated with poor prognosis in human hepatocellular carcinoma. 2008 , 14, 7405-12	40
2095	Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. 2008 , 9, 1903-16	21

2094	Epigenetics--a helpful tool to better understand processes in clinical nephrology?. 2008 , 23, 1493-6	18
2093	Molecular targets and targeted therapies for malignant mesothelioma. 2008 , 15, 855-67	29
2092	The epigenetics of cancer in children. 2008 , 220, 333-41	15
2091	[New approaches to early detection, estimation of prognosis and therapy for malignant tumours of the gastrointestinal tract]. 2008 , 46, 216-22	0
2090	Methylenetetrahydrofolate reductase (MTHFR): a novel target for cancer therapy. 2008 , 14, 1143-50	18
2089	Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylation. 2009 , 19, 1-11	62
2088	Comprehensive high-throughput arrays for relative methylation (CHARM). 2008 , 18, 780-90	350
2087	Epigenetic silencing of cell adhesion molecule 1 in different cancer progenitor cells of transgenic c-Myc and c-Raf mouse lung tumors. 2008 , 68, 7587-96	25
2086	Germ-line mutations, DNA damage, and global hypermethylation in mice exposed to particulate air pollution in an urban/industrial location. 2008 , 105, 605-10	230
2085	Cancer stem cells: Models, mechanisms and implications for improved treatment. 2008 , 7, 1360-70	77
2084	Genetic modification of neural stem cells. 2008 , 16, 450-7	38
2083	Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. 2008 , 7, 2591-600	652
2082	An integrated resource for genome-wide identification and analysis of human tissue-specific differentially methylated regions (tDMRs). 2008 , 18, 1518-29	304
2081	DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia. 2008 , 111, 2374-7	38
2080	Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response. 2008 , 111, 1797-804	136
2079	Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. 2008 , 112, 1366-73	124
2078	Epigenetic regulation and therapeutic approaches in cancer. 2008 , 8, 1367-78	
2077	Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression. 2008 , 2, 297-305	1

2076 ?????????????????? DNA?????????????????????????????. **2008**, 46, 150-151

2075 Demethylating agents in myeloid malignancies. **2008**, 20, 705-10

83

2074 Bibliography. Current world literature. Breast. **2008**, 20, 719-23

2073 Bibliography. Current world literature. Gastrointestinal infections. **2008**, 24, 75-85

2072 . **2008**,

2071 [Differential epigenetic marking on imprinted genes and consequences in human diseases]. **2008**, 24, 747-52

2

2070 Cancer Genomics. **2008**, 267-282

2069 Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. **2008**, 3, e2656

116

2068 CHIP-Seq: Mapping of ProteinDNA Interactions. 201-215

1

2067 The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. **2008**, 33, 61-73

231

2066 . **2009**,

3

2065 Challenging issues in molecular-targeted therapy. **2009**, 5, 239-45

1

2064 Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma. **2009**, 2009, 848695

10

2063 Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. **2009**, 50, 455-63

136

2062 Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. **2009**, 4, e4717

78

2061 Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. **2009**, 4, e4941

95

2060 A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. **2009**, 4, e6986

104

2059 Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. **2009**, 4, e8002

77

2058 Epigenetically-Regulated Therapeutic Tumor-Associated Antigens. 143-160

2057 Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. **2009**, 27, 549-60 108

2056 Histone demethylases and cancer. **2009**, 102, 103-69 44

2055 MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. **2009**, 101, 699-706 229

2054 Epigenetic biomarker development. **2009**, 1, 99-110 94

2053 Epigenetically regulated tumor-associated antigens in melanoma. **2009**, 4, 145-154 1

2052 Concomitant promoter methylation of multiple genes in lung adenocarcinomas from current, former and never smokers. **2009**, 30, 1132-8 60

2051 Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. **2009**, 7, 523-35 90

2050 Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. **2009**, 69, 8447-54 131

2049 A human B cell methylome at 100-base pair resolution. **2009**, 106, 671-8 291

2048 Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. **2009**, 106, 21830-5 162

2047 Lack of TNFalpha expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. **2009**, 106, 15843-8 16

2046 Epigenetic regulation of the alternatively activated macrophage phenotype. **2009**, 114, 3244-54 338

2045 Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. **2009**, 5, 601-12 111

2044 DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. **2009**, 8, 1579-88 444

2043 Genome-wide screen of promoter methylation identifies novel markers in melanoma. **2009**, 19, 1462-70 144

2042 Acetylated NPM1 localizes in the nucleoplasm and regulates transcriptional activation of genes implicated in oral cancer manifestation. **2009**, 29, 5115-27 72

2041 High DNA methyltransferase 3B expression mediates 5-aza-deoxycytidine hypersensitivity in testicular germ cell tumors. **2009**, 69, 9360-6 82

2040	Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. 2009 , 8, 939-50	78
2039	The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. 2009 , 19, 1974-82	103
2038	Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival. 2009 , 23, 1054-63	47
2037	A pipeline for the quantitative analysis of CG dinucleotide methylation using mass spectrometry. 2009 , 25, 2164-70	64
2036	Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. 2009 , 27, 3161-8	119
2035	Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. 2009 , 18, 2723-5	25
2034	Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 2009 , 15, 5002-7	87
2033	Targeting histone demethylases in cancer therapy. 2009 , 15, 7111-3	22
2032	A DNA methyltransferase inhibitor and all-trans retinoic acid reduce oral cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. 2009 , 2, 1100-10	36
2031	Promoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancer. 2009 , 30, 242-8	26
2030	The changing face of HDAC inhibitor depsipeptide. 2009 , 9, 91-100	20
2029	Considerations for the processing and analysis of GoldenGate-based two-colour Illumina platforms. 2009 , 18, 437-52	17
2028	Targeting of EZH2 to a defined genomic site is sufficient for recruitment of Dnmt3a but not de novo DNA methylation. 2009 , 4, 404-14	66
2027	Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2. 2009 , 8, 1991-6	64
2026	Epigenetics and cancer without genomic instability. 2009 , 8, 23-6	41
2025	Reprogramming of HeLa cells upon DNMT3L overexpression mimics carcinogenesis. 2009 , 4, 322-9	22
2024	Paving the way for H2AX phosphorylation: chromatin changes in the DNA damage response. 2009 , 8, 1494-500	28
2023	Cancer stem cells and hepatocellular carcinoma. 2009 , 8, 1691-8	70

2022	TET proteins in malignant hematopoiesis. 2009 , 8, 4044-8	44
2021	Reversing DNA methylation: new insights from neuronal activity-induced Gadd45b in adult neurogenesis. 2009 , 2, pe17	31
2020	DNA methylation analysis of chromosome 21 gene promoters at single base pair and single allele resolution. 2009 , 5, e1000438	127
2019	Novel targeted drug therapies for the treatment of childhood acute leukemia. 2009 , 2, 145	25
2018	Targeted therapy in acute myeloid leukaemia: current status and future directions. 2009 , 18, 433-55	31
2017	The silent estrogen receptor--can we make it speak?. 2009 , 8, 485-96	14
2016	The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. 2009 , 69, 2623-9	343
2015	Rational combinations using HDAC inhibitors. 2009 , 15, 3970-7	195
2014	The Human Epigenome: Implications for the Understanding of Human Disease. 2009 , 151-163	1
2013	Molecular expression analysis of beta-naphthoflavone-induced hepatocellular tumors in rats. 2009 , 37, 446-55	14
2012	Epigenetics of human T cells during the G0-->G1 transition. 2009 , 19, 1325-37	19
2011	Alternative transcription initiation and splicing variants of the DHRS4 gene cluster. 2009 , 29, 47-56	9
2010	Epigenetic alterations in human prostate cancers. 2009 , 150, 3991-4002	117
2009	Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure. 2009 , 15, 3672-9	25
2008	SALL3 interacts with DNMT3A and shows the ability to inhibit CpG island methylation in hepatocellular carcinoma. 2009 , 29, 1944-58	41
2007	Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. 2009 , 69, 5251-8	102
2006	Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. 2009 , 30, 1041-8	42
2005	Epigenetic deregulation of DNA repair and its potential for therapy. 2009 , 15, 5026-31	49

2004	An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. 2009 , 15, 6292-300	95
2003	Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. 2009 , 122, 2473-80	68
2002	Integrated analysis of genetic and epigenetic alterations in cancer. 2009 , 1, 291-9	3
2001	Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. 2009 , 76, 1072-81	32
2000	Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. 2009 , 15, 7217-28	175
1999	Systematic identification of cis-silenced genes by trans complementation. 2009 , 18, 835-46	12
1998	Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. 2009 , 69, 4691-9	182
1997	Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. 2009 , 69, 9038-46	243
1996	Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. 2009 , 69, 6322-30	67
1995	A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. 2009 , 69, 4277-85	206
1994	Role of DNA damage and alterations in cytosine DNA methylation in rat liver carcinogenesis induced by a methyl-deficient diet. 2009 , 669, 56-62	42
1993	Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. 2009 , 45, 610-4	84
1992	DNA methylation patterns in lung carcinomas. 2009 , 19, 181-7	85
1991	Excavating relics of DNA methylation changes during the development of neoplasia. 2009 , 19, 198-208	18
1990	Arsenicals produce stable progressive changes in DNA methylation patterns that are linked to malignant transformation of immortalized urothelial cells. 2009 , 241, 221-9	41
1989	Polycomb group complexes--many combinations, many functions. 2009 , 19, 692-704	106
1988	Identifying differentially methylated genes using mixed effect and generalized least square models. 2009 , 10, 404	7
1987	Mechanism-anchored profiling derived from epigenetic networks predicts outcome in acute lymphoblastic leukemia. 2009 , 10 Suppl 9, S6	6

1986	Definition, conservation and epigenetics of housekeeping and tissue-enriched genes. 2009 , 10, 269	103
1985	ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. 2009 , 9, 80	17
1984	Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?. 2009 , 7, 78	3
1983	What will it take to obtain DNA methylation markers for early cervical cancer detection?. 2009 , 112, 291-2	7
1982	Familial and racial determinants of tumour suppressor genes promoter hypermethylation in breast tissues from healthy women. 2010 , 14, 1468-75	32
1981	The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. 2009 , 1795, 104-9	11
1980	Cancer gene discovery in mouse and man. 2009 , 1796, 140-61	8
1979	Kaiso is a bimodal modulator for Wnt/beta-catenin signaling. 2009 , 583, 627-32	26
1978	Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. 2009 , 8, 1056-72	473
1977	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. 2009 , 36, S27-35	34
1976	DNA Methyltransferase Inhibitors. 2009 , 161-183	1
1975	Enzymatic incorporation of multiple dyes for increased sensitivity in QD-FRET sensing for DNA methylation detection. 2010 , 11, 71-4	28
1974	The presence of a methylation fingerprint of Helicobacter pylori infection in human gastric mucosae. 2009 , 124, 905-10	93
1973	Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers. 2009 , 125, 1613-21	31
1972	DNA methylation analysis in liquid-based cytology for cervical cancer screening. 2009 , 125, 2995-3002	44
1971	The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. 2009 , 115, 3412-26	109
1970	Automated quantification of DNA demethylation effects in cells via 3D mapping of nuclear signatures and population homogeneity assessment. 2009 , 75, 569-83	20
1969	Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology. 2009 , 1, 178-91	59

1968	Quantification of global DNA methylation with infrared fluorescence in liver and muscle tissues of differentially fed boars. 2009 , 24, 213-6	3
1967	Expression profile and differential regulation of the Human I-mfa domain-Containing protein (HIC) gene in immune cells. 2009 , 123, 179-84	8
1966	Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model. 2009 , 115, 269-77	35
1965	Promoter methylation and the detection of breast cancer. 2009 , 20, 1539-50	67
1964	Biology of urothelial tumorigenesis: insights from genetically engineered mice. 2009 , 28, 281-90	37
1963	Epigenetic contributions to cancer metastasis. 2009 , 26, 5-18	30
1962	DNA hypomethylation in the origin and pathogenesis of human diseases. 2009 , 66, 2249-61	169
1961	Epigenetic regulation of Myc on retinoic acid receptor beta and PDLIM4 in RWPE1 cells. 2009 , 69, 1643-50	11
1960	Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. 2009 , 2, 34	165
1959	Bisulfite-based epityping on pooled genomic DNA provides an accurate estimate of average group DNA methylation. 2009 , 2, 3	40
1958	The histone 3 lysine 4 methyltransferase, Mll2, is only required briefly in development and spermatogenesis. 2009 , 2, 5	129
1957	Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. 2009 , 100, 787-91	54
1956	Array-based DNA methylation profiling in follicular lymphoma. 2009 , 23, 1858-66	61
1955	MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. 2009 , 22, 1588-99	58
1954	Human DNA methylomes at base resolution show widespread epigenomic differences. 2009 , 462, 315-22	3401
1953	Sensitive digital quantification of DNA methylation in clinical samples. 2009 , 27, 858-63	273
1952	Protein methyltransferases as a target class for drug discovery. 2009 , 8, 724-32	360
1951	Linking DNA methylation and histone modification: patterns and paradigms. 2009 , 10, 295-304	1665

1950	Causes and consequences of microRNA dysregulation in cancer. 2009 , 10, 704-14	2482
1949	Mechanisms of polycomb gene silencing: knowns and unknowns. 2009 , 10, 697-708	1044
1948	Carcinogenesis: evolution of concepts. 2009 , 74, 353-61	7
1947	Epigenetic DNA-(cytosine-5-carbon) modifications: 5-aza-2'-deoxycytidine and DNA-demethylation. 2009 , 74, 613-9	40
1946	Inhibition of C5-cytosine-DNA-methyltransferases. 2009 , 74, 1175-86	8
1945	Chromatin organization marks exon-intron structure. 2009 , 16, 990-5	469
1944	Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. 2009 , 28, 209-18	346
1943	Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. 2009 , 28, 184-94	122
1942	Impaired recruitment of the histone methyltransferase DOT1L contributes to the incomplete reactivation of tumor suppressor genes upon DNA demethylation. 2009 , 28, 4212-24	26
1941	Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. 2009 , 28, 4491-500	176
1940	The context and potential of epigenetics in oncology. 2009 , 100, 571-7	84
1939	Anti-inflammatory and anticarcinogenic effect of genistein alone or in combination with capsaicin in TPA-treated rat mammary glands or mammary cancer cell line. 2009 , 1171, 415-20	48
1938	Noninvasive prenatal detection of fetal chromosomal aneuploidies by maternal plasma nucleic acid analysis: a review of the current state of the art. 2009 , 116, 152-7	49
1937	Predictors of the scleroderma phenotype in fibroblasts from systemic sclerosis patients. 2009 , 23, 160-8	24
1936	Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. 2009 , 9, 877-81	26
1935	Aberrant DNA methylation of the transcription factor C/EBPalpha in acute myelogenous leukemia. 2009 , 33, 443-9	19
1934	DNA hypomethylation as Achilles' heel of tumorigenesis: a working hypothesis. 2009 , 33, 904-10	8
1933	Sanguinarine interacts with chromatin, modulates epigenetic modifications, and transcription in the context of chromatin. 2009 , 16, 203-16	59

1932	Histone deacetylase inhibitors: Potential in cancer therapy. 2009 , 107, 600-8	570
1931	Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. 2009 , 16, 2270-9	15
1930	CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. 2009 , 58, 90-6	610
1929	DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. 2009 , 15, 3663-71	111
1928	Identification and verification of lysine propionylation and butyrylation in yeast core histones using PTMap software. 2009 , 8, 900-6	105
1927	The rationale and use of hypomethylation agents in adult acute myeloid leukemia. 2009 , 4, 195-205	1
1926	Methods in DNA methylation profiling. 2009 , 1, 331-45	67
1925	Minireview: epigenetic changes in ovarian cancer. 2009 , 150, 4003-11	127
1924	Methylated genes as new cancer biomarkers. 2009 , 45, 335-46	84
1923	Epigenetic therapies in haematological malignancies: searching for true targets. 2009 , 45, 1137-1145	40
1922	New agents for AML and MDS. 2009 , 22, 501-7	4
1921	HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. 2009 , 41, 26-33	62
1920	Epigenomic profiling of cancer cells. 2009 , 41, 127-35	35
1919	Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. 2009 , 41, 199-213	158
1918	Transcription factors, chromatin and cancer. 2009 , 41, 164-75	33
1917	DNA methylomes, histone codes and miRNAs: tying it all together. 2009 , 41, 87-95	250
1916	Epigenetic therapy of leukemia: An update. 2009 , 41, 72-80	39
1915	Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. 2009 , 281, 24-31	30

1914	Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. 2009 , 280, 233-41	312
1913	Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. 2009 , 280, 134-44	94
1912	Histone deacetylase inhibitors as anti-neoplastic agents. 2009 , 280, 192-200	133
1911	Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. 2009 , 285, 182-9	36
1910	Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. 2009 , 379, 726-31	198
1909	Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. 2009 , 27, 315-21	16
1908	Design and analysis issues in genome-wide somatic mutation studies of cancer. 2009 , 93, 17-21	75
1907	High-throughput bisulfite sequencing in mammalian genomes. 2009 , 48, 226-32	161
1906	Effects of CpG methylation on recognition of DNA by the tumour suppressor p53. 2009 , 386, 72-80	14
1905	Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary. 2009 , 34, 271-84	178
1904	Breaching the boundaries that safeguard against repression. 2009 , 34, 395-7	4
1903	Loss of human ribosomal gene CpG methylation enhances cryptic RNA polymerase II transcription and disrupts ribosomal RNA processing. 2009 , 35, 414-25	82
1902	Epithelial metaplasia: adult stem cell reprogramming and (pre)neoplastic transformation mediated by inflammation?. 2009 , 15, 245-53	39
1901	Approaches to target the genome and its epigenome in cancer. 2009 , 1, 1481-95	9
1900	Epigenetic progenitors in tumor initiation and development. 2009 , 6, 5-12	1
1899	Epigenetic approaches to cancer therapy. 2009 , 6, 71-79	4
1898	Global repression of cancer gene expression in a zebrafish model of melanoma is linked to epigenetic regulation. 2009 , 6, 417-24	44
1897	Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. 2009 , 1, 387-98	71

1896	Methods in cancer epigenetics and epidemiology. 2009 , 471, 273-88	20
1895	Identificaci3n de genes de susceptibilidad para el c3ncer colorrectal: aportaci3n de los Genome-Wide Association Studies. 2009 , 8, 144-148	
1894	Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism. 2009 , 137, 649-59, 659.e1-2	98
1893	Histone deacetylase inhibitors: current status and overview of recent clinical trials. 2009 , 69, 1911-34	186
1892	Genomic prognostic models in early-stage lung cancer. 2009 , 10, 151-7	29
1891	What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. 2009 , 9 Suppl 3, S296-301	5
1890	Stem cells and somatic cells: reprogramming and plasticity. 2009 , 9 Suppl 3, S319-28	11
1889	High-throughput sequence-based epigenomic analysis of Alu repeats in human cerebellum. 2009 , 37, 4331-40	75
1888	The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability. 2009 , 8, 54	56
1887	The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. 2009 , 8, 124	28
1886	Polyamine analogues targeting epigenetic gene regulation. 2009 , 46, 95-110	39
1885	Stem cells, cancer, and epigenetics. 2009 ,	11
1884	Exposure to formaldehyde induces heritable DNA mutations in mice. 2009 , 72, 767-73	11
1883	Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. 2009 , 9, 293-301	178
1882	Androgen Action in Prostate Cancer. 2009 ,	6
1881	Skin cancer: new markers for better prevention. 2009 , 76, 64-81	59
1880	MicroRNA dysregulation during chemical carcinogenesis. 2009 , 1, 281-90	20
1879	Histone deacetylase inhibitors in cancer therapy. 2009 , 27, 5459-68	721

1878	Epigenetic targets in cancer epidemiology. 2009 , 471, 457-67	7
1877	Epigenetics and ovarian cancer. 2009 , 149, 131-46	9
1876	Microarray Analysis of the Physical Genome. 2009 ,	2
1875	Recent advances in the development of polyamine analogues as antitumor agents. 2009 , 52, 4551-73	128
1874	Cancer Epidemiology. 2009 ,	6
1873	Yeast Functional Genomics and Proteomics. 2009 ,	1
1872	Tissue inhibitor of metalloproteinase 1 expression associated with gene demethylation confers anoikis resistance in early phases of melanocyte malignant transformation. 2009 , 2, 329-40	20
1871	New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. 2009 , 113, 2488-97	121
1870	CpG island methylation patterns in chronic lymphocytic leukemia. 2009 , 50, 419-26	22
1869	Targeting DNA methylation. 2009 , 15, 3938-46	328
1868	Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia. 2009 , 106, 13433-8	73
1867	Global levels of histone modifications predict prognosis in different cancers. 2009 , 174, 1619-28	396
1866	Biophysical models of tumour growth. 2009 , 72, 056701	124
1865	Epigenetics of acute lymphocytic leukemia. 2009 , 46, 24-32	67
1864	Acute lymphoblastic leukemia: introduction. 2009 , 46, 1-2	34
1863	Does the uremic milieu affect the epigenotype?. 2009 , 19, 82-5	10
1862	Epigenetic mechanisms in cancer. 2009 , 3, 397-410	29
1861	Association between frequent CpG island methylation and HER2 amplification in human breast cancers. 2009 , 30, 466-71	23

1860	Epigenetics in cancer: targeting chromatin modifications. 2009 , 8, 1409-20	384
1859	Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. 2009 , 20, 321-33	34
1858	Development of a novel output value for quantitative assessment in methylated DNA immunoprecipitation-CpG island microarray analysis. 2009 , 16, 275-86	33
1857	Global reduction of the epigenetic H3K79 methylation mark and increased chromosomal instability in CALM-AF10-positive leukemias. 2009 , 114, 651-8	51
1856	Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. 2009 , 114, 1576-84	38
1855	Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. 2009 , 114, 2733-43	299
1854	Missteps in "tango" for epigenome targeting. 2009 , 114, 2569-70	1
1853	UHRF1 Links the Histone Code and DNA Methylation to Ensure Faithful Epigenetic Memory Inheritance. 2009 , 2, GEG.S3992	12
1852	Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy. 2009 , 10, 336-52	57
1851	Cellular regulation of SIRT1. 2009 , 15, 39-44	45
1850	Systems diagnostics: the systems approach to molecular imaging. 2009 , 193, 287-94	4
1849	Resolution of ventilator-associated pneumonia: is my patient getting better?. 2010 , 38, 308-9	0
1848	Critical care medicine in the United States: what we know, what we do not, and where we go from here. 2010 , 38, 304-6	3
1847	Meningococcal sepsis in children: persistent problem; new insights?. 2010 , 38, 316-7	
1846	Cytosine methyltransferases as tumor markers. 2010 , 11, 568-77	3
1845	Rhythms and outcomes of cardiac arrest. 2010 , 38, 310	2
1844	Tele-intensive care unit: the horse out of the barn. 2010 , 38, 292-3	35
1843	Should critical care patients receive or remain on treatment with antiplatelet drugs?. 2010 , 38, 298-300	1

1842	Not much turbulence: addition of heliox to noninvasive ventilation fails to improve outcomes in patients with exacerbations of chronic obstructive pulmonary disease. 2010 , 38, 319-20	3
1841	Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. 2010 , 11, 95-110	35
1840	A Bioinformatics Pipeline for Cancer Epigenetics. 2010 , 5, 153-163	2
1839	Epigenetic tools in potential anticancer therapy. 2010 , 21, 565-77	24
1838	Another small step on the long way to control methicillin-resistant <i>Staphylococcus aureus</i> cross-transmission. 2010 , 38, 311-2	
1837	Measuring the quantity of pulmonary edema in clinical lung injury. 2010 , 38, 312-4	4
1836	Recent favorable outcomes in critically ill patients with cancer may mitigate historic acquiescent optimism in critical care unit therapy. 2010 , 38, 293-4	
1835	Traumatic brain injury: the continued quest for early prognostic determination. 2010 , 38, 325-6	5
1834	Diffusion of carbon monoxide: any place in intensive care?. 2010 , 38, 314-5	1
1833	Should the oldest-old be admitted to the intensive care unit and receive advanced life-supporting care?. 2010 , 38, 303-4	3
1832	New life for physiologic dead space?. 2010 , 38, 335-6	21
1831	Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis. 2010 , 38, 306-8	18
1830	The race for biomarkers in traumatic brain injury: what science promises and the clinicians still expect. 2010 , 38, 318-9	0
1829	Addition of rifampin to vancomycin for the treatment of pneumonias due to methicillin-resistant <i>Staphylococcus aureus</i> : caveat emptor. 2010 , 38, 326-7	4
1828	Use of intra-aortic balloon counterpulsation in cardiogenic shock complicating acute myocardial infarction. Do we really need more evidence?. 2010 , 38, 321-2	2
1827	Donation after cardiac death in children: do transplant outcomes influence implementation?. 2010 , 38, 333	
1826	Cross-transmission of bacterial pathogens in the intensive care unit: What lessons can we learn?. 2010 , 38, 302-3	
1825	Innate immune defense on the attack in acute lung injury. 2010 , 38, 328-9	6

1824	Poison to the heart. 2010 , 38, 331-2	6
1823	Heat maps, random forests, and nearest neighbors: a peek into the new molecular diagnostic world. 2010 , 38, 296-8	3
1822	Haunted by delusions: Trauma, delusional memories, and intensive care unit morbidity. 2010 , 38, 300-1	
1821	From the bedside back to the bench: the role of preclinical studies in understanding clinical therapies. 2010 , 38, 329-30	3
1820	Prediction of sepsis after multiple trauma: does C-type natriuretic peptide do the trick?. 2010 , 38, 323-4	3
1819	The real reasons not to rely on severity scores. 2010 , 38, 334-5	7
1818	Moving closer to untangling a sweet web: hyperglycemia, diabetic status, and mortality in the critically ill. 2010 , 38, 295-6	9
1817	Structural Genomics, Its Application in Chemistry, Biology, and Drug Discovery. 2010 , 569-600	
1816	Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. 2010 , 20, 513-9	34
1815	The therapeutic promise of the cancer stem cell concept. 2010 , 120, 41-50	483
1814	Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. 2010 , 116, 3564-71	82
1813	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. 2010 , 116, 1025-34	120
1812	CpG methylation of transcription factor 4 in gastric carcinoma. 2010 , 17, 3344-53	12
1811	Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. 2010 , 17, 3336-43	55
1810	DNA-based nano-sized systems for pharmaceutical and biomedical applications. 2010 , 62, 626-32	29
1809	Nuclear receptor coregulators as a new paradigm for therapeutic targeting. 2010 , 62, 1227-37	48
1808	Transcription factor-mediated epigenetic regulation of cell growth and phenotype for biological control and cancer. 2010 , 50, 160-7	11
1807	Hypomethylation of repeated DNA sequences in cancer. 2010 , 2, 245-69	85

1806	Silencing of gene expression by targeted DNA methylation: concepts and approaches. 2010 , 649, 149-61	19
1805	DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. 2010 , 89, 191-9	32
1804	DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. 2010 , 34, 717-23	35
1803	Heavy ions, radioprotectors and genomic instability: implications for human space exploration. 2010 , 49, 303-16	22
1802	Global histone modification profiles are well conserved between normal B lymphocytes and neoplastic counterparts. 2010 , 16, 447-51	2
1801	Cancer: evolutionary, genetic and epigenetic aspects. 2010 , 1, 85-100	12
1800	Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. 2010 , 1, 117-136	310
1799	DNA methylation: an introduction to the biology and the disease-associated changes of a promising biomarker. 2010 , 44, 71-81	159
1798	Myelodysplastic syndromes: an update on molecular pathology. 2010 , 12, 652-61	15
1797	Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. 2010 , 15, 35-47	44
1796	Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. 2010 , 119, 601-12	63
1795	Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. 2010 , 120, 581-92	102
1794	CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. 2010 , 120, 593-601	33
1793	Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. 2010 , 122, 699-710	57
1792	Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. 2010 , 29, 73-93	39
1791	Histone deacetylase inhibitors in Hodgkin lymphoma. 2010 , 28 Suppl 1, S21-7	22
1790	The effect of epigenetic regulation of fucosylation on TRAIL-induced apoptosis. 2010 , 27, 649-59	24
1789	The DNA methylome of glioblastoma multiforme. 2010 , 39, 40-6	45

1788	Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. 2010 , 20, 246-53	78
1787	Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. 2010 , 248, 111-21	95
1786	DNA methylation and cellular reprogramming. 2010 , 20, 609-17	164
1785	An integrated analysis of molecular aberrations in NCI-60 cell lines. 2010 , 11, 495	6
1784	DNA methylation patterns provide insight into epigenetic regulation in the Pacific oyster (<i>Crassostrea gigas</i>). 2010 , 11, 483	111
1783	LPS-induced IL-8 activation in human intestinal epithelial cells is accompanied by specific histone H3 acetylation and methylation changes. 2010 , 10, 172	82
1782	Cancer epigenetics. 2010 , 60, 376-92	330
1781	NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. 2010 , 10, 160	14
1780	The aberrant asynchronous replication - characterizing lymphocytes of cancer patients - is erased following stem cell transplantation. 2010 , 10, 230	9
1779	Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients. 2010 , 10, 63	28
1778	Role of HDAC1 in senescence, aging, and cancer. 2010 , 45, 279-85	57
1777	Tumor heterogeneity: causes and consequences. 2010 , 1805, 105-17	750
1776	HELP for AML: methylation profiling opens new avenues. 2010 , 17, 1-3	20
1775	Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. 2010 , 17, 510-22	1754
1774	To infinium, and beyond!. 2010 , 17, 419-20	10
1773	Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. 2010 , 18, 316-28	430
1772	Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells. 2010 , 316, 3150-60	19
1771	Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. 2010 , 116, 195-201	79

1770	Promoter hypermethylation of CIDEA, HAAO and RXFP3 associated with microsatellite instability in endometrial carcinomas. 2010 , 117, 239-47	33
1769	Epigenetics of ovarian cancer: from the lab to the clinic. 2010 , 118, 81-7	64
1768	New anacardic acid-inspired benzamides: histone lysine acetyltransferase activators. 2010 , 5, 1530-40	16
1767	A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. 2010 , 116, 4043-53	121
1766	Epigenetic silence of ankyrin-repeat-containing, SH3-domain-containing, and proline-rich-region-containing protein 1 (ASPP1) and ASPP2 genes promotes tumor growth in hepatitis B virus-positive hepatocellular carcinoma. 2010 , 51, 142-53	83
1765	Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. 2010 , 51, 1635-44	164
1764	Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer. 2010 , 126, 1378-89	37
1763	Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. 2010 , 127, 1866-74	94
1762	Silencing of the UCHL1 gene in giant cell tumors of bone. 2010 , 127, 1804-12	20
1761	Effects of Dietary Natural Compounds on DNA Methylation Related to Cancer Chemoprevention and Anticancer Epigenetic Therapy. 2010 , 141-155	
1760	Epigenetics and parental effects. 2010 , 32, 818-27	97
1759	Epigenetic cancer therapy: Proof of concept and remaining challenges. 2010 , 32, 949-57	57
1758	Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome. 2010 , 49, 999-1006	4
1757	Epigenetic modifications in AML and MDS. 2010 , 34, 139-40	5
1756	Targeting epigenetic enzymes for drug discovery. 2010 , 14, 505-10	90
1755	Double recognition of oligonucleotide and protein in the detection of DNA methylation with surface plasmon resonance biosensors. 2010 , 26, 850-3	51
1754	Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. 2010 , 18, 822-9	138
1753	From 'omics' to complex disease: a systems biology approach to gene-environment interactions in cancer. 2010 , 10, 11	60

1752	Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 1: human papillomavirus-mediated carcinogenesis. 2010 , 6, 14	24
1751	An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer. 2010 , 3, 55	12
1750	Aberrant epigenetic silencing of tumor suppressor genes is reversed by direct reprogramming. 2010 , 28, 1349-54	21
1749	DNA methylation and gene expression. 2010 , 2, 362-371	85
1748	DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. 2010 , 2, 654-69	40
1747	Our changing view of the genomic landscape of cancer. 2010 , 220, 231-43	64
1746	[Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors]. 2010 , 39, 217-27	
1745	Aberrant demethylation of the recoverin gene is involved in the aberrant expression of recoverin in cancer cells. 2010 , 19, 1023-5	11
1744	Genome-wide DNA methylation profiles in precancerous conditions and cancers. 2010 , 101, 36-45	102
1743	Aberrant DNA methylation in contrast with mutations. 2010 , 101, 300-5	81
1742	Role of Helicobacter pylori infection in aberrant DNA methylation along multistep gastric carcinogenesis. 2010 , 101, 1337-46	50
1741	Epigenetic aberrations and therapeutic implications in gliomas. 2010 , 101, 1331-6	20
1740	Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. 2010 , 101, 1501-10	81
1739	Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway. 2010 , 101, 1618-23	15
1738	DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae. 2010 , 101, 1708-16	44
1737	Clinical significance and prognostic value of chromatin assembly factor-1 overexpression in human solid tumours. 2010 , 57, 716-24	36
1736	FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma. 2010 , 162, 1093-7	36
1735	Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines. 2010 , 29, 2217-27	81

1734	A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1. 2010 , 29, 2467-76	37
1733	Global analysis of CpG methylation reveals epigenetic control of the radiosensitivity in lung cancer cell lines. 2010 , 29, 4725-31	45
1732	Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. 2010 , 29, 5775-84	72
1731	CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. 2010 , 29, 6390-401	158
1730	Chromatin density and splicing destiny: on the cross-talk between chromatin structure and splicing. 2010 , 29, 1629-36	113
1729	Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy. 2010 , 105, 152-60	23
1728	Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. 2010 , 464, 1351-6	390
1727	Epigenetic modifications as therapeutic targets. 2010 , 28, 1069-78	580
1726	Quantitative comparison of genome-wide DNA methylation mapping technologies. 2010 , 28, 1106-14	486
1725	Epigenetic modifications in pluripotent and differentiated cells. 2010 , 28, 1079-88	302
1724	Structural and functional features of the 5-methylcytosine distribution in the eukaryotic genome. 2010 , 44, 171-185	9
1723	Linking cell signaling and the epigenetic machinery. 2010 , 28, 1033-8	72
1722	The NIH Roadmap Epigenomics Mapping Consortium. 2010 , 28, 1045-8	1284
1721	Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. 2010 , 12, 235-46	153
1720	Grand challenge commentary: Beyond discovery: probes that see, grab and poke. 2010 , 6, 868-70	7
1719	Grand challenge commentary: The chemistry of a dynamic genome. 2010 , 6, 866-8	3
1718	Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. 2010 , 10, 457-69	848
1717	Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. 2010 , 10, 669-82	206

1716	Next-generation genomics: an integrative approach. 2010 , 11, 476-86	488
1715	Mitotic bookmarking of genes: a novel dimension to epigenetic control. 2010 , 11, 583-9	114
1714	Stress and the epigenetic landscape: a link to the pathobiology of human diseases?. 2010 , 11, 806-12	81
1713	Principles for the post-GWAS functional characterisation of risk loci. 2010 ,	1
1712	The Interplay of Cancer and Biology. 2010 , 97-167	
1711	Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies. 2010 , 3, 2411-2469	49
1710	SETDB1 is involved in postembryonic DNA methylation and gene silencing in Drosophila. 2010 , 5, e10581	20
1709	Oligonucleotide sequence motifs as nucleosome positioning signals. 2010 , 5, e10933	18
1708	Epigenetic silencing of peroxisome proliferator-activated receptor α is a biomarker for colorectal cancer progression and adverse patients' outcome. 2010 , 5, e14229	65
1707	Advances in genome-wide DNA methylation analysis. 2010 , 49, iii-xi	62
1706	Epigenomics in cancer management. 2010 , 255	38
1705	Promoter hypermethylation and histone hypoacetylation contribute to pancreatic-duodenal homeobox 1 silencing in gastric cancer. 2010 , 31, 1552-60	22
1704	Architectural epigenetics: mitotic retention of mammalian transcriptional regulatory information. 2010 , 30, 4758-66	41
1703	DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. 2010 , 70, 5840-50	51
1702	Genome-wide analysis of DNA methylation and gene expression changes in the mouse lung following subchronic arsenate exposure. 2010 , 117, 404-17	38
1701	IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. 2010 , 31, 342-9	81
1700	The fission yeast inhibitor of growth (ING) protein Png1p functions in response to DNA damage. 2010 , 285, 15786-93	8
1699	Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. 2010 , 16, 398-409	43

1698	Cancer epigenetics. 2010 , 95, 299-349	8
1697	DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine. 2010 , 31, 184-91	14
1696	Computational analysis of genome-wide DNA methylation during the differentiation of human embryonic stem cells along the endodermal lineage. 2010 , 20, 1441-50	137
1695	Estrogen-mediated epigenetic repression of large chromosomal regions through DNA looping. 2010 , 20, 733-44	73
1694	A candidate gene study of folate-associated one carbon metabolism genes and colorectal cancer risk. 2010 , 19, 1812-21	33
1693	Three DNA methylation epigenotypes in human colorectal cancer. 2010 , 16, 21-33	183
1692	Epigenetic modifications in double-strand break DNA damage signaling and repair. 2010 , 16, 4543-52	111
1691	Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. 2010 , 140, 1607-14	106
1690	Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. 2010 , 12, 1244-56	27
1689	CpG island hypermethylation in human astrocytomas. 2010 , 70, 2718-27	111
1688	The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. 2010 , 16, 2949-58	110
1687	Identification of a functional network of human epigenetic silencing factors. 2010 , 285, 422-33	53
1686	Evaluation of affinity-based genome-wide DNA methylation data: effects of CpG density, amplification bias, and copy number variation. 2010 , 20, 1719-29	100
1685	Therapeutic modulation of epigenetic drivers of drug resistance in ovarian cancer. 2010 , 2, 319-29	28
1684	Multiple functions for Drosophila Mcm10 suggested through analysis of two Mcm10 mutant alleles. 2010 , 185, 1151-65	23
1683	General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. 2010 , 70, 1398-407	86
1682	Identification of DIM-7, a protein required to target the DIM-5 H3 methyltransferase to chromatin. 2010 , 107, 8310-5	36
1681	Epigenetic mechanisms regulating normal and malignant haematopoiesis: new therapeutic targets for clinical medicine. 2010 , 12, e6	12

1680	CpG methylation of half-CRE sequences creates C/EBPalpha binding sites that activate some tissue-specific genes. 2010 , 107, 20311-6	166
1679	Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome. 2010 , 285, 36112-20	34
1678	A real-time assay for CpG-specific cytosine-C5 methyltransferase activity. 2010 , 38, e107	37
1677	Epigenetic drugs for cancer treatment and prevention: mechanisms of action. 2010 , 1, 239-51	12
1676	Epigenetic regulation of protein glycosylation. 2010 , 1, 253-61	14
1675	Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. 2010 , 9, 2309-21	66
1674	Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. 2010 , 3, 917-28	2
1673	DAMD to epigenetic silence. 2010 , 107, 3-4	14
1672	Application of OMICS technologies in occupational and environmental health research; current status and projections. 2010 , 67, 136-43	72
1671	Epigenetics and cancer. 2010 , 109, 598-605	76
1670	Epigenetically altered wound healing in keloid fibroblasts. 2010 , 130, 2489-96	112
1669	Research resource: genome-wide profiling of methylated promoters in endometriosis reveals a subtelomeric location of hypermethylation. 2010 , 24, 1872-85	76
1668	Cancer-related epigenome changes associated with reprogramming to induced pluripotent stem cells. 2010 , 70, 7662-73	65
1667	Epigenetic alterations in aging. 2010 , 109, 586-97	162
1666	Global reactivation of epigenetically silenced genes in prostate cancer. 2010 , 3, 1084-92	35
1665	Role of epigenomics in ovarian and endometrial cancers. 2010 , 2, 419-47	40
1664	Genetics of medulloblastoma: clues for novel therapies. 2010 , 10, 811-23	10
1663	Epigenetic mechanisms and the relationship to childhood asthma. 2010 , 36, 950-61	64

1662	Widespread and tissue specific age-related DNA methylation changes in mice. 2010 , 20, 332-40	391
1661	Chromatin remodeling in mammary gland differentiation and breast tumorigenesis. 2010 , 2, a004515	28
1660	DNA methylation profiling in cancer. 2010 , 12, e23	28
1659	Influence of sex hormones on cancer progression. 2010 , 28, 4038-44	137
1658	Genetically engineered mouse models in cancer research. 2010 , 106, 113-64	127
1657	Modulation of gene expression in ovarian cancer by active and repressive histone marks. 2010 , 2, 39-51	4
1656	Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. 2010 , 5, 716-29	48
1655	Epigenomics and ovarian carcinoma. 2010 , 4, 543-70	33
1654	Blood-based peptide, genetic, and epigenetic biomarkers for diagnosing gastrointestinal cancers. 2010 , 4, 459-71	1
1653	A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. 2010 , 285, 41062-73	50
1652	Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. 2010 , 31, 376-81	25
1651	H3K27 trimethylation is an early epigenetic event of p16INK4a silencing for regaining tumorigenesis in fusion reprogrammed hepatoma cells. 2010 , 285, 18828-37	24
1650	Pathology tissue-chromatin immunoprecipitation, coupled with high-throughput sequencing, allows the epigenetic profiling of patient samples. 2010 , 107, 21535-40	50
1649	DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences. 2010 , 107, 234-9	57
1648	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. 2010 , 28, E6	40
1647	HHMD: the human histone modification database. 2010 , 38, D149-54	65
1646	Aberrant crypt foci: the case for inclusion as a biomarker for colon cancer. 2010 , 2, 1705-16	25
1645	Di-butyl phthalate-induced hypomethylation of the c-myc gene in rat liver. 2010 , 26, 407-16	17

1644	Differential expression of microRNAs between eutopic and ectopic endometrium in ovarian endometriosis. 2010 , 2010, 369549	106
1643	Induced Pluripotent Stem Cells: The Dragon Awakens. 2010 , 60, 278-285	9
1642	Research recommendations for selected IARC-classified agents. 2010 , 118, 1355-62	64
1641	DNA methylation and normal chromosome behavior in <i>Neurospora</i> depend on five components of a histone methyltransferase complex, DCDC. 2010 , 6, e1001196	72
1640	Cancer and neurodegeneration: between the devil and the deep blue sea. 2010 , 6, e1001257	106
1639	Epigenetic biomarkers. 2012 , 355, 189-216	16
1638	MetMap enables genome-scale Methylation typing for determining methylation states in populations. 2010 , 6, e1000888	9
1637	Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. 2010 , 70, 8015-24	28
1636	The Salmonella mutagenicity assay: the stethoscope of genetic toxicology for the 21st century. 2010 , 118, 1515-22	101
1635	Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. 2010 , 63, 994-8	22
1634	Omics Approaches in Cancer Research. 2010 , 1-9	4
1633	Dietary folate, alcohol and B vitamins in relation to LINE-1 hypomethylation in colon cancer. 2010 , 59, 794-9	113
1632	VEZF1 elements mediate protection from DNA methylation. 2010 , 6, e1000804	77
1631	DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination. 2010 , 3, ra80	230
1630	mTORC1 signaling in Parkinson's disease and L-DOPA-induced dyskinesia: A sensitized matter. 2010 , 9, 2713-8	26
1629	p73 is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. 2010 , 9, 2758-2766	5
1628	A novel neuronal differentiation mechanism in which Slug and Escargot are major players. 2010 , 9, 2767-2775	
1627	Dancing with p53: The role of p38MAPK in mitosis of p53-deficient tetraploid cells. 2010 , 9, 2776-2784	

1626	Kinases involved in Rec8 phosphorylation revealed. 2010 , 9, 2740-2748	1
1625	New functions for the Snail family of transcription factors: Two-faced proteins. 2010 , 9, 2706-8	5
1624	DNA demethylating antineoplastic strategies: a comparative point of view. 2010 , 1, 197-209	28
1623	New functions for the Snail family of transcription factors: Two-faced proteins. 2010 , 9, 2731-2739	24
1622	Methylation destiny: Moira takes account of histones and RNA polymerase II. 2010 , 5, 89-95	21
1621	HDAC inhibitors repress the polycomb protein BMI1. 2010 , 9, 2705-6	3
1620	Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. 2010 , 5, 499-508	92
1619	Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A. 2010 , 37, 963-71	10
1618	[Epigenetic perturbations and cancer: innovative therapeutic strategies against cancer]. 2010 , 97, 1265-74	0
1617	Feedback regulators of hypoxia-inducible factors and their role in cancer biology. 2010 , 9, 2749-63	52
1616	A longitudinal study of epigenetic variation in twins. 2010 , 5, 516-26	243
1615	Epigenetic mechanisms involved in the pathogenesis of hepatobiliary malignancies. 2010 , 2, 233-243	21
1614	Lung cancer therapeutics that target signaling pathways: an update. 2010 , 4, 631-45	19
1613	Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. 2010 , 70, 6968-77	63
1612	DNA methylation-based fecal biomarkers for the noninvasive screening of GI cancers. 2010 , 6, 333-6	11
1611	Epigenetic approaches for the detection of fetal DNA in maternal plasma. 2010 , 1, 30-5	18
1610	Epigenetic targets in human neoplasms. 2010 , 2, 221-32	5
1609	Specific hypomethylated CpGs at the IGF2 locus act as an epigenetic biomarker for familial adenomatous polyposis colorectal cancer. 2010 , 2, 365-75	8

1608	PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer. 2010 , 10, 520-7	42
1607	Quantitative analysis of promoter methylation in exfoliated epithelial cells isolated from breast milk of healthy women. 2010 , 5, 645-55	28
1606	Lymphoma stem cells: enough evidence to support their existence?. 2010 , 95, 293-302	48
1605	The human sperm epigenome and its potential role in embryonic development. 2010 , 16, 37-47	179
1604	Tumor-initiating and -propagating cells: cells that we would like to identify and control. 2010 , 12, 506-15	68
1603	Methylation of DNA in cancer. 2010 , 52, 145-67	103
1602	The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. 2010 , 19, 1049-66	212
1601	Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. 2010 , 132, 3164-76	131
1600	Single-tube analysis of DNA methylation with silica superparamagnetic beads. 2010 , 56, 1022-5	38
1599	Molecular Techniques for DNA Methylation Studies. 2010 , 199-228	1
1598	Introduction: epigenetics and cancer. 2010 , 70, 1-23	24
1597	Cancer epigenome. 2010 , 70, 247-76	32
1596	DNA demethylating agents and epigenetic therapy of cancer. 2010 , 70, 327-40	37
1595	Detection of DNA methylation changes in body fluids. 2010 , 71, 177-207	4
1594	An Overview of Biomarkers and Molecular Signatures in HCC. 2010 , 2, 809-23	23
1593	Methylation-specific loop-mediated isothermal amplification for detecting hypermethylated DNA in simplex and multiplex formats. 2010 , 56, 1287-96	25
1592	Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer. 2010 , 2, 731-42	32
1591	The epigenetics of breast cancer. 2010 , 4, 242-54	200

1590	Protocol matters: which methylome are you actually studying?. 2010 , 2, 587-98	39
1589	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. 2010 , 9, 125	119
1588	Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. 2010 , 9, 259	27
1587	Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. 2010 , 9, 59	154
1586	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. 2010 , 8, 56	79
1585	Development of a diagnostic microarray assay to assess the risk of recurrence of prostate cancer based on PITX2 DNA methylation. 2010 , 12, 345-53	24
1584	Large non-coding RNAs: missing links in cancer?. 2010 , 19, R152-61	416
1583	Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. 2010 , 31, 93-101	30
1582	Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. 2010 , 70, 1430-40	305
1581	Epigenetic Targets and Cancer Drug Discovery. 2010 , 245-260	
1580	Telomeres, Epigenetics, and Aging. 2010 , 205-225	
1579	The Role of the Epigenome in Human Cancers. 2010 , 471-486	
1578	The possible evolutionary role of tumors in the origin of new cell types. 2010 , 74, 177-85	8
1577	Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. 2010 , 87, 83-91	72
1576	Epigenetic mechanisms regulating CYP19 transcription in human breast adipose fibroblasts. 2010 , 321, 123-30	32
1575	Breast cancer genomes--form and function. 2010 , 20, 4-14	43
1574	Epigenetics in AML. 2010 , 23, 463-8	21
1573	Aberrant epigenetic landscape in cancer: how cellular identity goes awry. 2010 , 19, 698-711	440

1572	Interplay between microRNAs and the epigenetic machinery: an intricate network. 2010 , 1799, 694-701	229
1571	Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. 2010 , 1799, 717-25	139
1570	Protein lysine acetylation in cellular function and its role in cancer manifestation. 2010 , 1799, 702-16	35
1569	NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. 2010 , 16, 709-28	28
1568	TSPYL5 is involved in cell growth and the resistance to radiation in A549 cells via the regulation of p21(WAF1/Cip1) and PTEN/AKT pathway. 2010 , 392, 448-53	30
1567	Natural antisense transcripts regulate gene expression in an epigenetic manner. 2010 , 396, 177-81	51
1566	Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. 2010 , 6, 591-602	68
1565	Targeting DNA methylation for epigenetic therapy. 2010 , 31, 536-46	235
1564	Genetics for the practicing dermatologist. 2010 , 29, 127-36	8
1563	Histone methyltransferases in cancer. 2010 , 21, 209-20	228
1562	Redefining regulation of DNA methylation by RNA interference. 2010 , 96, 191-8	9
1561	DNA methylation profiling using bisulfite-based epityping of pooled genomic DNA. 2010 , 52, 255-8	34
1560	Role of nuclear architecture in epigenetic alterations in cancer. 2010 , 75, 507-15	8
1559	DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. 2010 , 2, 467-81	30
1558	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. 2010 , 330, 228-31	915
1557	Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. 2010 , 12, R3	113
1556	Epigenetic codes in stem cells and cancer stem cells. 2010 , 70, 177-99	13
1555	(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. 2010 , 53, 5197-212	114

1554	The most redundant sequences in human CpG island library are derived from mitochondrial genome. 2010 , 8, 81-91	1
1553	Epigenetic changes in the myelodysplastic syndrome. 2010 , 24, 317-30	80
1552	Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells. 2010 , 12, 177-83	119
1551	The application of next generation sequencing in DNA methylation analysis. 2010 , 1, 85-101	45
1550	Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. 2010 , 2, 9-38	18
1549	Epigenetics in cancer. 2010 , 31, 27-36	1743
1548	Circulating Fetal DNA/RNA in Maternal Plasma for Aneuploidy Detection. 2010 , 111-124	
1547	Methylation determines fibroblast activation and fibrogenesis in the kidney. 2010 , 16, 544-50	462
1546	DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. 2010 , 6, 1415-31	15
1545	Histone deacetylase inhibitors in the therapy of cancer: much to learn. 2010 , 2, 723-5	9
1544	Mammalian Su(var) genes in chromatin control. 2010 , 26, 471-501	83
1543	Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 2010 , 51, 2275-84	37
1542	Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. 2010 , 70, 568-74	69
1541	Role of Epigenetics in the Placenta: Alterations in DNA Promoter Methylation and Imprinted Genes. 2011 , 28, 103-109	
1540	EZH2-mediated concordant repression of Wnt antagonists promotes E-cadherin-dependent hepatocarcinogenesis. 2011 , 71, 4028-39	166
1539	Oligomerization and binding of the Dnmt3a DNA methyltransferase to parallel DNA molecules: heterochromatic localization and role of Dnmt3L. 2011 , 286, 24200-7	72
1538	The electrical signals measurement for nanowire field effect transistors. 2011 ,	
1537	Identification of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers. 2011 , 6, 1217-27	43

1536	Dimeric bisbenzimidazoles inhibit the DNA methylation catalyzed by the murine Dnmt3a catalytic domain. 2011 , 26, 295-300	18
1535	Genome-wide DNA methylation profiling of CpG islands in breast cancer identifies novel genes associated with tumorigenicity. 2011 , 71, 2988-99	125
1534	Genomic DNA hypomethylation by histone deacetylase inhibition implicates DNMT1 nuclear dynamics. 2011 , 31, 4119-28	48
1533	Bookmarking the genome: maintenance of epigenetic information. 2011 , 286, 18355-61	66
1532	DNA methylation: superior or subordinate in the epigenetic hierarchy?. 2011 , 2, 607-17	400
1531	Manifestations and mechanisms of stem cell aging. 2011 , 193, 257-66	241
1530	Differential expression of thrombospondin (THBS1) in tumorigenic and nontumorigenic prostate epithelial cells in response to a chromatin-binding soy peptide. 2011 , 63, 623-36	18
1529	A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. 2011 , 103, 47-60	59
1528	Cell type-specific DNA methylation at intragenic CpG islands in the immune system. 2011 , 21, 1074-86	215
1527	Cancer epigenetics: above and beyond. 2011 , 21, 275-88	73
1526	Determining coding CpG islands by identifying regions significant for pattern statistics on Markov chains. 2011 , 10,	0
1525	Transcription factor binding sites and other features in human and Drosophila proximal promoters. 2011 , 52, 205-22	8
1524	Epigenetics and Chronic Diseases: An Overview. 2011 , 1-20	4
1523	Mechanisms of Epigenetic Gene Activation in Disease: Dynamics of DNA Methylation and Demethylation. 2011 , 55-73	
1522	Epigenetic regulation of cancer-associated genes in ovarian cancer. 2011 , 12, 983-1008	49
1521	Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 2011 , 43, 875-8	554
1520	DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter. 2011 , 20, 4299-310	145
1519	Cancer Epigenetics. 2011 , 521-534	4

1518	Promises and challenges of anticancer drugs that target the epigenome. 2011 , 3, 547-65	19
1517	Role of epigenetic events in chemical carcinogenesis--a justification for incorporating epigenetic evaluations in cancer risk assessment. 2011 , 21, 289-97	66
1516	Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. 2011 , 106, 1110-8	86
1515	Cancer epigenetics: linking basic biology to clinical medicine. 2011 , 21, 502-17	223
1514	Epigenetic Aberrant Hypermethylation of DNA in Endometrial Cancer: Application as a Biomarker. 2011 , 02, 610-615	
1513	Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer. 2011 , 5, 61-76	100
1512	Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. 2011 , 5, 438-53	28
1511	The Biology of Acute Lymphoblastic Leukemia. 2011 , 29-61	1
1510	Epigenetic-based therapies in cancer: progress to date. 2011 , 71, 2391-403	81
1509	DNA methylation changes in cancer. 2011 , 101, 447-57	15
1508	Mechanistic and functional links between histone methylation and DNA methylation. 2011 , 101, 335-48	11
1507	Genome-wide distribution of DNA methylation at single-nucleotide resolution. 2011 , 101, 459-77	2
1506	Evaluation of the Infinium Methylation 450K technology. 2011 , 3, 771-84	426
1505	Epigenetic Aspects of Chronic Diseases. 2011 ,	2
1504	Role of DNA methylation in the development of diffuse-type gastric cancer. 2011 , 83, 241-9	46
1503	DNA methylation and cancer. 2011 , 67, 1-23	81
1502	Epigenomics in hematopoietic transplantation: novel treatment strategies. 2011 , 3, 611-23	6
1501	Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. 2011 , 108, 3642-7	554

1500	Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. 2011 , 133, 16746-9	130
1499	Emerging Therapeutic Targets in Ovarian Cancer. 2011 ,	1
1498	Synthesis and biochemical evaluation of α (2)-isoxazoline derivatives as DNA methyltransferase 1 inhibitors. 2011 , 54, 7663-77	131
1497	Simultaneous single-molecule mapping of protein-DNA interactions and DNA methylation by MAPit. 2011 , Chapter 21, Unit 21.22	13
1496	Evolutionary mechanisms and diversity in cancer. 2011 , 112, 217-53	72
1495	The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. 2011 , 179, 1645-56	55
1494	Advances in DNA methylation: 5-hydroxymethylcytosine revisited. 2011 , 412, 831-6	80
1493	Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. 2011 , 412, 1472-5	13
1492	Transcriptional regulation by DNA methylation. 2011 , 37 Suppl 1, S8-12	31
1491	DNA methylation as a pathogenic event and as a therapeutic target in AML. 2011 , 37 Suppl 1, S13-8	30
1490	Heterogeneity and degree of TIMP4, GATA4, SOX18, and EGFL7 gene promoter methylation in non-small cell lung cancer and surrounding tissues. 2011 , 204, 492-500	30
1489	Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). 2011 , 311, 85-95	56
1488	[Targeted therapies and radiation therapy in non-small cell lung cancer]. 2011 , 15, 527-35	4
1487	Repeated assessment by high-throughput assay demonstrates that sperm DNA methylation levels are highly reproducible. 2011 , 96, 1325-30	6
1486	Epigenetics and psychoneuroimmunology: mechanisms and models. 2011 , 25, 25-39	43
1485	National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. 2011 , 17, 443-54	35
1484	Retrotransposon-specific DNA hypomethylation and two-step loss-of-imprinting during WW45 haploinsufficiency-induced hepatocarcinogenesis. 2011 , 404, 728-34	9
1483	Transcriptional activity of DNMT3B in pancreatic cancer cells: effects of -149 (C->T) promoter polymorphism. 2011 , 415, 220-3	9

1482	Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. 2011 , 74, 2031-8	90
1481	Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. 2011 , 32, 35-41	68
1480	The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. 2011 , 722, 106-13	25
1479	Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. 2011 , 54, 705-15	127
1478	Methylation profile as a new tool for classification of hepatocellular carcinoma. 2011 , 54, 602-3	7
1477	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. 2011 , 108, 4394-9	183
1476	Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. 2011 , 98, 182-8	13
1475	Genome-wide profiling of DNA methylation in human cancer cells. 2011 , 98, 280-7	40
1474	Purification of histone ubiquitin ligases from HeLa cells. 2011 , 54, 315-25	6
1473	The path to epigenetic treatment of memory disorders. 2011 , 96, 13-8	33
1472	Molecular mechanisms of genomic imprinting and clinical implications for cancer. 2011 , 13, e2	61
1471	Epigenetic modifications and human pathologies: cancer and CVD. 2011 , 70, 47-56	78
1470	Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. 2011 , 18, 867-74	297
1469	Targeting the epigenome with bioactive food components for cancer prevention. 2011 , 4, 275-92	70
1468	Accurate genome-scale percentage DNA methylation estimates from microarray data. 2011 , 12, 197-210	62
1467	Profiling epigenetic alterations in disease. 2011 , 711, 162-77	42
1466	Unraveling the genetics of cancer: genome sequencing and beyond. 2011 , 12, 407-30	73
1465	The origins of cancer robustness and evolvability. 2011 , 3, 17-30	114

1464	MicroRNA, epigenetic machinery and lung cancer. 2011 , 2, 35-44	10
1463	Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. 2011 , 30, 41	81
1462	Epigenetics in breast cancer: what's new?. 2011 , 13, 225	92
1461	A comparative analysis of DNA methylation across human embryonic stem cell lines. 2011 , 12, R62	75
1460	Potential of histone deacetylase inhibitors for bladder cancer treatment. 2011 , 11, 959-65	6
1459	The use of microarray technologies in mantle cell lymphoma. 2011 , 48, 166-71	2
1458	Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. 2011 , 41, 334-44	12
1457	Developmental exposure to TCDD reduces fertility and negatively affects pregnancy outcomes across multiple generations. 2011 , 31, 344-50	138
1456	[Letter to the editor]: whole-genome amplification of sodium bisulfite-converted DNA can substantially impact quantitative methylation analysis using pyrosequencing. 2011 , 50, 161-4	3
1455	MicroRNA-124a and microRNA-34b/c are frequently methylated in all histological types of colorectal cancer and polyps, and in the adjacent normal mucosa. 2011 , 2, 175-180	29
1454	Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. 2011 , 30, 231-9	50
1453	Current Drug Targets and the Druggable Genome. 320-332	2
1452	Principles for the post-GWAS functional characterisation of risk loci. 2011 ,	
1451	Discovery and Optimization of Inhibitors of DNA Methyltransferase as Novel Drugs for Cancer Therapy. 2011 ,	4
1450	Metastasis Genes: Epigenetics. 85-95	
1449	Epigenetic biomarkers in ovarian cancer. 31-40	
1448	Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. 2011 , 2, 627-37	330
1447	Methylation profile of selected TSGs in non-cancerous thyroid tissue adjacent to primary PTC. 2011 , 4, 191-197	3

1446	Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. 2011 , 2011, 679457	19
1445	The transcribed-ultraconserved regions: a novel class of long noncoding RNAs involved in cancer susceptibility. 2011 , 11, 340-52	31
1444	Epigenetic regulation in cancer development. 2011 , 16, 2682-94	16
1443	Epigenomics of ovarian cancer and its chemoprevention. 2011 , 2, 67	29
1442	Structural and functional profiling of the human histone methyltransferase SMYD3. 2011 , 6, e22290	74
1441	ZIC1 is downregulated through promoter hypermethylation, and functions as a tumor suppressor gene in colorectal cancer. 2011 , 6, e16916	51
1440	Phenobarbital mediates an epigenetic switch at the constitutive androstane receptor (CAR) target gene Cyp2b10 in the liver of B6C3F1 mice. 2011 , 6, e18216	68
1439	Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. 2011 , 6, e20584	51
1438	The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. 2011 , 6, e20793	39
1437	Pipeline for large-scale microdroplet bisulfite PCR-based sequencing allows the tracking of hepitype evolution in tumors. 2011 , 6, e21332	8
1436	Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications. 2011 , 6, e21382	32
1435	The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. 2011 , 6, e23332	76
1434	Epigenetic subgroups of esophageal and gastric adenocarcinoma with differential GATA5 DNA methylation associated with clinical and lifestyle factors. 2011 , 6, e25985	10
1433	Human RNA polymerase II-association factor 1 (hPaf1/PD2) regulates histone methylation and chromatin remodeling in pancreatic cancer. 2011 , 6, e26926	20
1432	Epigenetic regulation of miR-212 expression in lung cancer. 2011 , 6, e27722	64
1431	Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. 2011 , 6, e28503	73
1430	The Human Epigenome. 2011 ,	
1429	Epigenetics in cardiovascular disease. 2011 , 26, 209-15	66

1428	DNA methylation and cancer: ghosts and angels above the genes. 2011 , 23, 69-76	46
1427	Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer. 2011 , 21, 760-8	30
1426	P16 methylation is an early event in cervical carcinogenesis. 2011 , 21, 452-6	20
1425	Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. 2011 , 11, 882-93	14
1424	Emerging targeted therapies for pediatric acute myeloid leukemia. 2011 , 6, 354-66	1
1423	Vitamin D deficiency: universal risk factor for multifactorial diseases?. 2011 , 12, 97-106	24
1422	Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. 2011 , 6, 131-45	25
1421	c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6. 2011 , 117, 4065-75	29
1420	Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. 2011 , 117, 3658-68	118
1419	Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. 2011 , 117, 234-41	82
1418	Deregulation of Aiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. 2011 , 117, 1917-27	30
1417	EV(I1)olution of AML DNA methylation. 2011 , 117, 4-5	
1416	An event of shear importance. 2011 , 117, 5-7	1
1415	Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. 2011 , 118, 3062-71	25
1414	Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. 2011 , 6, e16080	122
1413	Maintenance therapy in ovarian cancer: Molecular basis and therapeutic approach. 2011 , 2, 173-180	3
1412	Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. 2011 , 26, 19-27	97
1411	Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. 2011 , 102, 18-24	63

1410	Methylation silencing of angiotensin-like 4 in rat and human mammary carcinomas. 2011 , 102, 1337-43	17
1409	Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines. 2011 , 34, 110-23	17
1408	Infection, immunoregulation, and cancer. 2011 , 240, 141-59	69
1407	HDAC2 promotes cell migration/invasion abilities through HIF-1 β stabilization in human oral squamous cell carcinoma. 2011 , 40, 567-75	41
1406	DNA methylation in oral squamous cell carcinoma: molecular mechanisms and clinical implications. 2011 , 17, 771-8	24
1405	Principles for the post-GWAS functional characterization of cancer risk loci. 2011 , 43, 513-8	326
1404	DNMT3A mutations in acute myeloid leukemia. 2011 , 43, 289-90	46
1403	Cancer epigenetics reaches mainstream oncology. 2011 , 17, 330-9	920
1402	Resistance, epigenetics and the cancer ecosystem. 2011 , 17, 288-9	47
1401	Unravelling the complexity of metastasis - molecular understanding and targeted therapies. 2011 , 11, 735-48	277
1400	A decade of exploring the cancer epigenome - biological and translational implications. 2011 , 11, 726-34	2002
1399	Charting histone modifications and the functional organization of mammalian genomes. 2011 , 12, 7-18	852
1398	A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. 2011 , 30, 1923-35	43
1397	Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. 2011 , 30, 480-93	112
1396	Monocyte polarization: the relationship of genome-wide changes in H4 acetylation with polarization. 2011 , 12, 445-56	16
1395	Initial impact of the sequencing of the human genome. 2011 , 470, 187-97	750
1394	DSC3 expression is regulated by p53, and methylation of DSC3 DNA is a prognostic marker in human colorectal cancer. 2011 , 104, 1013-9	50
1393	Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. 2011 , 15, 2735-44	67

1392	Exposing the DNA methylome iceberg. 2011 , 36, 381-7	70
1391	Genome-wide approaches for cancer gene discovery. 2011 , 29, 558-68	25
1390	Chromatin and heritability: how epigenetic studies can complement genetic approaches. 2011 , 27, 172-6	18
1389	Emerging patterns of epigenomic variation. 2011 , 27, 242-50	30
1388	Radiation-induced epigenetic alterations after low and high LET irradiations. 2011 , 707, 24-33	86
1387	Epigenetic mechanisms in hepatocellular carcinoma: how environmental factors influence the epigenome. 2011 , 727, 55-61	133
1386	The negative side of retinoic acid receptors. 2011 , 33, 631-40	9
1385	On the origin of cancer: can we ignore coherence?. 2011 , 106, 380-90	25
1384	Treatment of higher-risk myelodysplastic syndrome. 2011 , 38, 673-81	10
1383	Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer. 2011 , 121, 224-9	21
1382	Quantitative detection of RASSF1A DNA promoter methylation in tumors and serum of patients with serous epithelial ovarian cancer. 2011 , 123, 581-7	44
1381	Aberrant DNA methylation of cancer-related genes in giant breast fibroadenoma: a case report. 2011 , 5, 516	7
1380	Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results. 2011 , 204, 21.e1-7	23
1379	The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. 2011 , 39, 1007-1017.e1	38
1378	Dissecting DNA hypermethylation in cancer. 2011 , 585, 2078-86	58
1377	Translational application of epigenetic alterations: ovarian cancer as a model. 2011 , 585, 2112-20	23
1376	Environmental regulation of the neural epigenome. 2011 , 585, 2049-58	66
1375	Reactive oxygen species downregulate catalase expression via methylation of a CpG island in the Oct-1 promoter. 2011 , 585, 3436-41	41

1374	POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis. 2011 , 1391, 125-31	19
1373	Quantitative mass spectrometry reveals the epigenome as a target of arsenic. 2011 , 192, 113-7	33
1372	Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. 2011 , 20, 606-19	389
1371	Detection and quantification of rare mutations with massively parallel sequencing. 2011 , 108, 9530-5	817
1370	Hallmarks of cancer: the next generation. <i>Cell</i> , 2011 , 144, 646-74	56.2 39819
1369	Breast cancer methylomes establish an epigenomic foundation for metastasis. 2011 , 3, 75ra25	215
1368	Epigenetic diet: impact on the epigenome and cancer. 2011 , 3, 503-18	253
1367	CpG islands and the regulation of transcription. 2011 , 25, 1010-22	2006
1366	Chromatin immunoprecipitation and high-throughput sequencing from paraffin-embedded pathology tissue. 2011 , 6, 1905-19	47
1365	Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. 2011 , 60, 397-411	396
1364	Radiation-induced genomic instability: are epigenetic mechanisms the missing link?. 2011 , 87, 179-91	63
1363	[DNA sequence-specific ligands: XIV. Synthesis of fluorescent biologically active dimeric bisbenzimidazoles-DB(3, 4, 5, 7, 11)]. 2011 , 37, 530-41	9
1362	Studying the epigenome using next generation sequencing. 2011 , 48, 721-30	87
1361	Regulation of mammalian DNA methyltransferases: a route to new mechanisms. 2011 , 12, 647-56	272
1360	Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. 2011 , 18, 687-97	62
1359	DNA methylation topology: potential of a chromatin landmark for epigenetic drug toxicology. 2011 , 3, 761-70	15
1358	Identification and validation of DNA methylation markers to predict lymph node metastasis of esophageal squamous cell carcinomas. 2011 , 18, 1185-94	19
1357	Elevated expression of the stem cell marker CD133 associated with Line-1 demethylation in hepatocellular carcinoma. 2011 , 18, 2373-80	28

1356	Insulation of tumor suppressor genes by the nuclear factor CTCF. 2011 , 89, 479-88	15
1355	Nanoparticles: a promising modality in the treatment of sarcomas. 2011 , 28, 260-72	12
1354	Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. 2011 , 15, 293-304	117
1353	Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures. 2011 , 105, 241-51	30
1352	Cancer stem cell theory in gastrointestinal malignancies: recent progress and upcoming challenges. 2011 , 46, 1145-57	20
1351	Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. 2011 , 458, 313-22	269
1350	Elevated expression of USP22 in correlation with poor prognosis in patients with invasive breast cancer. 2011 , 137, 1245-53	86
1349	Statistical approaches for the analysis of DNA methylation microarray data. 2011 , 129, 585-95	50
1348	Die Rolle der Mikro-RNA bei der Entstehung onkologischer Erkrankungen. 2011 , 17, 487-494	2
1347	DNA methylation changes in murine breast adenocarcinomas allow the identification of candidate genes for human breast carcinogenesis. 2011 , 22, 249-59	11
1346	Epigenetic aberrations during oncogenesis. 2011 , 68, 1681-702	133
1345	The optimal conditions for the estimation of DNA methylation levels using high throughput microarray derived DNA immunoprecipitation (MeDIP)-enrichment in human bloods. 2011 , 3, 185-192	1
1344	Mammalian cell dedifferentiation as a possible outcome of stress. 2011 , 7, 488-93	20
1343	Molecular marks for epigenetic identification of developmental and cancer stem cells. 2011 , 2, 27-53	29
1342	5-Aza-2'-deoxycytidine stress response and apoptosis in prostate cancer. 2011 , 2, 339-48	20
1341	Epigenetic regulation of prostate cancer. 2011 , 2, 151-69	25
1340	Klotho, an anti-senescence related gene, is frequently inactivated through promoter hypermethylation in colorectal cancer. 2011 , 32, 729-35	67
1339	Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. 2011 , 32, 737-44	27

1338	Beyond genome-wide association studies: new strategies for identifying genetic determinants of hypertension. 2011 , 13, 442-51	27
1337	CGGBP1 regulates cell cycle in cancer cells. 2011 , 12, 28	18
1336	Gain of DNA methylation is enhanced in the absence of CTCF at the human retinoblastoma gene promoter. 2011 , 11, 232	23
1335	Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study. 2011 , 11, 463	8
1334	Squamosin modulates histone H3 phosphorylation levels and induces G1 phase arrest and apoptosis in cancer cells. 2011 , 11, 58	12
1333	MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. 2011 , 10, 124	94
1332	Deciphering causal and statistical relations of molecular aberrations and gene expressions in NCI-60 cell lines. 2011 , 5, 186	7
1331	Comparison of DNA methylation levels of repetitive loci during bovine development. 2011 , 5 Suppl 4, S3	9
1330	Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. 2011 , 4, 45	34
1329	Identification of DNA methylation changes associated with human gastric cancer. 2011 , 4, 82	44
1328	The inhibition of the mammalian DNA methyltransferase 3a (Dnmt3a) by dietary black tea and coffee polyphenols. 2011 , 12, 16	49
1327	Identifying hypermethylated CpG islands using a quantile regression model. 2011 , 12, 54	7
1326	Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. 2011 , 225, 222-31	104
1325	Reduced levels of 5- α -reductase 2 in adult prostate tissue and implications for BPH therapy. 2011 , 71, 1317-24	30
1324	The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication. 2011 , 3, 48-73	12
1323	Epigenetics, Nutrition, and Cancer. 2011 , 127-143	
1322	Enrichment of Nur77 mediated by retinoic acid receptor β leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. 2011 , 53, 865-74	32
1321	Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. 2011 , 54, 1031-42	66

1320	DNA methylation profiling reveals a predominant immune component in breast cancers. 2011 , 3, 726-41	167
1319	DNMT3B gene amplification predicts resistance to DNA demethylating drugs. 2011 , 50, 527-34	27
1318	The DNA methylome of benign and malignant parathyroid tumors. 2011 , 50, 735-45	44
1317	Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. 2011 , 117, 5121-32	21
1316	Frequent changes in subtelomeric DNA methylation patterns and its relevance to telomere regulation during human hepatocarcinogenesis. 2011 , 128, 857-68	22
1315	Alu and Sat α hypomethylation in <i>Helicobacter pylori</i> -infected gastric mucosae. 2011 , 128, 33-9	51
1314	Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. 2011 , 129, 1170-9	32
1313	New insights into the inactivation of gastric tumor suppressor RUNX3: the role of <i>H. pylori</i> infection. 2011 , 112, 381-6	14
1312	Control of RUNX3 by histone methyltransferases. 2011 , 112, 394-400	22
1311	Cooperative DNA and histone binding by Uhrf2 links the two major repressive epigenetic pathways. 2011 , 112, 2585-93	53
1310	In defense of the somatic mutation theory of cancer. 2011 , 33, 341-3	49
1309	Anthraquinone-sensitized photooxidation of 5-methylcytosine in DNA leading to piperidine-induced efficient strand cleavage. 2011 , 17, 2225-35	3
1308	Structure and function of mammalian DNA methyltransferases. 2011 , 12, 206-22	481
1307	Methyltransferases prefer monomer over core-trimmed nucleosomes as in vitro substrates. 2011 , 415, 84-6	7
1306	The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. 2011 , 35, 295-6	7
1305	Epigenomics of leukemia: from mechanisms to therapeutic applications. 2011 , 3, 581-609	85
1304	Epigenetic regulation in myelodysplastic syndromes: implications for therapy. 2011 , 20, 465-93	16
1303	Epigenetic regulations in adult stem cells: the role of DNA methyltransferase in stem cell aging. 2011 , 3, 671-3	5

1302	Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. 2011 , 6, 1413-24	30
1301	Genomic and epigenomic integration identifies a prognostic signature in colon cancer. 2011 , 17, 1535-45	125
1300	Epigenome sequencing comes of age in development, differentiation and disease mechanism research. 2011 , 3, 207-20	5
1299	DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. 2011 , 13, 280-9	54
1298	Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder. 2011 , 6, 1454-62	97
1297	Methylation of specific CpG sites in the P2 promoter of parathyroid hormone-related protein determines the invasive potential of breast cancer cell lines. 2011 , 6, 1035-46	8
1296	Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells. 2011 , 6, 1138-48	7
1295	Epigenetic mechanisms regulating neural development and pediatric brain tumor formation. 2011 , 8, 119-32	7
1294	Cancer chemoprevention by targeting the epigenome. 2011 , 12, 1925-56	140
1293	DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. 2011 , 1, e9	24
1292	ANCA vasculitis meets epigenetics--closing in on the molecular roots of disease. 2011 , 26, 1146-8	2
1291	Control of DNMT1 abundance in epigenetic inheritance by acetylation, ubiquitylation, and the histone code. 2011 , 4, pe3	39
1290	Simultaneous methylation profiling of tumor suppressor genes in head and neck cancer. 2011 , 30, 17-24	15
1289	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. 2011 , 20, 823-9	80
1288	The effect of radiation quality on genomic DNA methylation profiles in irradiated human cell lines. 2011 , 175, 575-87	64
1287	Epigenetic Contributions in Autoimmune Disease. 2011 ,	2
1286	DNA methyltransferase inhibition may limit cancer cell growth by disrupting ribosome biogenesis. 2011 , 6, 128-33	7
1285	Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. 2011 , 6, 1425-35	28

1284	Detection of p16INK4a promoter methylation status in non-small cell lung cancer by a fluorescence polarization assay. 2011 , 20, 138-42	1
1283	Epigenetic imbalance and the floral developmental abnormality of the in vitro-regenerated oil palm <i>Elaeis guineensis</i> . 2011 , 108, 1453-62	52
1282	Epigenetic regulation of cellular adhesion in cancer. 2011 , 32, 1414-8	14
1281	MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells. 2011 , 18, 711-9	69
1280	Epigenetic mechanisms and cancer: an interface between the environment and the genome. 2011 , 6, 804-19	174
1279	GADD45A protein plays an essential role in active DNA demethylation during terminal osteogenic differentiation of adipose-derived mesenchymal stem cells. 2011 , 286, 41083-94	81
1278	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. 2011 , 17, 1582-90	81
1277	Making sense of cancer genomic data. 2011 , 25, 534-55	260
1276	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. 2011 , 21, 1028-41	144
1275	Genes methylated by DNA methyltransferase 3b are similar in mouse intestine and human colon cancer. 2011 , 121, 1748-52	58
1274	Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation. 2011 , 286, 13193-204	31
1273	Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. 2011 , 6, 692-702	767
1272	Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. 2011 , 17, 4531-40	31
1271	Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. 2011 , 3, 451-70	26
1270	MethylViewer: computational analysis and editing for bisulfite sequencing and methyltransferase accessibility protocol for individual templates (MAPit) projects. 2011 , 39, e5	26
1269	Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. 2011 , 71, 1752-62	49
1268	Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. 2011 , 22, 2516-2522	29
1267	Retrotransposon-encoded reverse transcriptase in the genesis, progression and cellular plasticity of human cancer. 2011 , 3, 1141-57	21

1266	Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay. 2011 , 2011, 868095	11
1265	The role of epigenetic alterations in papillary thyroid carcinogenesis. 2011 , 2011, 895470	12
1264	Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. 2011 , 17, 4341-54	131
1263	Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. 2011 , 10, 313-24	8
1262	Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. 2011 , 9, 1139-51	38
1261	Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. 2011 , 9, 1152-62	27
1260	Epigenetic alteration of DNA in mucosal wash fluid predicts invasiveness of colorectal tumors. 2011 , 4, 674-83	35
1259	Molecular biology. Preference by exclusion. 2011 , 331, 1017-8	3
1258	IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. 2011 , 108, 11977-82	39
1257	Aberrant TGF β /SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. 2011 , 6, 727-39	28
1256	Synergism between DNA methylation and macroH2A1 occupancy in epigenetic silencing of the tumor suppressor gene p16(CDKN2A). 2011 , 39, 1326-35	35
1255	Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. 2011 , 12, 278-87	29
1254	2'-deoxy-5,6-dihydro-5-azacytidine - a less toxic alternative of 2'-deoxy-5-azacytidine: a comparative study of hypomethylating potential. 2011 , 6, 769-76	22
1253	Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. 2011 , 6, 508-15	39
1252	Cancer Epigenetics for the 21st Century: What's Next?. 2011 , 2, 604-6	45
1251	Copy number alterations in urothelial carcinomas: their clinicopathological significance and correlation with DNA methylation alterations. 2011 , 32, 462-9	11
1250	Regulation of histone H2A and H2B deubiquitination and Xenopus development by USP12 and USP46. 2011 , 286, 7190-201	76
1249	Detection of HOXA9 gene methylation in tumor tissues and induced sputum samples from primary lung cancer patients. 2011 , 49, 699-704	35

1248	Lsh, chromatin remodeling family member, modulates genome-wide cytosine methylation patterns at nonrepeat sequences. 2011 , 108, 5626-31	66
1247	Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts. 2011 , 17, 2819-29	21
1246	Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. 2011 , 10, 1611-23	12
1245	p66Alpha-MBD2 coiled-coil interaction and recruitment of Mi-2 are critical for globin gene silencing by the MBD2-NuRD complex. 2011 , 108, 7487-92	87
1244	Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. 2011 , 71, 4653-63	76
1243	Sodium butyrate inhibits the self-renewal capacity of endometrial tumor side-population cells by inducing a DNA damage response. 2011 , 10, 1430-9	25
1242	Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. 2011 , 108, 18061-6	98
1241	mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. 2011 , 17, 3600-18	192
1240	Aberrant promoter methylation in overexpression of CITED1 in papillary thyroid cancer. 2011 , 21, 511-7	19
1239	Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status. 2011 , 105, 1533-41	39
1238	Septin roles in tumorigenesis. 2011 , 392, 725-38	64
1237	Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1. 2011 , 71, 5859-70	49
1236	Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification. 2011 , 2011, 780836	6
1235	Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance. 2011 , 7, e1001286	88
1234	The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer. 2011 , 3, 1426-53	31
1233	Epigenetic mechanisms of mouse interstrain variability in genotoxicity of the environmental toxicant 1,3-butadiene. 2011 , 122, 448-56	44
1232	Recent advances in molecular diagnosis of thyroid cancer. 2011 , 2011, 384213	13
1231	Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. 2011 , 3, 1691-707	63

1230	Smad phosphoisoform signaling specificity: the right place at the right time. 2011 , 32, 1578-88	87
1229	WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. 2011 , 32, 1625-33	27
1228	Distinct p53 genomic binding patterns in normal and cancer-derived human cells. 2011 , 10, 4237-49	73
1227	Improving early breast cancer detection: focus on methylation. 2011 , 22, 24-29	43
1226	The microenvironment and molecular biology of the multiple myeloma tumor. 2011 , 110, 19-42	55
1225	Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. 2011 , 1, 598-607	500
1224	Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. 2012 , 33, 436-41	61
1223	Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia. 2012 , 6, 85-100	4
1222	Dnmt3a protects active chromosome domains against cancer-associated hypomethylation. 2012 , 8, e1003146	36
1221	RASSF Signalling and DNA Damage: Monitoring the Integrity of the Genome?. 2012 , 2012, 141732	12
1220	The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. 2012 , 8, e1002517	88
1219	Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. 2012 , 8, e1002604	43
1218	Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker. 2012 , 13, 11044-62	21
1217	Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. 2012 , 13, 1951-2011	106
1216	The pituitary tumour epigenome: aberrations and prospects for targeted therapy. 2012 , 8, 486-94	34
1215	Interactions between epigenetics and metabolism in cancers. 2012 , 2, 163	59
1214	The regulatory mechanism of the LY6K gene expression in human breast cancer cells. 2012 , 287, 38889-900	21
1213	Reproductive consequences of developmental phytoestrogen exposure. 2012 , 143, 247-60	129

1212	DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. 2012 , 21, 93-104	73
1211	Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. 2012 , 21, 569-75	36
1210	Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. 2012 , 18, 3387-95	79
1209	A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. 2012 , 22, 2339-55	137
1208	Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. 2012 , 2, 1004-23	70
1207	Analysis of aberrant methylation in DNA repair genes during malignant transformation of human bronchial epithelial cells induced by cadmium. 2012 , 125, 412-7	73
1206	Controversies in fumonisin mycotoxicology and risk assessment. 2012 , 31, 215-35	30
1205	SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. 2012 , 7, 447-57	27
1204	Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. 2012 , 72, 2304-13	121
1203	DNA methylation changes associated with risk factors in tumors of the upper aerodigestive tract. 2012 , 7, 270-7	16
1202	A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells. 2012 , 13, 681-93	16
1201	The tumor suppressor gene ARF as a sensor of oxidative stress. 2012 , 12, 704-15	18
1200	An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. 2012 , 12, 439-52	24
1199	Function and disruption of DNA methyltransferase 3a cooperative DNA binding and nucleoprotein filament formation. 2012 , 40, 569-80	84
1198	Polycomb and DNA methyltransferase complexes participate in global and focal epigenetic alteration in cancer cells. 2012 , 4, 133-4	
1197	CpG island hypermethylation-associated silencing of small nucleolar RNAs in human cancer. 2012 , 9, 881-90	45
1196	Widespread plasticity in CTCF occupancy linked to DNA methylation. 2012 , 22, 1680-8	371
1195	Copy-number-aware differential analysis of quantitative DNA sequencing data. 2012 , 22, 2489-96	23

1194	RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. 2012 , 132, 687-94	35
1193	Human cytomegalovirus infection is sensitive to the host cell DNA methylation state and alters global DNA methylation capacity. 2012 , 7, 585-93	23
1192	DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences. 2012 , 7, 1039-51	15
1191	Gadd45a inhibits cell migration and invasion by altering the global RNA expression. 2012 , 13, 1112-22	19
1190	Comparative effects of retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. 2012 , 107, 781-90	86
1189	Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. 2012 , 53, 123-9	48
1188	DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. 2012 , 97, E1004-13	80
1187	Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. 2012 , 106, 248-53	131
1186	Oligoamine analogues in combination with 2-difluoromethylornithine synergistically induce re-expression of aberrantly silenced tumour-suppressor genes. 2012 , 442, 693-701	27
1185	A novel pit pattern identifies the precursor of colorectal cancer derived from sessile serrated adenoma. 2012 , 107, 460-9	133
1184	Genome-scale analysis of aberrant DNA methylation in colorectal cancer. 2012 , 22, 271-82	466
1183	The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/ β -catenin signaling and silenced in common carcinomas. 2012 , 31, 3901-12	69
1182	Position-dependent correlations between DNA methylation and the evolutionary rates of mammalian coding exons. 2012 , 109, 15841-6	30
1181	Transcriptional regulation of the protocadherin β cluster during Her-2 protein-induced mammary tumorigenesis results from altered N-glycan branching. 2012 , 287, 24941-54	18
1180	The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). 2012 , 287, 5366-78	29
1179	Role of the SMYD3 histone methyltransferase in tumorigenesis: local or global effects?. 2012 , 11, 1865	14
1178	Evaluation of single CpG sites as proxies of CpG island methylation states at the genome scale. 2012 , 40, 11490-8	33
1177	Altered DNA methylation profile in idiopathic pulmonary fibrosis. 2012 , 186, 525-35	163

1176	A DNA methylation fingerprint of 1628 human samples. 2012 , 22, 407-19	273
1175	Epigenetics of estrogen receptor-negative primary breast cancer. 2012 , 12, 371-82	10
1174	Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. 2012 , 22, 2315-27	158
1173	Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers. 2012 , 33, 1542-7	8
1172	Incorporating Genomic Annotation into a Hidden Markov Model for DNA Methylation Tiling Array Data. 2012 , 11,	
1171	Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice. 2012 , 50, 1699-701	5
1170	The STAT3-DNMT1 connection. 2012 , 1, 257-60	10
1169	Epigenetic regulation of kallikrein-related peptidases: there is a whole new world out there. 2012 , 393, 319-30	30
1168	Methylation markers for urine-based detection of bladder cancer: the next generation of urinary markers for diagnosis and surveillance of bladder cancer. 2012 , 2012, 503271	25
1167	Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events. 2012 , 2012, 519807	11
1166	DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil. 2012 , 2012, 697691	10
1165	CpG site-specific hypermethylation of p16INK4 in peripheral blood lymphocytes of PAH-exposed workers. 2012 , 21, 182-90	52
1164	Epigenetic alterations in bladder cancer and their potential clinical implications. 2012 , 2012, 546917	17
1163	Interplay between menin and K-Ras in regulating lung adenocarcinoma. 2012 , 287, 40003-11	30
1162	Expression of P16 cell cycle inhibitor in human cord blood CD34+ expanded cells following co-culture with bone marrow-derived mesenchymal stem cells. 2012 , 17, 334-40	7
1161	A DNA hypermethylation module for the stem/progenitor cell signature of cancer. 2012 , 22, 837-49	196
1160	Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. 2012 , 9, 74-9	22
1159	Polysialyltransferase: a new target in metastatic cancer. 2012 , 12, 925-39	68

1158	Carcinogenesis: Mechanisms and models. 2012 , 406-425	1
1157	Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma. 2013 , 19, 1192-200	10
1156	Aberrant methylation of RASSF2A in human pancreatic ductal adenocarcinoma and its relation to clinicopathologic features. 2012 , 41, 206-11	13
1155	Epigenome-Wide Association Studies (EWAS) in Cancer. 2012 , 13, 308-13	34
1154	Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma. 2012 , 4, 33-42	10
1153	Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review). 2012 , 41, 393-406	44
1152	Discovery and mechanism of natural products as modulators of histone acetylation. 2012 , 13, 1029-47	20
1151	B1, a novel topoisomerase II inhibitor, induces apoptosis and cell cycle G1 arrest in lung adenocarcinoma A549 cells. 2012 , 23, 191-9	12
1150	5-Aza-2'-deoxycytidine increases the sensitivity of human bone marrow mesenchymal stem cells to chemotherapeutic agents by demethylation of p73. 2012 , 34, 108-15	4
1149	GSTP1 methylation and polymorphism increase the risk of breast cancer and the effects of diet and lifestyle in breast cancer patients. 2012 , 4, 1097-1103	30
1148	Estimation of a non-parametric variable importance measure of a continuous exposure. 2012 , 6, 1059-1099	13
1147	PIK3CA mutation and methylation influences the outcome of colorectal cancer. 2012 , 3, 565-570	26
1146	Cancer Epigenomics. 2012 , 129-159	2
1145	Nanowire TransistorBased DNA Methylation Detection. 2012 , 713-730	
1144	Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. 2012 , 28, 454-63	122
1143	The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. 2012 , 9, 64-5	43
1142	Gene silencing of EREG mediated by DNA methylation and histone modification in human gastric cancers. 2012 , 92, 1033-44	31
1141	Widespread existence of cytosine methylation in yeast DNA measured by gas chromatography/mass spectrometry. 2012 , 84, 7249-55	67

1140	Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. 2012 , 143, 550-563	269
1139	DNA methylation and microRNA dysregulation in cancer. 2012 , 6, 567-78	194
1138	DNA methylation screening and analysis. 2012 , 889, 385-406	25
1137	De novo DNA methyltransferases: oncogenes, tumor suppressors, or both?. 2012 , 28, 474-9	29
1136	Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. 2012 , 33, 1277-85	52
1135	Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. 2012 , 7, 1368-78	55
1134	Factors influencing epigenetic mechanisms and related diseases. 2012 , 17, 192-4	13
1133	IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data. 2012 , 28, 729-30	231
1132	Environmental chemical exposures and human epigenetics. 2012 , 41, 79-105	310
1131	5-aza-2'-deoxycytidine-induced genome rearrangements are mediated by DNMT1. 2012 , 31, 5172-9	41
1130	Polyamine-based small molecule epigenetic modulators. 2012 , 3, 14-21	27
1129	DNA methylation pattern of the SLC25A43 gene in breast cancer. 2012 , 7, 300-6	13
1128	Epigenetic deregulation of the COX pathway in cancer. 2012 , 51, 301-13	34
1127	Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. 2012 , 72, 4714-23	30
1126	Sus1/ENY2: a multitasking protein in eukaryotic gene expression. 2012 , 47, 556-68	12
1125	Diet, epigenetics, and cancer. 2012 , 863, 377-93	13
1124	The Human Epigenome. 2012 , 5-20	3
1123	Whole DNA methylome profiling in mice exposed to secondhand smoke. 2012 , 7, 1302-14	17

1122	Trials with 'epigenetic' drugs: an update. 2012 , 6, 657-82	184
1121	Nuclear exclusion of TET1 is associated with loss of 5-hydroxymethylcytosine in IDH1 wild-type gliomas. 2012 , 181, 675-83	83
1120	MTHFR C677T polymorphisms are associated with aberrant methylation of the IGF-2 gene in transitional cell carcinoma of the bladder. 2012 , 26, 77-83	9
1119	Balance of DNA methylation and demethylation in cancer development. 2012 , 13, 173	22
1118	Gel-free multiplexed reduced representation bisulfite sequencing for large-scale DNA methylation profiling. 2012 , 13, R92	183
1117	Molecular biology techniques for the surgeon. 2012 , 2, 5	
1116	Methylation subtypes and large-scale epigenetic alterations in gastric cancer. 2012 , 4, 156ra140	134
1115	A DNA methyltransferase modulator inspired by peyssonenyne natural product structures. 2012 , 7, 2101-12	3
1114	Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. 2012 , 56, 1817-27	117
1113	SOX1 functions as a tumor suppressor by antagonizing the WNT/ β -catenin signaling pathway in hepatocellular carcinoma. 2012 , 56, 2277-87	75
1112	Diagnostic values of GHSR DNA methylation pattern in breast cancer. 2012 , 135, 705-13	15
1111	Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. 2012 , 136, 705-15	40
1110	ChAP-MS: a method for identification of proteins and histone posttranslational modifications at a single genomic locus. 2012 , 2, 198-205	92
1109	Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. 2012 , 187, 302-9	34
1108	Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. 2012 , 188, 300-6	9
1107	Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. 2012 , 33, 1951-72	14
1106	Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development. 2012 , 35, 473-9	24
1105	Epigenetics in cancer and inflammation. 2012 , 1, 7-12	3

1104	Non-invasive prenatal diagnosis of aneuploidies: new technologies and clinical applications. 2012 , 4, 46	26
1103	Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. 2012 , 53, 1722-7	37
1102	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. 2012 , 119, 5201-10	111
1101	UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. 2012 , 31, 5061-72	69
1100	DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. 2012 , 11, 370-82	49
1099	Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancers. 2012 , 2, 979-81	7
1098	The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. 2012 , 11, 286-95	75
1097	Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy. 2012 , 31 Suppl 1, S62-71	19
1096	Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. 2012 , 55, 1465-77	106
1095	Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. 2012 , 72, 335-45	251
1094	Next generation sequencing in epigenetics: insights and challenges. 2012 , 23, 192-9	61
1093	Functional heterologous expression and purification of a mammalian methyl-CpG binding domain in suitable yield for DNA methylation profiling assays. 2012 , 82, 332-8	4
1092	Developing novel non-hydroxamate histone deacetylase inhibitors: the chelidamic warhead. 2012 , 3, 298-304	6
1091	Binding profiles of chromatin-modifying proteins are predictive for transcriptional activity and promoter-proximal pausing. 2012 , 19, 126-38	8
1090	Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. 2012 , 26, 4937-50	72
1089	Study of methylation of histone H3 lysine 9 and H3 lysine 27 during X chromosome inactivation in three types of cells. 2012 , 20, 769-78	12
1088	Development of second generation epigenetic agents. 2012 , 3, 135-161	15
1087	Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. 2012 , 119, 2346-57	69

1086	Indole-derived psammaplin A analogues as epigenetic modulators with multiple inhibitory activities. 2012 , 55, 9467-91	43
1085	Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. 2012 , 180, 616-25	45
1084	CpG methylation recruits sequence specific transcription factors essential for tissue specific gene expression. 2012 , 1819, 763-70	72
1083	Targeting epigenetic mediators of gene expression in thoracic malignancies. 2012 , 1819, 836-45	11
1082	Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells. 2012 , 420, 325-30	16
1081	Histone modifications as a pathogenic mechanism of colorectal tumorigenesis. 2012 , 44, 1276-89	36
1080	BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. 2012 , 36, e177-82	46
1079	Development of a novel approach, the epigenome-based outlier approach, to identify tumor-suppressor genes silenced by aberrant DNA methylation. 2012 , 322, 204-12	29
1078	Novel therapeutic approaches for small cell lung cancer: the future has arrived. 2012 , 36, 156-73	4
1077	Cancer epigenomics: beyond genomics. 2012 , 22, 50-5	369
1076	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. 2012 , 3, 1091-6	270
1075	Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors. 2012 , 51, 1133-43	18
1074	The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. 2012 , 12, 350	12
1073	Cancer specific promoter CpG Islands hypermethylation of HOP homeobox (HOPX) gene and its potential tumor suppressive role in pancreatic carcinogenesis. 2012 , 12, 397	32
1072	Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas. 2012 , 10, 209	24
1071	A genetic association study of DNA methylation levels in the DRD4 gene region finds associations with nearby SNPs. 2012 , 8, 31	31
1070	Epigenetics of regional lymph node metastasis in solid tumors. 2012 , 29, 747-56	8
1069	The role of aberrant promoter hypermethylation of DACT1 in bladder urothelial carcinoma. 2012 , 26, 319-24	2

1068	DNA Methylation Alterations in Human Cancers. 2012 , 29-52	2
1067	AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. 2012 , 132, 1689-97	64
1066	Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. 2012 , 14, 336-45	22
1065	Promoter methylation in coagulation F7 gene influences plasma FVII concentrations and relates to coronary artery disease. 2012 , 49, 192-9	50
1064	Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. 2012 , 287, 38427-32	151
1063	Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. 2012 , 3, 623	95
1062	The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells. 2012 , 16, 1758-65	11
1061	Molecular modeling of inhibitors of human DNA methyltransferase with a crystal structure: discovery of a novel DNMT1 inhibitor. 2012 , 87, 219-47	45
1060	Intra-tumour heterogeneity: a looking glass for cancer?. 2012 , 12, 323-34	1320
1059	Targeted therapy for gastric adenocarcinoma. 2012 , 65, 437-70	9
1058	Linking epithelial-to-mesenchymal-transition and epigenetic modifications. 2012 , 22, 404-10	25
1057	Antibody-free reading of the histone code using a simple chemical sensor array. 2012 , 134, 11674-80	89
1056	DNA Methylation Analysis by MALDI Mass Spectrometry. 2012 ,	3
1055	Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells. 2012 , 55, 10937-47	70
1054	Global DNA hypomethylation in cancer: review of validated methods and clinical significance. 2012 , 50, 1733-42	74
1053	Cancer chemoprevention and nutriepigenetics: state of the art and future challenges. 2013 , 329, 73-132	119
1052	Cancer cell signaling pathways targeted by spice-derived nutraceuticals. 2012 , 64, 173-97	139
1051	Epigenetics of colorectal cancer. 2012 , 143, 1442-1460.e1	173

1050	Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. 2012 , 181, 1847-61	65
1049	Development and therapeutic impact of HDAC6-selective inhibitors. 2012 , 84, 756-65	107
1048	DNA methylation based biomarkers: practical considerations and applications. 2012 , 94, 2314-37	118
1047	DNA methylation inhibitors in cancer: recent and future approaches. 2012 , 94, 2280-96	162
1046	Regulation of leptin receptor expression in human papillary thyroid cancer cells. 2012 , 66, 469-73	15
1045	LTBP-2 confers pleiotropic suppression and promotes dormancy in a growth factor permissive microenvironment in nasopharyngeal carcinoma. 2012 , 325, 89-98	24
1044	Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro. 2012 , 34, 959-68	44
1043	BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. 2012 , 23, 1324-32	60
1042	Epigenetic modifications and diabetic nephropathy. 2012 , 31, 139-50	9
1041	Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. 2012 , 79, 678-97	13
1040	Chromatin remodeling in cancer: a gateway to regulate gene transcription. 2012 , 6, 611-9	62
1039	Epigenetic alterations involved in cancer stem cell reprogramming. 2012 , 6, 620-36	142
1038	DNA methylation-based biomarkers in serum of patients with breast cancer. 2012 , 751, 304-325	50
1037	Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. 2012 , 7, 1413-20	60
1036	Cell-type specific DNA methylation patterns define human breast cellular identity. 2012 , 7, e52299	19
1035	Identification and functional analysis of 9p24 amplified genes in human breast cancer. 2012 , 31, 333-41	65
1034	Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1. 2012 , 55, 7378-91	63
1033	High-throughput sequencing of the methylome using two-base encoding. 2012 , 910, 71-86	1

1032	The Molecular Toxicology of Mitomycin C. 2012 , 6, 243-299	10
1031	Risk-association of DNA methyltransferases polymorphisms with gastric cancer in the Southern Chinese population. 2012 , 13, 8364-78	40
1030	Toxic endpoints in the study of human exposure to environmental chemicals. 2012 , 112, 89-115	11
1029	Ectopic expression of guanylyl cyclase C and endogenous ligand guanylin correlates significantly with Helicobacter pylori infection in gastric carcinogenesis. 2012 , 29, 1748-57	2
1028	Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese. 2012 , 29, 1561-8	12
1027	Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer. 2012 , 14, 559-71	46
1026	Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. 2012 , 14, 29-33	43
1025	Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. 2012 , 19, 2726-32	39
1024	DNA methylation: TET proteins-guardians of CpG islands?. 2011 , 13, 28-35	236
1023	Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. 2012 , 31, 2062-74	284
1022	Screening for mutation R882 in the DNMT3A gene in Chinese patients with hematological disease. 2012 , 96, 229-33	3
1021	Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. 2012 , 55, 8066-74	73
1020	LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. 2012 , 19, 4238-43	36
1019	Current limitations and future opportunities for epigenetic therapies. 2012 , 4, 425-46	34
1018	Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. 2012 , 31, 1408-18	68
1017	DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. 2012 , 31, 1609-22	279
1016	Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. 2012 , 31, 4409-19	60
1015	Panobinostat for the treatment of multiple myeloma. 2012 , 21, 733-47	29

1014	Omics Era in Stem Cell Research: Data Integration of Multi-regulatory Layers. 2012 , 119-137	
1013	Epigenetic Modifications in Chemical Carcinogenesis. 2012 , 631-643	3
1012	Histone deacetylase inhibitors and rational combination therapies. 2012 , 116, 199-237	35
1011	DNA methylation profiling identifies epigenetic dysregulation in pancreatic islets from type 2 diabetic patients. 2012 , 31, 1405-26	301
1010	Epigenetics in ovarian cancer. 2012 , 863, 253-69	31
1009	Cancer Epigenetics. 2012 ,	4
1008	Stem Cell Epigenetics and Human Disease. 2012 , 481-501	
1007	DNMT3A rs36012910 A>G polymorphism and gastric cancer susceptibility in a Chinese population. 2012 , 39, 10949-55	15
1006	Tumor suppressor BLU inhibits proliferation of nasopharyngeal carcinoma cells by regulation of cell cycle, c-Jun N-terminal kinase and the cyclin D1 promoter. 2012 , 12, 267	15
1005	Clinicopathological significance and prognostic value of DNA methyltransferase 1, 3a, and 3b expressions in sporadic epithelial ovarian cancer. 2012 , 7, e40024	34
1004	Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. 2012 , 7, e41036	128
1003	Targeted DNA methylation using an artificially bisected M.HhaI fused to zinc fingers. 2012 , 7, e44852	27
1002	A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. 2012 , 7, e45357	129
1001	Multi-analyte network markers for tumor prognosis. 2012 , 7, e52973	18
1000	Clinicopathological significance of PTPN12 expression in human breast cancer. 2012 , 45, 1334-40	13
999	The molecular biology of brain metastasis. 2012 , 2012, 723541	36
998	Epigenetics modifications and therapeutic prospects in human thyroid cancer. 2012 , 3, 40	32
997	Epigenetic Contributions to the Relationship between Cancer and Dietary Intake of Nutrients, Bioactive Food Components, and Environmental Toxicants. 2011 , 2, 91	18

996	Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. 2012 , 2, 26	178
995	Circulating Methylated DNA as Biomarkers for Cancer Detection. 2012 ,	1
994	Functional networks of human epigenetic factors. 30-46	
993	Detection of CpG methylation patterns by affinity capture methods. 197-209	1
992	Cancer classification by genome-wide and quantitative DNA methylation analyses. 293-305	
991	Epigenomic diversity of colorectal cancer. 491-504	
990	Breaking the Silence: The Interplay Between Transcription Factors and DNA Methylation. 2012 ,	3
989	Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. 2012 , 18, 389-400	45
988	Runt-related transcription factor 3 methylation as a possible prognosticator in muscle-invasive bladder cancer. 2011 , 10, 205-11	3
987	Bladder Cancer and Schistosomiasis: Is There a Difference for the Association?. 2012 ,	1
986	Methylation in Tumorigenesis. 2012 ,	
985	Pitx2 expression promotes p21 expression and cell cycle exit in neural stem cells. 2012 , 11, 884-92	11
984	G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. 2012 , 122, 1469-86	342
983	The chemopreventive and chemotherapeutic potentials of tea polyphenols. 2012 , 13, 191-9	46
982	Aberrant DNA Methylation in Endometrial Cancer. 2012 , 471-480	
981	Therapeutic Polycomb Targeting in Human Cancer. 2012 , 2, 22-29	
980	Molecular biomarkers of glioblastoma: current targets and clinical implications. 2012 , 63	4
979	Linking genome to epigenome. 2012 , 4, 297-309	23

978	Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. 2012 , 26, 1247-54	109
977	Epigenetic protein families: a new frontier for drug discovery. 2012 , 11, 384-400	1003
976	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. 2012 , 483, 479-83	1373
975	Epigenetic resensitization to platinum in ovarian cancer. 2012 , 72, 2197-205	287
974	A systematic comparison of quantitative high-resolution DNA methylation analysis and methylation-specific PCR. 2012 , 7, 772-80	52
973	Early-stage formation of an epigenetic field defect in a mouse colitis model, and non-essential roles of T- and B-cells in DNA methylation induction. 2012 , 31, 342-51	59
972	Molecular markers of adrenocortical tumors. 2012 , 106, 549-56	11
971	Cancer proteomics. 2012 , 31, 583-605	47
970	Chemical and biochemical approaches in the study of histone methylation and demethylation. 2012 , 32, 815-67	43
969	Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer. 2012 , 228, 88-98	41
968	Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. 2012 , 51, 949-60	59
967	Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers. 2012 , 18, 641-8	25
966	Epigenetics: Concepts and relevance to IBD pathogenesis. 2012 , 18, 1982-96	45
965	Frequent epigenetic inactivation of the chaperone SGNE1/7B2 in human gliomas. 2012 , 131, 612-22	8
964	Prognostic role of methylated free circulating DNA in colorectal cancer. 2012 , 131, 2308-19	73
963	Tumor suppressor function of RUNX3 in breast cancer. 2012 , 113, 1470-7	35
962	Epigenetic regulation of miRNA genes in acute leukemia. 2012 , 26, 395-403	61
961	Dynamics of DNA methylation in aging and Alzheimer's disease. 2012 , 31 Suppl 1, S42-8	64

960	Distinct DNA methylomes of newborns and centenarians. 2012 , 109, 10522-7	563
959	Applications of High-Throughput Sequencing. 2012 , 27-53	1
958	Epigenetic cancer therapy: rationales, targets and drugs. 2012 , 31, 4257-65	118
957	How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. 2012 , 12, 621-8	121
956	Regulation of histone modification and chromatin structure by the p53-PADI4 pathway. 2012 , 3, 676	95
955	Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. 2012 , 33, 1487-93	89
954	Potential usefulness of DNA methylation as a risk marker for digestive cancer associated with inflammation. 2012 , 12, 489-97	8
953	Efficient hit-finding approaches for histone methyltransferases: the key parameters. 2012 , 17, 85-98	5
952	Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action. 2012 , 55, 1-35	117
951	Hypomethylation of Alu repetitive elements in esophageal mucosa, and its potential contribution to the epigenetic field for cancerization. 2012 , 23, 865-73	17
950	Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population. 2012 , 39, 5553-60	26
949	Methylation pattern of oncogene HRAS gene promoter region and its clinical relevance to urocytic tumorigenesis. 2012 , 39, 8431-7	4
948	F10 gene hypomethylation, a putative biomarker for glioma prognosis. 2012 , 107, 479-85	8
947	DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas. 2012 , 27, 709-14	23
946	Molecular targeted agents for gastric and gastroesophageal junction cancer. 2012 , 42, 313-27	18
945	Epigenetics of colorectal cancer. 2012 , 81, 312-8	44
944	High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. 2012 , 103, 73-9	42
943	Diagnostic and prognostic molecular biomarkers for prostate cancer. 2012 , 60, 125-41	63

942	DNA methylation screening identifies driver epigenetic events of cancer cell survival. 2012 , 21, 655-667	198
941	p53 at the crossroads between cancer and neurodegeneration. 2012 , 52, 1727-33	71
940	Sensitization of tumor cells by targeting histone deacetylases. 2012 , 83, 987-94	26
939	Mutational determinants of epigenetic instability in myeloid malignancies. 2012 , 39, 80-96	2
938	Epigenetic alterations in ultraviolet radiation-induced skin carcinogenesis: interaction of bioactive dietary components on epigenetic targets. 2012 , 88, 1066-74	51
937	An ISFET based translinear sensor for DNA methylation detection. 2012 , 161, 156-162	27
936	Evolution of the cancer genome. 2012 , 28, 155-63	98
935	A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation. 2012 , 125, 720-6	11
934	Epigenetics and blood disorders. 2012 , 158, 307-22	9
933	Down-regulation of the cavin family proteins in breast cancer. 2012 , 113, 322-8	57
932	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. 2012 , 130, 885-95	20
931	Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. 2012 , 130, 1319-28	70
930	DNA methylation biomarkers for lung cancer. 2012 , 33, 287-96	96
929	DNA methylation biomarker candidates for early detection of colon cancer. 2012 , 33, 363-72	49
928	Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. 2012 , 33, 277-85	30
927	Hypermethylation in bladder cancer: biological pathways and translational applications. 2012 , 33, 347-61	42
926	Epigenetic changes induced by oxidative stress in colorectal cancer cells: methylation of tumor suppressor RUNX3. 2012 , 33, 403-12	87
925	Epigenetic silencing of sFRP1 activates the canonical Wnt pathway and contributes to increased cell growth and proliferation in hepatocellular carcinoma. 2012 , 33, 325-36	39

924	Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RAR β in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. 2012 , 132, 165-73	65
923	Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. 2012 , 30, 249-57	57
922	Next generation sequencing and a new era of medicine. 2013 , 62, 920-32	19
921	Role of epigenetic and miR-22 and miR-29b alterations in the downregulation of Mat1a and Mthfr genes in early preneoplastic livers in rats induced by 2-acetylaminofluorene. 2013 , 52, 318-27	32
920	Epigenetic regulation and measurement of epigenetic changes. 2013 , 15, 373-81	21
919	Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. 2013 , 32, 2249-60, 2260.e1-21	98
918	DACT1, an antagonist to Wnt/ β -catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. 2013 , 15, R23	65
917	Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. 2013 , 5, 3	143
916	DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. 2013 , 34, 2857-61	9
915	Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. 2013 , 34, 1635-9	34
914	Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. 2013 , 61, 262-9	40
913	Down-regulation of DNA methyltransferase 3B in staurosporine-induced apoptosis and its mechanism in human hepatocarcinoma cell lines. 2013 , 376, 111-9	12
912	The significance of epigenetic alterations in lung carcinogenesis. 2013 , 40, 309-25	63
911	Micro- and nanofluidic technologies for epigenetic profiling. 2013 , 7, 41301	17
910	Docking of a novel DNA methyltransferase inhibitor identified from high-throughput screening: insights to unveil inhibitors in chemical databases. 2013 , 17, 337-44	17
909	Detection of aberrant methylation of tumor suppressor genes in plasma from cancer patients. 2013 , 2, 20-24	6
908	Molecular patterns in the evolution of serrated lesion of the colorectum. 2013 , 132, 1800-10	26
907	Aberrant regulation of DNA methylation in amyotrophic lateral sclerosis: a new target of disease mechanisms. 2013 , 10, 722-33	50

906	Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer. 2013 , 109, 408-15	35
905	Genomic instability in multiple myeloma: mechanisms and therapeutic implications. 2013 , 13 Suppl 1, S69-82	28
904	DNA methylation profile dynamics of tissue-dependent and differentially methylated regions during mouse brain development. 2013 , 14, 82	11
903	Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. 2013 , 13, 146	14
902	Stem cell plasticity in development and cancer: epigenetic origin of cancer stem cells. 2013 , 61, 545-65	22
901	Basic mechanics of DNA methylation and the unique landscape of the DNA methylome in metal-induced carcinogenesis. 2013 , 43, 493-514	95
900	A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. 2013 , 60, 1452-7	51
899	Next generation analysis of breast cancer genomes for precision medicine. 2013 , 339, 1-7	19
898	Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. 2013 , 16, 292-300	34
897	The role of DNA methylation as biomarkers in the clinical management of lung cancer. 2013 , 7, 363-83	31
896	3-D DNA methylation phenotypes correlate with cytotoxicity levels in prostate and liver cancer cell models. 2013 , 14, 11	15
895	Molecular and cellular processes underlying the hallmarks of head and neck cancer. 2013 , 270, 2585-93	25
894	From natural products to drugs for epimutation computer-aided drug design. 2013 , 170, 164-75	20
893	Epigenetic modifications induced by Helicobacter pylori infection through a direct microbe-gastric epithelial cells cross-talk. 2013 , 202, 327-37	19
892	Role of epigenetic modulation for the treatment of sarcoma. 2013 , 14, 454-64	14
891	Decreased expression of the DBC2 gene and its clinicopathological significance in breast cancer: correlation with aberrant DNA methylation. 2013 , 35, 1175-81	7
890	Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy. 2013 , 30, 587-604	25
889	Targeting deregulated epigenetic control in cancer. 2013 , 228, 2103-8	20

888	Sloped-Gate Voltage Method for Improving Measurement of Poly-Si Nanowire FET in Aqueous Environment. 2013 , 117, 9004-9008	
887	Histone mimics: digging down under. 2013 , 8, 228-233	3
886	Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. 2013 , 71, 115-21	64
885	A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L. 2013 , 56, 8972-83	53
884	Colorectal cancer cells Caco-2 and HCT116 resist epigenetic effects of isothiocyanates and selenium in vitro. 2013 , 52, 1327-41	21
883	Discovery of a Pair of Diastereomers as Potent HDACs Inhibitors: Determination of Absolute Configuration, Biological Activity Comparison and Computational Study. 2013 , 3,	2
882	Nasopharyngeal Carcinoma. 2013 ,	5
881	Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells. 2013 , 15, 192-203	13
880	Genotoxicity of tobacco smoke-derived aromatic amines and bladder cancer: current state of knowledge and future research directions. 2013 , 27, 2090-100	38
879	A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. 2013 , 4, e00558-12	93
878	Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. 2013 , 88, 231-45	23
877	Excision of 8-oxoguanine from methylated CpG dinucleotides by human 8-oxoguanine DNA glycosylase. 2013 , 587, 3129-34	14
876	Micro- and nanoscale devices for the investigation of epigenetics and chromatin dynamics. 2013 , 8, 709-18	47
875	Myelodysplastic syndromes: toward a risk-adapted treatment approach. 2013 , 6, 611-24	21
874	Novel methylation biomarker panel for the early detection of pancreatic cancer. 2013 , 19, 6544-6555	103
873	Cancer genome landscapes. 2013 , 339, 1546-58	5058
872	Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. 2013 , 33, 4321-33	45
871	Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies. 2013 , 5, 919-42	30

870	Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model. 2013 , 222, 295-302	16
869	Epigenetic regulation of microRNA expression in renal cell carcinoma. 2013 , 436, 79-84	15
868	Comparison of the structural and dynamic effects of 5-methylcytosine and 5-chlorocytosine in a CpG dinucleotide sequence. 2013 , 52, 8590-8	10
867	Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. 2013 , 50, 16-37	35
866	Epigenetic disorder may cause downregulation of HOXA10 in the eutopic endometrium of fertile women with endometriosis. 2013 , 20, 78-84	24
865	Molecular mechanism of SLC5A8 inactivation in breast cancer. 2013 , 33, 3920-35	22
864	Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells. 2013 , 7, 1129-41	13
863	Epigenome-wide association study of breast cancer using prospectively collected sister study samples. 2013 , 105, 694-700	103
862	Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. 2013 , 34, 2750-6	35
861	Bioinformatics for Diagnosis, Prognosis and Treatment of Complex Diseases. 2013 ,	
860	Aberrant NDRG1 methylation associated with its decreased expression and clinicopathological significance in breast cancer. 2013 , 20, 52	17
859	Epigenetic regulation in adult stem cells and cancers. 2013 , 3, 41	13
858	Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. 2013 , 16, 488-97	21
857	LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis. 2013 , 16, 480-7	72
856	Screening for herbal medicines that affect ZIC1 gene methylation in colorectal cancer. 2013 , 9, 211-218	2
855	The distinct expression patterns of claudin-2, -6, and -11 between human gastric neoplasms and adjacent non-neoplastic tissues. 2013 , 8, 133	24
854	Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. 2013 , 5, 12	72
853	Expression and potential role of apolipoprotein D on the death-survival balance of human colorectal cancer cells under oxidative stress conditions. 2013 , 28, 751-66	13

852	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NF κ B pathway. 2013 , 12, 173	60
851	Epigenetic silencing of glutaminase 2 in human liver and colon cancers. 2013 , 13, 601	33
850	Single-cell genomics: An overview. 2013 , 8, 569-576	3
849	Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. 2013 , 142, 619-27	29
848	LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway. 2013 , 12, 114	50
847	DNA methylation status of NKX2-5, GATA4 and HAND1 in patients with tetralogy of fallot. 2013 , 6, 46	35
846	Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. 2013 , 13, 456	57
845	Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. 2013 , 11, 284	16
844	Quantitative assessment of lung cancer associated with genes methylation in the peripheral blood. 2013 , 39, 182-90	17
843	Patho-Epigenetics. 2013 , 1, 37-45	3
842	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3. 2013 , 56, 7358-71	57
841	Recent Advances in Small-Molecule Modulation of Epigenetic Targets. 2013 , 185-203	7
840	Genome-wide screening for understanding the role of DNA methylation in colorectal cancer. 2013 , 5, 569-81	10
839	Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. 2013 , 27, 852-60	134
838	Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies. 2013 , 15, 29-42	9
837	The chemopreventive activity of the butyric acid prodrug tributyrin in experimental rat hepatocarcinogenesis is associated with p53 acetylation and activation of the p53 apoptotic signaling pathway. 2013 , 34, 1900-6	29
836	Lung cancer stem cells and low-intensity laser irradiation: a potential future therapy?. 2013 , 4, 129	15
835	A robust and simple-to-design multiplex DNA methylation assay based on MS-MLPA-CE-SSCP. 2013 , 138, 6969-76	5

834	Synthesis, Activity and Metabolic Stability of Non-Ribose Containing Inhibitors of Histone Methyltransferase DOT1L. 2013 , 4, 822-826	29
833	Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. 2013 , 19, 5788-5797	34
832	The myelodysplastic syndrome as a prototypical epigenetic disease. 2013 , 121, 3811-7	69
831	Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. 2013 , 34, 1717-27	15
830	Epigenetics makes its mark on women-specific cancers--an opportunity to redefine oncological approaches?. 2013 , 128, 134-143	13
829	H1 linker histone promotes epigenetic silencing by regulating both DNA methylation and histone H3 methylation. 2013 , 110, 1708-13	88
828	The epigenome of AML stem and progenitor cells. 2013 , 8, 92-104	35
827	DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. 2013 , 5, 169ra10	190
826	Cell plasticity and heterogeneity in cancer. 2013 , 59, 168-79	263
825	Analyzing the cancer methylome through targeted bisulfite sequencing. 2013 , 340, 171-8	60
824	Epigenetic targeting therapies to overcome chemotherapy resistance. 2013 , 754, 285-311	18
823	Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability. 2013 , 8, 272-9	16
822	Regional activation of the cancer genome by long-range epigenetic remodeling. 2013 , 23, 9-22	150
821	Cellular heterogeneity and molecular evolution in cancer. 2013 , 8, 277-302	340
820	Epigenetic regulation of cancer stem cell gene expression. 2013 , 61, 419-34	6
819	Mammalian cells acquire epigenetic hallmarks of human cancer during immortalization. 2013 , 41, 182-95	31
818	Cardiovascular epigenetics: from DNA methylation to microRNAs. 2013 , 34, 883-901	125
817	miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. 2013 , 25, 439-46	114

816	Genome-wide profiling of methylation identifies novel targets with aberrant hypermethylation and reduced expression in low-risk myelodysplastic syndromes. 2013 , 27, 610-8	29
815	HDAC Inhibitors and Other Histone Modifying Natural Products as Emerging Anticancer Agents. 2013 , 59-95	4
814	Histone H3 lysine 27 and 9 hypermethylation within the Bad promoter region mediates 5-Aza-2'-deoxycytidine-induced Leydig cell apoptosis: implications of 5-Aza-2'-deoxycytidine toxicity to male reproduction. 2013 , 18, 99-109	19
813	Transglutaminase 2 and NF- κ B: an odd couple that shapes breast cancer phenotype. 2013 , 137, 329-36	48
812	On the role of retinoblastoma family proteins in the establishment and maintenance of the epigenetic landscape. 2013 , 228, 276-84	19
811	Suppression of Lefty expression in induced pluripotent cancer cells. 2013 , 27, 2165-74	16
810	Toxicogenomic approaches for understanding molecular mechanisms of heavy metal mutagenicity and carcinogenicity. 2013 , 216, 587-98	119
809	Electrochemical evaluation of DNA methylation level based on the stoichiometric relationship between purine and pyrimidine bases. 2013 , 45, 34-9	42
808	Electrochemical strategy for sensing DNA methylation and DNA methyltransferase activity. 2013 , 768, 76-81	52
807	Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex. 2013 , 15, 511-22	36
806	Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer. 2013 , 5, 1661-70	9
805	Oxidative stress associated to dysfunctional adipose tissue: a potential link between obesity, type 2 diabetes mellitus and breast cancer. 2013 , 47, 243-56	88
804	Identification of a novel gene by whole human genome tiling array. 2013 , 516, 33-8	1
803	The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. 2013 , 430, 250-5	32
802	The EPIIC hypothesis: intrapartum effects on the neonatal epigenome and consequent health outcomes. 2013 , 80, 656-62	63
801	Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers. 2013 , 7, 419-27	23
800	Resveratrol activates the histone H2B ubiquitin ligase, RNF20, in MDA-MB-231 breast cancer cells. 2013 , 5, 790-800	14
799	Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. 2013 , 335, 343-50	17

798	TERT hypermethylation: biomarker in paediatric brain tumours. 2013 , 14, 447-8	6
797	Rescue of silenced UCHL1 and IGFBP4 expression suppresses clonogenicity of giant cell tumor-derived stromal cells. 2013 , 336, 61-7	10
796	Involvement of histone methyltransferase GLP in HIV-1 latency through catalysis of H3K9 dimethylation. 2013 , 440, 182-9	42
795	Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. 2013 , 49, 80-93	110
794	Methylation and liver cancer. 2013 , 37, 564-71	14
793	DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. 2013 , 441, 57-65	24
792	Frequent CpG methylation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in sporadic and hereditary Tunisian breast cancer patients: clinical significance. 2013 , 30, 418	11
791	MiR-30a and miR-379 modulate retinoic acid pathway by targeting DNA methyltransferase 3B in oral cancer. 2020 , 27, 46	16
790	Epigenetics: A New Frontier in Probiotic Research. 2021 , 29, 117-126	13
789	NCBP3/SNHG6 inhibits GBX2 transcription in a histone modification manner to facilitate the malignant biological behaviour of glioma cells. 2021 , 18, 47-63	3
788	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. 2021 , 209, 112904	16
787	Live intraoperative diagnosis of hepatic metastasis via HDACs targeting molecular theranostic agent. 2021 , 406, 126900	3
786	DNA methylation methods: Global DNA methylation and methylomic analyses. 2021 , 187, 28-43	13
785	Epigenetic modulation of FBW7/Mcl-1 pathway for lung cancer therapy. 2021 , 22, 55-65	2
784	Cadmium-stimulated invasion of rat liver cells during malignant transformation: Evidence of the involvement of oxidative stress/TET1-sensitive machinery. 2021 , 447, 152631	5
783	Epigenetic modification-dependent androgen receptor occupancy facilitates the ectopic TSPY1 expression in prostate cancer cells. 2021 , 112, 691-702	2
782	Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer. 2021 , 28, 448-458	2
781	DNA Modifications. 2021 ,	

780	Purification of TET Proteins. 2021 , 2272, 225-237	1
779	Molecular and epigenetic modes of Fumonisin B mediated toxicity and carcinogenesis and detoxification strategies. 2021 , 51, 76-94	1
778	Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. 2021 ,	3
777	Targeting (de)acetylation: A Diversity of Mechanism and Disease. 2021 ,	
776	ADHFE1 is a correlative factor of patient survival in cancer. 2021 , 16, 571-582	1
775	Epigenetics of infectious diseases. 2021 , 407-424	
774	Epigenetic regulation in cancer metastasis. 2021 , 471-489	
773	Evaluation and measurement of epigenetic modifications in population-based studies. 2021 , 17-39	
772	Knockdown of NIR Suppresses Breast Cancer Cell Proliferation via Promoting FOXO3. 2021 , 14, 637-651	0
771	Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. 2021 , 13, 9	5
770	Cholesterol: A Prelate in Cell Nucleus and its Serendipity. 2020 , 20, 692-707	2
769	Nutrients, metabolism, and epigenetic change. 2021 , 65-83	
768	Decreases in different Dnmt3b activities drive distinct development of hematologic malignancies in mice. 2021 , 296, 100285	2
767	DNA methylation age as a biomarker for cancer. 2021 , 148, 2652-2663	6
766	Ways into Understanding HIF Inhibition. 2021 , 13,	11
765	TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction. 2021 , 147, 1609-1622	1
764	Transcription Chromatin: Methyl-CpG-Binding Proteins. 2021 , 390-396	
763	Epigenetic regulations in gastrointestinal: Implications on sensitivity to ionizing radiation, inflammatory diseases, and cancer development. 2021 , 199-235	

762	Neuroblastoma and the epigenome. 2021 , 40, 173-189	15
761	Classification of Sequences with Deep Artificial Neural Networks: Representation and Architectural Issues. 2021 , 27-59	
760	Relationship between BsmI polymorphism and VDR gene methylation profile, gender, metabolic profile, oxidative stress, and inflammation in adolescents. 2021 , 38, 911-918	0
759	Unsupervised subtyping and methylation landscape of pancreatic ductal adenocarcinoma. 2021 , 7, e06000	5
758	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. 2021 , 12, 687	9
757	The Differential Antitumor Activity of 5-Aza-2'-deoxycytidine in Prostate Cancer DU145, 22RV1, and LNCaP Cells. 2021 , 12, 5593-5604	2
756	Epigenetic Events in Ovarian Cancer.	
755	Targeting DNA methyltransferases in non-small-cell lung cancer. 2021 ,	4
754	CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. 2021 , 13, 15	4
753	What Have We Learned from Molecular Biology of Paragangliomas and Pheochromocytomas?. 2021 , 32, 134-153	7
752	CRISPR/Cas mediated epigenome editing for cancer therapy. 2021 ,	3
751	Epigenetic modulators combination with chemotherapy in breast cancer cells. 2021 , 39, 571-583	0
750	DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution. 2021 , 40, 1884-1895	9
749	Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention. 2021 , 13, 44	3
748	Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. 2021 , 131,	1
747	A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer. 2021 , 11, 614927	4
746	The Impact of Epstein-Barr Virus Infection on Epigenetic Regulation of Host Cell Gene Expression in Epithelial and Lymphocytic Malignancies. 2021 , 11, 629780	10
745	Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies. 2021 , 21, 404-425	2

744	Landscape of epigenetically regulated lncRNAs and DNA methylation in smokers with lung adenocarcinoma. 2021 , 16, e0247928	0
743	DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. 2021 , 31, 747-761	4
742	Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter. 2021 , 11, 650473	6
741	Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities. 2021 , 11,	7
740	Current paradigms in epigenetic anticancer therapeutics and future challenges. 2021 ,	8
739	The Role of Epigenetic Changes in Ovarian Cancer: A Review. 2021 , 19, 1	3
738	Effects of Epigenetic Regulation on Cancer.	
737	Chemopreventive potential of plant-derived epigenetic inhibitors silibinin and quercetin: an involvement of apoptotic signaling cascade modulation. 2021 , 7,	0
736	The DNA methylation inhibitor RG108 protects against noise-induced hearing loss. 2021 , 37, 751-771	3
735	Correlation Between Promoter Hypomethylation and Increased Expression of Syncytin-1 in Non-Small Cell Lung Cancer. 2021 , 14, 957-965	4
734	Integrative Analysis of Methylation and Copy Number Variations of Prostate Adenocarcinoma Based on Weighted Gene Co-expression Network Analysis. 2021 , 11, 647253	2
733	DNA Methylation in Ovarian Tumors-a Comparison Between Fresh Tissue and FFPE Samples. 2021 , 28, 3212-3218	0
732	The effect of SiNPs on DNA methylation of genome in mouse spermatocytes. 2021 , 28, 43684-43697	1
731	Natural products in the reprogramming of cancer epigenetics. 2021 , 417, 115467	6
730	DNA Methylation Change Profiling of Colorectal Disease: Screening towards Clinical Use. 2021 , 11,	2
729	Identification of TNIK as a novel potential drug target in thyroid cancer based on protein druggability prediction. 2021 , 100, e25541	1
728	Insight Into Chromatin-Enriched RNA: A Key Chromatin Regulator in Tumors. 2021 , 9, 649605	1
727	Advances in epigenetic therapeutics with focus on solid tumors. 2021 , 13, 83	14

726	CpG content-dependent associations between transcription factors and histone modifications. 2021 , 16, e0249985	
725	Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma. 2021 , 21, 226	2
724	The Detection of Cancer Epigenetic Traces in Cell-Free DNA. 2021 , 11, 662094	2
723	Influence of degree of DNA degradation in formalin-fixed and paraffin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis. 2021 , 13, 565-576	2
722	DNA methylation of tumour necrosis factor (TNF) alpha gene is associated with specific blood fatty acid levels in a gender-specific manner. 2021 , e1679	1
721	Methylation as a critical epigenetic process during tumor progressions among Iranian population: an overview. 2021 , 43, 14	
720	Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex. 2021 , 12,	2
719	A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb target genes. 2021 , 12, 2485	6
718	Exploring effects of DNA methylation and gene expression on pan-cancer drug response by mathematical models. 2021 , 246, 1626-1642	0
717	DNA methylation landscape of 16 canine somatic tissues by methylation-sensitive restriction enzyme-based next generation sequencing. 2021 , 11, 10005	1
716	Current understanding of epigenetics mechanism as a novel target in reducing cancer stem cells resistance. 2021 , 13, 120	12
715	Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers.	
714	Multi-Omics Model Applied to Cancer Genetics. 2021 , 22,	3
713	TET1 upregulation drives cancer cell growth through aberrant enhancer hydroxymethylation of HMGA2 in hepatocellular carcinoma. 2021 , 112, 2855-2869	4
712	How metabolism bridles cytotoxic CD8 T cells through epigenetic modifications. 2021 , 42, 401-417	6
711	MiR-206 promotes extracellular matrix accumulation and relieves infantile hemangioma through targeted inhibition of DNMT3A. 2021 , 20, 978-992	
710	Turning tumors from cold to inflamed to improve immunotherapy response. 2021 , 101, 102227	4
709	Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice. 2021 , 29, 1758-1771	8

708	Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. 2021 , 53, 761-771	1
707	Is Associated With Immune Cell Infiltration and Serves as a Favorable Prognostic Biomarker for Breast Cancer. 2021 , 11, 658547	3
706	Synthesis and Biological Evaluation of Spirocyclic Chromane Derivatives as a Potential Treatment of Prostate Cancer. 2021 , 26,	2
705	Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety. 2021 , 17, 601-615	2
704	Activation of EHF via STAT3 phosphorylation by LMP2A in Epstein-Barr virus-positive gastric cancer. 2021 , 112, 3349-3362	3
703	Food and omics: unraveling the role of food in breast cancer development. 2021 , 39, 197-207	1
702	Methylation patterns partition pancreatic cancer into distinct prognostic subtypes. 2021 , 17, 2027-2039	
701	Nanopore Technology and Its Applications in Gene Sequencing. 2021 , 11,	15
700	Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer. 2021 , 80, 71-81	10
699	Microbiota and epigenetics: promising therapeutic approaches?. 2021 , 28, 49343-49361	6
698	Functional Interplay between Methyltransferases and Inflammasomes in Inflammatory Responses and Diseases. 2021 , 22,	3
697	Multidimensional analysis of the epigenetic alterations in toxicities induced by mycotoxins. 2021 , 153, 112251	4
696	Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside. 2021 , 22,	7
695	Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus. 2021 , 13, 148	0
694	A methylation-driven gene panel predicts survival in patients with colon cancer. 2021 , 11, 2490-2506	1
693	The role of melatonin hormone and its receptor (type1A) as anti-cancer against carcinogenic effect of polyaromatic hydrocarbons in Iraqi refinery workers. 2021 ,	
692	A panel of epigenetically dysregulated Wnt signaling pathway genes for non-invasive diagnosis of pediatric acute lymphoblastic leukemia. 2021 ,	2
691	miR-377-3p-Mediated EGR1 Downregulation Promotes B[a]P-Induced Lung Tumorigenesis by Wnt/Beta-Catenin Transduction. 2021 , 11, 699004	2

690	Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia. 2021 , 14, 765-775	0
689	DNA methylation detection technology and plasma-based methylation biomarkers in screening of gastrointestinal carcinoma. 2021 , 13, 1327-1339	0
688	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. 2021 ,	1
687	Advances in 2-substituted benzothiazole scaffold-based chemotherapeutic agents. 2021 , 354, e2100246	4
686	Targeting Autophagy-Related Epigenetic Regulators for Cancer Drug Discovery. 2021 , 64, 11798-11815	4
685	Epigenetic modifiers synergize with immune-checkpoint blockade to enhance long-lasting antitumor efficacy. 2021 , 131,	0
684	Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential. 2021 , 22,	0
683	Proteome-Wide Profiling of Readers for DNA Modification. 2021 , 8, e2101426	2
682	Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay. 2021 , 17, 4785-4795	1
681	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer. 2021 , 11, 16782	3
680	Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in lung epithelial cells. 2021 , 1-24	
679	miR-204: Molecular Regulation and Role in Cardiovascular and Renal Diseases. 2021 , 78, 270-281	5
678	Cell-Membrane-Derived Nanoparticles with Notch-1 Suppressor Delivery Promote Hypoxic Cell-Cell Packing and Inhibit Angiogenesis Acting as a Two-Edged Sword. 2021 , 33, e2101558	2
677	Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. 2021 , 43, e2100125	1
676	Molecular Pathology of Prostate Cancer. 2021 , 14, 387-401	1
675	A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer. 2021 , 15, 3348-3362	0
674	Targeting the Transcriptome Through Globally Acting Components. 2021 , 12, 749850	1
673	Exposure to glyphosate and tetrachlorovinphos induces cytotoxicity and global DNA methylation in human cells. 2021 , 37, 610-618	1

672	Development and Validation of a Prognostic Nomogram Based on DNA Methylation-Driven Genes for Patients With Ovarian Cancer. 2021 , 12, 675197	3
671	Aberrant epigenetic and transcriptional events associated with breast cancer risk.	0
670	A simple and robust methylation test for risk stratification of patients with juvenile myelomonocytic leukemia. 2021 ,	1
669	Multi 'omic data integration: A review of concepts, considerations, and approaches. 2021 , 45, 151456	5
668	mSEPT9 Can Monitor the Response and Predict the Prognosis of Stage IV colorectal cancer Patients with Liver Metastasis Undergoing Potentially Curative Surgery. 2021 , 267, 485-494	1
667	Genome-wide DNA methylation profile in feline haematological tumours: A preliminary study. 2021 , 140, 221-228	0
666	Histone methylatic modification mediates the tumor-suppressive activity of curcumol in hepatocellular carcinoma via an Hotair/EZH2 regulatory axis. 2021 , 280, 114413	1
665	Comprehensive analysis reveals common DNA methylation patterns of tobacco-associated cancers: A pan-cancer analysis. 2021 , 804, 145900	1
664	Epigenetic programming of the immune responses in cancer. 2022 , 197-235	0
663	Regulation of cancer stem cells in triple negative breast cancer.. 2021 , 4, 321-342	4
662	Mechanisms Involved in Carcinogenesis. 2021 , 11-36	
661	DNA methyltransferase inhibitors (DNMTis) as sensitizing agents to overcome chemoresistance. 2021 , 9-23	
660	Molecular Genetics of Multiple Myeloma.	1
659	Chemical and biochemical approaches in the study of histone methylation and demethylation. 2010 , 32, n/a-n/a	3
658	Chromatin Remodeling and Androgen Receptor-Mediated Transcription. 2009 , 405-424	1
657	Sequencing the Epigenome. 2009 , 19-35	2
656	Age-Related Genomic Hypomethylation. 2010 , 11-27	14
655	The biology of thyroid oncogenesis. 2010 , 153, 3-21	6

654	Precursor Lesions of Pancreatic Cancer. 2011 , 395-420	3
653	Genetics and Epigenetics of Head and Neck Cancer. 2011 , 93-106	1
652	Epigenetics and Human Disease. 2012 , 253-279	1
651	Microsatellite Repeats: Canaries in the Coalmine. 2013 , 119-150	2
650	Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer. 2015 , 1238, 677-88	7
649	Epigenetics of gastric cancer. 2015 , 1238, 783-99	17
648	Analysis of DNA Methylation by Pyrosequencing. 2015 , 1343, 249-64	54
647	5'-azacytidine expression arrays. 2009 , 507, 165-74	8
646	Identification of inhibitors of chromatin modifying enzymes using the yeast phenotypic screens. 2009 , 548, 145-60	2
645	Methylation analysis by microarray. 2009 , 556, 117-39	8
644	Solid Tumor Stem Cells – Implications for Cancer Therapy. 2009 , 527-543	1
643	Remodeling genomes with artificial transcription factors (ATFs). 2010 , 649, 163-82	8
642	Analysis of epigenetic alterations to proprotein convertase genes in disease. 2011 , 768, 231-45	2
641	Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy. 2011 , 780, 277-91	21
640	DNA methyltransferase assays. 2011 , 791, 157-77	34
639	Using ChIP-seq technology to generate high-resolution profiles of histone modifications. 2011 , 791, 265-86	90
638	Inhibition of histone deacetylases. 2011 , 791, 297-311	4
637	Simultaneous single-molecule detection of endogenous C-5 DNA methylation and chromatin accessibility using MAPit. 2012 , 833, 125-41	9

636	Clinical implications of epigenetic alterations in human thoracic malignancies: epigenetic alterations in lung cancer. 2012 , 863, 221-39	5
635	Role of epigenetics in cancer health disparities. 2012 , 863, 395-410	28
634	Histone modification profiling in normal and transformed human embryonic stem cells using micro chromatin immunoprecipitation, scalable to genome-wide microarray analyses. 2013 , 1029, 149-61	2
633	Histone Modifying Enzymes and Chromatin Modifiers in Glioma Pathobiology and Therapy Responses. 2020 , 1202, 259-279	8
632	Epigenetic Control Using Small Molecules in Cancer. 2020 , 111-148	1
631	Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition. 2014 , 149-179	2
630	Helicobacter pylori: The Cancer Bug. 2015 , 171-211	1
629	Radiation Therapy Towards Laser-Driven Particle Beams: An μ MICS Approach in Radiobiology. 2016 , 67-98	1
628	Retrotransposon-Driven Transcription and Cancer. 2017 , 259-273	3
627	Antibody-Dependent Enzyme Prodrug Therapy (ADEPT). 2010 , 431-451	2
626	Decitabine. 2010 , 184, 131-57	36
625	Encyclopedia of Cancer. 2017 , 2085-2088	1
624	The Epigenomics of Cancer. 2010 , 51-67	2
623	A Network Systems Approach to Identify Functional Epigenetic Drivers in Cancer. 2013 , 131-152	1
622	Our Current Knowledge. 2015 , 35-67	1
621	Cancer Methylation Biomarkers in Circulating Cell-Free DNA. 2019 , 217-245	3
620	Gastric Cancer: Epigenetic Mechanisms: Aberrant DNA Methylation and Dysregulation of MicroRNA. 2016 , 257-267	2
619	β Catenin gene promoter hypermethylation by reactive oxygen species correlates with the migratory and invasive potentials of colon cancer cells. 2018 , 41, 569-580	12

618	Epigenetic Biomarkers. 2016 , 1-18	6
617	Progressing from Gene Mutations to Cancer. 2008 , 207-222	1
616	Cancer Immunology. 2014 , 78-97.e5	2
615	A novel epigenetic signature to predict recurrence-free survival in patients with colon cancer. 2020 , 508, 54-60	2
614	Molecular epigenetic targets for liver diseases: current challenges and future prospects. 2017 , 22, 1620-1636	5
613	Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?. 2017 , 122, 8-19	40
612	Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches. 2020 ,	18
611	SETD3 acts as a prognostic marker in breast cancer patients and modulates the viability and invasion of breast cancer cells. 2020 , 10, 2262	20
610	Chapter 10:The Design and Development of Polyamine-Based Analogs with Epigenetic Targets. 2011 , 238-256	1
609	Automatic identification of informative regions with epigenomic changes associated to hematopoiesis.	1
608	Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability.	1
607	Transcriptional silencing of ALDH2 in acute myeloid leukemia confers a dependency on Fanconi anemia proteins.	2
606	Bivalent chromatin protects reversibly repressed genes from irreversible silencing.	5
605	The proto CpG island methylator phenotype of sessile serrated adenomas/polyps.	1
604	Quantification of DNA methylation using methylation-sensitive restriction enzymes and multiplex digital PCR.	3
603	MYC and Chromatin. 2015 , 3,	3
602	Diverse repetitive element RNA expression defines epigenetic and immunologic features of colon cancer. 2017 , 2, e91078	13
601	hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing. 2010 , 120, 2920-30	77

600	Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. 2012 , 122, 163-77	54
599	Balance of DNA methylation and demethylation in cancer development. 2012 , 13, 173	27
598	Histone Methylation and the Initiation of Cancer. 2008 , 109-150	6
597	Folate and Carcinogenesis. 2009 , 235-262	3
596	Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration. 2018 , 24, 1034-1043	11
595	Polyunsaturated fatty acids and DNA methylation in colorectal cancer. 2019 , 7, 4172-4185	9
594	PcG proteins, DNA methylation, and gene repression by chromatin looping. 2008 , 6, 2911-27	154
593	Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). 2009 , 5, e1000559	207
592	Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. 2016 , 12, e1005778	102
591	Epigenetics in Cancer: A Hematological Perspective. 2016 , 12, e1006193	55
590	Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. 2008 , 5, e114	113
589	The Drosophila cytosine-5 methyltransferase Dnmt2 is associated with the nuclear matrix and can access DNA during mitosis. 2008 , 3, e1414	30
588	Cancer genes hypermethylated in human embryonic stem cells. 2008 , 3, e3294	63
587	Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. 2008 , 3, e3698	245
586	High-resolution analysis of the 5'-end transcriptome using a next generation DNA sequencer. 2009 , 4, e4108	39
585	Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. 2009 , 4, e6555	71
584	Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. 2009 , 4, e8357	116
583	Investigating the epigenetic effects of a prototype smoke-derived carcinogen in human cells. 2010 , 5, e10594	16

582	DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. 2010 , 5, e12197	66
581	Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery. 2011 , 6, e16702	22
580	Characterization of the contradictory chromatin signatures at the 3' exons of zinc finger genes. 2011 , 6, e17121	60
579	Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. 2011 , 6, e17388	100
578	Modeling initiation of Ewing sarcoma in human neural crest cells. 2011 , 6, e19305	124
577	Statistical quantification of methylation levels by next-generation sequencing. 2011 , 6, e21034	12
576	B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). 2011 , 6, e21102	40
575	Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. 2011 , 6, e25564	93
574	Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma. 2011 , 6, e26121	57
573	Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. 2011 , 6, e29085	46
572	Chromatin states accurately classify cell differentiation stages. 2012 , 7, e31414	9
571	The influence of cis-regulatory elements on DNA methylation fidelity. 2012 , 7, e32928	7
570	DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission. 2012 , 7, e34513	33
569	Linking the epigenome to the genome: correlation of different features to DNA methylation of CpG islands. 2012 , 7, e35327	22
568	Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation. 2012 , 7, e36125	10
567	Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes. 2012 , 7, e44822	19
566	High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. 2012 , 7, e51527	48
565	MLH1 region polymorphisms show a significant association with CpG island shore methylation in a large cohort of healthy individuals. 2012 , 7, e51531	17

564	DNA methylation in the malignant transformation of meningiomas. 2013 , 8, e54114	53
563	Maternal diet supplemented with methyl-donors protects against atherosclerosis in F1 ApoE(-/-) mice. 2013 , 8, e56253	25
562	Similarities in the Age-Specific Incidence of Colon and Testicular Cancers. 2013 , 8, e66694	6
561	EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. 2013 , 8, e68226	41
560	Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes. 2013 , 8, e68439	12
559	Methylome analysis and epigenetic changes associated with menarcheal age. 2013 , 8, e79391	26
558	Aberrant methylation of gene associated CpG sites occurs in borderline personality disorder. 2013 , 8, e84180	23
557	Eicosapentaenoic acid activates RAS/ERK/C/EBP β pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. 2014 , 9, e85025	20
556	Embryonic caffeine exposure acts via A1 adenosine receptors to alter adult cardiac function and DNA methylation in mice. 2014 , 9, e87547	36
555	Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. 2014 , 9, e91666	9
554	The CpG island encompassing the promoter and first exon of human DNMT3L gene is a PcG/TrX response element (PRE). 2014 , 9, e93561	10
553	Combination effect of epigenetic regulation and ionizing radiation in colorectal cancer cells. 2014 , 9, e105405	11
552	Diet-induced obesity modulates epigenetic responses to ionizing radiation in mice. 2014 , 9, e106277	25
551	Direct but no transgenerational effects of decitabine and vorinostat on male fertility. 2015 , 10, e0117839	10
550	Overlapping DNA methylation dynamics in mouse intestinal cell differentiation and early stages of malignant progression. 2015 , 10, e0123263	12
549	LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy. 2014 , 10, e0123973	32
548	In vivo dedifferentiation of adult adipose cells. 2015 , 10, e0125254	21
547	DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. 2015 , 10, e0130651	25

546	Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. 2015 , 10, e0139740	7
545	Lgr5 Methylation in Cancer Stem Cell Differentiation and Prognosis-Prediction in Colorectal Cancer. 2015 , 10, e0143513	15
544	A Feature Selection Algorithm to Compute Gene Centric Methylation from Probe Level Methylation Data. 2016 , 11, e0148977	18
543	The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. 2016 , 11, e0158208	15
542	Identification of Aging-Associated Gene Expression Signatures That Precede Intestinal Tumorigenesis. 2016 , 11, e0162300	6
541	Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies. 2016 , 11, e0163257	9
540	Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease. 2017 , 12, e0188178	12
539	Lung Cancer Staging and Associated Genetic and Epigenetic Events. 2020 , 43, 1-9	8
538	The prognostic value of whole blood SOX2, NANOG and OCT4 mRNA expression in advanced small-cell lung cancer. 2016 , 50, 188-96	21
537	DNA methylation in thyroid cancer. 2019 , 26, R415-R439	25
536	Non-edible plants as an attractive source of compounds with chemopreventive potential. 2014 , 19, 1-6	10
535	Epigenomic Hard Drive Imprinting: A Hidden Code Beyond the Biological Death of Cancer Patients. 2017 , 22, 211-218	3
534	Epigenetic Mechanisms of Glioblastoma. 43-58	4
533	-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. 2017 , 1, 55-67	3
532	Imunorreatividade da p53 associada à ausência de mutações no gene TP53 em linfomas caninos. 2010 , 40, 1444-1447	2
531	Twenty Years on: What Do We Really Know about Ewing Sarcoma and What Is the Path Forward?. 2015 , 20, 155-71	68
530	Liquid Biopsies for Assessing Metastatic Melanoma Progression. 2016 , 21, 141-54	13
529	Modulation of iron metabolism by iron chelation regulates intracellular calcium and increases sensitivity to doxorubicin. 2016 , 16, 14-20	11

528	The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms. 2014 , 5, 365-74	20
527	Hypomethylation and increased expression of the putative oncogene ELMO3 are associated with lung cancer development and metastases formation. 2014 , 1, 367-74	57
526	Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation. 2016 , 7, 43109-43123	17
525	The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent. 2016 , 7, 58939-58952	7
524	KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells. 2017 , 8, 17712-17725	30
523	UHRF1 regulates global DNA hypomethylation and is associated with poor prognosis in esophageal squamous cell carcinoma. 2016 , 7, 57821-57831	19
522	Improving needle biopsy accuracy in small renal mass using tumor-specific DNA methylation markers. 2017 , 8, 5439-5448	13
521	DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells. 2016 , 7, 70924-70935	20
520	Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells. 2016 , 7, 71841-71855	16
519	Methylation of promoter of RBL1 enhances the radioresistance of three dimensional cultured carcinoma cells. 2017 , 8, 4422-4435	8
518	Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. 2016 , 7, 78859-78871	28
517	TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. 2016 , 7, 81512-81526	38
516	Unique epigenetic gene profiles define human breast cancers with poor prognosis. 2016 , 7, 85819-85831	7
515	DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. 2017 , 8, 1074-1082	14
514	Large-scale DNA methylation expression analysis across 12 solid cancers reveals hypermethylation in the calcium-signaling pathway. 2017 , 8, 11868-11876	12
513	Aberrant methylation patterns in colorectal cancer: a meta-analysis. 2017 , 8, 12820-12830	11
512	Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer. 2017 , 8, 26600-26612	16
511	SET oncoprotein accumulation regulates transcription through DNA demethylation and histone hypoacetylation. 2017 , 8, 26802-26818	12

510	Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma. 2017 , 8, 23787-23802	11
509	Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. 2014 , 5, 544-60	63
508	Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk: a case-control study in China. 2017 , 8, 61239-61252	9
507	Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. 2014 , 5, 2016-29	91
506	Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development. 2017 , 8, 70035-70048	15
505	Decitabine reactivated pathways in platinum resistant ovarian cancer. 2014 , 5, 3579-89	35
504	Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. 2014 , 5, 5725-35	61
503	Epigenetic regulations in the IFN γ signalling pathway: IFN γ mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes. 2014 , 5, 6923-35	28
502	Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. 2014 , 5, 10665-77	64
501	Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression. 2014 , 5, 8039-51	23
500	Prognostic value of LINE-1 methylation level in 321 patients with primary liver cancer including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. 2018 , 9, 20795-20806	10
499	The frequency of promoter DNA hypermethylation is decreased in colorectal neoplasms of familial adenomatous polyposis. 2018 , 9, 32653-32666	2
498	Limitations of current models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. 2018 , 9, 36530-36541	6
497	DNA hypomethylation-related overexpression of SFN, GORASP2 and ZYG11A is a novel prognostic biomarker for early stage lung adenocarcinoma. 2019 , 10, 1625-1636	10
496	Decreased expression of GRIM-19 by DNA hypermethylation promotes aerobic glycolysis and cell proliferation in head and neck squamous cell carcinoma. 2015 , 6, 101-15	21
495	A high-throughput screen of pharmacologically active compounds for inhibitors of UHRF1 reveals epigenetic activity of anthracycline derivative chemotherapeutic drugs. 2019 , 10, 3040-3050	6
494	Sphingomyelin phosphodiesterase 3 methylation and silencing in oral squamous cell carcinoma results in increased migration and invasion and altered stress response. 2020 , 11, 523-534	4
493	Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors. 2015 , 6, 18105-15	41

492	LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. 2015 , 6, 23820-36	7
491	Singular v dual inhibition of SNF2L and its isoform, SNF2LT, have similar effects on DNA damage but opposite effects on the DNA damage response, cancer cell growth arrest and apoptosis. 2012 , 3, 475-89	4
490	Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. 2015 , 6, 29555-72	27
489	RASSF8 regulates progression of cutaneous melanoma through nuclear factor- κ B. 2015 , 6, 30165-77	10
488	BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. 2015 , 6, 31522-43	56
487	Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore. 2015 , 6, 37647-62	22
486	Helicobacter pylori CagA induces tumor suppressor gene hypermethylation by upregulating DNMT1 via AKT-NF κ B pathway in gastric cancer development. 2016 , 7, 9788-800	48
485	Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. 2016 , 7, 40781-40791	6
484	Emerging therapeutic targets in esophageal adenocarcinoma. 2016 , 7, 48644-48655	10
483	Overexpression of ankyrin1 promotes pancreatic cancer cell growth. 2016 , 7, 34977-87	14
482	Methylation-mediated repression of microRNA-129-2 suppresses cell aggressiveness by inhibiting high mobility group box 1 in human hepatocellular carcinoma. 2016 , 7, 36909-36923	49
481	Nuclear DNA methylation and chromatin condensation phenotypes are distinct between normally proliferating/aging, rapidly growing/immortal, and senescent cells. 2013 , 4, 474-93	16
480	High methylation of in cervical adenocarcinoma affects radiosensitivity and prognosis. 2019 , 7, 328	8
479	Epigenomics in cancer management. 2010 , 2, 255-65	20
478	Impact of Epigenetic Dietary Components on Cancer through Histone Modifications. 2015 , 22, 2051-64	41
477	Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. 2020 , 27, 6099-6111	11
476	Electrochemical and Optical Biosensing Strategies for DNA Methylation Analysis. 2020 , 27, 6159-6187	3
475	Epigenetic regulation of EMT: the Snail story. 2014 , 20, 1698-705	96

474	Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression. 2017 , 18, 175-205	32
473	Epigenetic Changes Associated with Early Life Experiences: Saliva, A Biospecimen for DNA Methylation Signatures. 2018 , 19, 676-698	6
472	Epigenetic Targeting of Platinum Resistant Testicular Cancer. 2016 , 16, 789-795	9
471	Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics. 2019 , 19, 82-100	13
470	Cell-Free Fetal DNA: A Novel Biomarker for Early Prediction of Pre-eclampsia and Other Obstetric Complications. 2019 , 15, 57-63	3
469	Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro. 2019 , 12, 281-300	12
468	Targets in epigenetics: inhibiting the methyl writers of the histone code. 2011 , 5, 72-84	48
467	Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients. 2017 , 18, 3307-3313	3
466	PAX6 Promoter Methylation Correlates with MDA-MB-231 Cell Migration, and Expression of MMP2 and MMP9. 2018 , 19, 2859-2866	7
465	Privacy-Preserving Similar Patient Queries for Combined Biomedical Data. 2019 , 2019, 47-67	5
464	LUCAT1 Epigenetically Downregulates the Tumor Suppressor Genes and in Gastric Cancer. 2020 , 61, 923-934	1
463	Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi. 2015 , 7, 1233-43	17
462	Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. 2011 , 17, 3407-19	21
461	MicroRNAs in pancreatic ductal adenocarcinoma. 2011 , 17, 817-27	38
460	Growth inhibitory effect of 4-phenyl butyric acid on human gastric cancer cells is associated with cell cycle arrest. 2012 , 18, 79-83	22
459	Epigenetics: an emerging player in gastric cancer. 2014 , 20, 6433-47	56
458	Accumulation of aberrant DNA methylation during colorectal cancer development. 2014 , 20, 978-87	43
457	Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma. 2015 , 21, 3960-9	10

456	Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment. 2018 , 24, 4635-4642	19
455	Role of epigenetics in transformation of inflammation into colorectal cancer. 2019 , 25, 2863-2877	31
454	Prognostic implications of aberrantly expressed methylation-driven genes in hepatocellular carcinoma: A study based on The Cancer Genome Atlas. 2019 , 20, 5304-5314	3
453	Genome-wide methylation profiles in monozygotic twins with discordance for ovarian carcinoma. 2020 , 20, 357	4
452	5-Aza-2''-deoxycytidine inhibits retinoblastoma cell by reactivating epigenetically silenced RASSF1A gene. 2014 , 7, 51-6	6
451	Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells. 2018 , 26, 591-598	2
450	Prostate cancer epigenetics and its clinical implications. 2016 , 18, 549-58	23
449	Structural changes in pancreatic acinar cells and E-cells of rat fed with genetically modified corn. 2016 , 15, 77	1
448	The Role of Myc and the miR-17~92 Cluster in Histone Deacetylase Inhibitor Induced Apoptosis of Solid Tumors. 2013 , 04, 907-918	5
447	Cancer and Infectious Causes. 2014 , 04, 161-177	2
446	Histone modifications: Targeting head and neck cancer stem cells. 2014 , 6, 511-25	24
445	Novel risk markers for gastric cancer screening: Present status and future prospects. 2010 , 2, 381-7	12
444	Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. 2010 , 1, 209-20	38
443	Complex interactomes and post-translational modifications of the regulatory proteins HABP4 and SERBP1 suggest pleiotropic cellular functions. 2019 , 10, 44-64	4
442	Epigenetic alterations in inflammatory bowel disease and cancer. 2015 , 13, 112-21	23
441	Hypermethylated promoters of tumor suppressor genes were identified in Crohn's disease patients. 2020 , 18, 297-305	3
440	Eagles report: Developing cancer biomarkers from genome-wide DNA methylation analyses. 2011 , 2, 1-7	5
439	Analysis of the Hox epigenetic code. 2012 , 3, 48-56	2

438	Fetal Nucleic Acids in Maternal Circulation: A Genetic Resource for Noninvasive Prenatal Diagnosis. 2013 , 2013, 1-10	0
437	Analysis of opposing histone modifications H3K4me3 and H3K27me3 reveals candidate diagnostic biomarkers for TNBC and gene set prediction combination. 2020 , 53, 266-271	1
436	Methylation analysis of tumor suppressor genes in endometrioid carcinoma of endometrium using MS-MLPA. 2013 , 157, 298-303	13
435	Importance of promoter methylation of GATA4 gene in epithelial ovarian cancer. 2013 , 157, 294-7	9
434	Epigenetic therapy in allogeneic hematopoietic stem cell transplantation. 2013 , 35, 126-33	14
433	Cancer research in an era when epigenetics is no longer "epi" - challenges and opportunities. 2013 , 32, 1-2	5
432	Molecular signatures of pancreatic cancer. 2011 , 135, 716-27	116
431	Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells. 2020 , 11, 1915-1926	9
430	Relationships among MTHFR a1298c gene polymorphisms and methylation status of Dact1 gene in transitional cell carcinomas. 2012 , 13, 5069-74	5
429	Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. 2013 , 14, 3139-42	21
428	DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. 2014 , 15, 75-84	33
427	Aberrant methylation of RASSF2A in tumors and plasma of patients with epithelial ovarian cancer. 2014 , 15, 1171-6	29
426	Promoter Methylation Status of Two Novel Human Genes, UBE2Q1 and UBE2Q2, in Colorectal Cancer: a New Finding in Iranian Patients. 2015 , 16, 8247-52	11
425	DNA methylation presents distinct binding sites for human transcription factors. 2013 , 2, e00726	228
424	Emerging targets for glioblastoma stem cell therapy. 2016 , 30, 19-31	26
423	Formal modeling and analysis of the hexosamine biosynthetic pathway: role of O-linked N-acetylglucosamine transferase in oncogenesis and cancer progression. 2016 , 4, e2348	11
422	The 100 Most Cited Papers About Cancer Epigenetics. 2020 , 12, e7623	2
421	Regulation of MUC6 Methylation Correlates with Progression of Gastric Cancer. 2021 , 62, 1005-1015	2

420	CHRAC1 promotes human lung cancer growth through regulating YAP transcriptional activity. 2021	0
419	Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC. 2021 ,	
418	Genetic and Epigenetic Impact of Chronic Inflammation on Colon Mucosa Cells. 2021 , 12, 722835	0
417	Immune checkpoint CD155 promoter methylation profiling reveals cancer-associated behaviors within breast neoplasia. 2021 , 1	0
416	Integration of Epigenetic Mechanisms into Non-Genotoxic Carcinogenicity Hazard Assessment: Focus on DNA Methylation and Histone Modifications. 2021 , 22,	1
415	Unboxing the molecular modalities of mutagens in cancer. 2021 , 1	2
414	Epigenetic Signaling of Cancer Stem Cells During Inflammation. 2021 , 9, 772211	4
413	Insulin Resistance and Cancer: In Search for a Causal Link. 2021 , 22,	4
412	DNA Methylation Profiling of MYC, SMAD2/3 and DNMT3A in Colorectal Cancer. 2021 , 36, e315	
411	DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer. 2021 , 13, 190	0
410	Decoding the function of bivalent chromatin in development and cancer. 2021 ,	3
409	Sonodynamic effect in A375 melanoma cells with chlorin e6 induced by 20 kHz ultrasound. 2022 , 55, 045402	
408	The prediction and expression of miR-203a-p and miR-29b* against DNMT3B as well as TNFAIP3 in melanoma. 2021 , 25, 101374	
407	Cancer-Specific Vaccines. 2008 , 649-669	
406	Cancer Immunology. 2008 , 77-93	1
405	Diagnosing Cancer Using Histone Modification Analysis. 2008 , 347-357	
404	Future Directions in Epigenetic Cancer Research. 2008 , 429-436	
403	Histone Modifications in Cancer Biology and Prognosis. 2008 , 359-379	

- 402 Role of DNA Methylation in Cancer Progression. **2008**, 79-93
- 401 Molecular Biology of Thyroid Cancer. **2009**, 97-110
- 400 Stem Cell Epigenetics. **2009**, 235-246 1
- 399 Stem Cell Chromatin Patterns and DNA Hypermethylation. **2009**, 85-97
- 398 Concepts and Mechanisms of Breast Cancer Metastasis. **2009**, 549-564
- 397 Molecular Basis of Human Malignancy. **2009**, 41-55 1
- 396 Introduction. **2009**, 1-6 1
- 395 5-Aza-2'-deoxycytidine Inhibits the Maintenance of Cancer Stem Cell in a Mouse Model of Breast Cancer. **2009**, 19, 1164-1169
- 394 Molecular Pathogenesis of Myelodysplastic Syndromes. **2010**, 417-427
- 393 Aberrant DNA Methylation in Cancer Cells. **2010**, 121-132
- 392 DNA Methylation Status in Chronic Liver Disease and Hepatocellular Carcinoma. **2010**, 147-159
- 391 The Human Epigenome: Implications for the Understanding of Human Disease. **2010**, 105-112
- 390 Genetische Aberration, Genexpressionprofile und Epigenetik. **2010**, 67-75
- 389 Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. **2010**, 463-471
- 388 Contribuci3n de la epigen3tica al manejo personalizado del c3ncer. **2010**, 301-320
- 387 A Cautiously Pessimistic Appraisal of Trends in Toxic Regulation.
- 386 Genetics and Genomics. 1-23 1
- 385 DNA Methylation. 307-321 1

384 Epigenetic Therapies. **2011**, 189-202

383 Cancer Stem Cells in Ovarian Cancer. **2011**, 151-176

382 The genetics and molecular biology of gynaecological cancer. **2011**, 522-538

381 Cytogenetic effect of 5-azacytidine in patients with hematological malignancies. **2011**, 33, 372-6

380 Molecular Biology for Urologists. **2011**, 161-174

379 Chapitre 6. Le rôle de l'expression aléatoire des gènes dans la genèse du cancer. **2011**, 174

378 Encyclopedia of Cancer. **2011**, 325-328

377 Encyclopedia of Cancer. **2011**, 1703-1705

376 A Finite Mixture Model for Gene Expression and Methylation Profiles in a Bayesian Framework. **2011**, 24, 609-622

375 Assessment of Radiosensitivity and Monitoring of Radiation-Induced Cellular Damage. **2012**, 345-356

374 Epigenomic Analysis in Toxicology.

373 Diet-Influenced Chromatin Modification and Expression of Chemopreventive Genes by the Soy Peptide Lunasin. **2011**, 25-40

372 Non-Hodgkin's Lymphomas. **2012**, 115-157

371 Epigenetic Reprogramming in Lung Carcinomas. **2012**, 159-177

1

370 Family History of Cancer and Smoking Cessation, Is There a Role for Physicians?. **2012**, 03, 9-13

369 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16

368 Cancer and Diet.

1

367 Epigenetic Drivers of Genetic Alterations in Cancer.

366 Head and Neck Carcinogenesis a Product of Complex Evolutionary Forces. **2013**, 401-457

365 Non-CDH1-Associated Familial Gastric Cancer and Epigenetics Factors. **2013**, 111-125

364 hiPSCs: Reprogramming towards cell-based therapies. **2013**, 02, 61-73

363 Pharmaco-epigenomics. **2013**, 63-75

362 Chemopreventive Action of Green Tea Polyphenols (Molecular-Biological Mechanisms). **2013**, 83-118

361 The Fundamental Role of Epigenetic Regulation in Normal and Disturbed Cell Growth, Differentiation, and Stemness. **2014**, 1-41

360 Clinical Implications of Epigenetic Alterations in Lung Cancer. **2014**, 257-282

359 Supervised Normalization of Large-Scale Omic Datasets Using Blind Source Separation. **2014**, 465-497

358 Pathology, Biomarkers, and Molecular Diagnostics. **2014**, 226-252.e6

357 Genetic and Epigenetic Alterations in Cancer. **2014**, 188-203

356 Encyclopedia of Cancer. **2014**, 420-424

355 MicroRNAs in Development and Progression of Breast Cancer. **2014**, 117-137

354 Encyclopedia of Cancer. **2014**, 1-5

353 Gene Expression in HNC. **2014**, 325-341

1

352 Epigenomics of Breast Cancer. **2014**, 105-126

351 Inflammation. **2014**, 15-99

350 FRET-Based Quantitative Discrimination of Bisulfite-Untreated DNA from Bisulfite-Treated DNA. **2014**, 35, 1455-1459

349 Drugs Affecting Epigenetic Modifications of ABC Transporters for Drug Resistance. **2015**, 273-297

- 348 Methylation in AML: Clinical Applications. **2015**, 441-458
- 347 The Generation, Detection, and Prevention of Genomic Instability During Cancer Progression and Metastasis. **2015**, 15-38
- 346 Early Biomarkers in Breast Cancer. **2015**, 61-142
- 345 Malignant Rhabdoid Tumor: Epigenetic Mechanism of Tumorigenesis. **2015**, 457-478
- 344 Genetic and Epigenetic Alterations in Urothelial Carcinoma. **2015**, 253-259
- 343 Encyclopedia of Cancer. **2015**, 1-4
- 342 Targeted Therapies for Gastric Cancer. **2015**, 103-126
- 341 CHAPTER 10:Dosing [When Less is More. **2015**, 249-266
- 340 Aberrant DNA Methylation of CDH1, p16 and DAPK in Childhood Acute Lymphoblastic Leukemia. **2015**, 22, 60-66
- 339 The Inhibition of the Mammalian DNA Methyltransferase 3a (Dnmt3a) by Dietary Black Tea and Coffee Polyphenols. **2015**, 213-231
- 338 Molecular genetic approaches in the diagnosis of lung cancer. **2015**, 6, 85-94
- 337 The Evolution of Explanatory Models of Cancer. **2016**, 17-41
- 336 Therapeutic Epigenetics- A Boon to the Future. **2016**, 5, 27-30
- 335 Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi Targeted Epigenetic Therapy (MTET). **2016**, 07, 254-269 1
- 334 Compendium of Inflammatory Diseases. **2016**, 253-259
- 333 Genetics and Epigenetics of Head and Neck Cancer. **2016**, 115-132
- 332 Dysregulated Signaling Pathways in Glioblastoma Cancer Stem-Like Cells: Potential Targets for Therapeutic Intervention. **2016**, 3,
- 331 Integrative modeling of tumor DNA methylation identifies a role for metabolism.

330 Encyclopedia of Signaling Molecules. **2017**, 1-23

329 The Role of Epigenetics. **2017**, 75-107

328 Molecular Pathology and Novel Therapy for Uterine Sarcomas. **2017**, 137-150

327 p53 binding sites in normal and cancer cells are characterized by distinct chromatin context.

326 Bisphenol A and Nongenotoxic Drivers of Cancer. 415-438

1

325 Encyclopedia of Signaling Molecules. **2018**, 4501-4523

324 DNA Methylation Research - My Experience in Johns Hopkins University -. **2018**, 64, 2-10

323 Multi-target analysis of neoplasms for the evaluation of tumor progression: stochastic approach of biologic processes. **2018**, 5, 14-62

322 Epigenetic modifications and gene expression in cancerogenesis. **2018**, 72, 80-89

2

321 Distinct oncogenes drive distinct genome and epigenome alterations in human mammary epithelial cells.

320 EBADIMEX: An empirical Bayes approach to detect joint differential expression and methylation and to classify samples.

319 Fast Detection of Differential Chromatin Domains with SCIDDO.

318 CpG Islands Methylation Alterations in Cancer: Functionally Intriguing Security Locks, Useful Early Tumor Biomarkers. **2019**, 53-62

317 The epigenome in pediatric acute lymphoblastic leukemia: drug resistance and therapeutic opportunities.. **2019**, 2, 313-325

1

316 LncRNA Dnmt3aos regulates Dnmt3a expression leading to aberrant DNA methylation in macrophage polarization.

315 Decreased expression of the Keap1 gene and its clinicopathological significance in gastric cancer: correlation with promoter DNA methylation. **2019**, 178,

2

314 Identification and Characterization of the First Fragment Hits for SETDB1 Tudor Domain.

313 Physical and data structure of 3D genome.

0

- 312 Detection and Analysis of RNAs Expression Profile for Methylated Candidate Tumor Suppressor Genes in Nasopharyngeal Carcinoma. **2019**, 19, 772-782 ○
- 311 Identification of Potential Biomarkers of Chronic Kidney Disease in Individuals with Diabetes: Protocol for a Cross-sectional Observational Study (Preprint).
- 310 The Relationship Between Promoter Methylation of RASSF1A Gene and Prognosis of Patients Affected with Breast Cancer in Khuzestan Province. **2019**, 7,
- 309 Dissection of demethylation and toxicity induced gene expression changes after decitabine treatment. ○
- 308 Dietary Phytochemicals as Epigenetic Modulators in Cancer Prevention: Emerging Research Trends, Gaps, and Future Perspectives. **2020**, 121-142
- 307 Rhythmic Epigenetics in Neuroendocrine and Immune Systems. **2020**, 295-314
- 306 Epigenetic Biomarkers for the Detection of Gastrointestinal Cancers. **2020**, 59-82
- 305 Requirement of DNMT1 to orchestrate epigenomic reprogramming during NPM-ALK driven T cell lymphomagenesis.
- 304 A pan-cancer analysis of CpG Island gene regulation reveals extensive plasticity within Polycomb targets.
- 303 Unified Analysis of Multiple ChIP-Seq Datasets. **2021**, 2198, 451-465 ○
- 302 Distinct DNA Methylation Patterns of Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex. **2021**, 1
- 301 TH Treatment in Patients with Cardiac Disorders: General Aspects and Rationale. **2020**, 373-380
- 300 Multi-Omics Characterization of Inflammatory Bowel Disease-Induced Hyperplasia/Dysplasia in the / Mouse Model. **2020**, 22, 1
- 299 Natural molecules as modulators of epigenetic silencing in human cells for cancer care and aging. **2020**, 65,
- 298 Epigenetic study of global gene methylation in PON1, XRCC1 and GSTs different genotypes in rural and urban pesticide exposed workers. **2020**, ○
- 297 Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK-driven lymphomagenesis. **2021**, 4, ○
- 296 Effect of Shengmai Yin on the DNA methylation status of nasopharyngeal carcinoma cell and its radioresistant strains.. **2021**, 11, 783-790 1
- 295 Epigenetics, Nutrition, Disease and Drug Development. **2019**, 16, 386-391 1

294	CHAPTER 9:Pharmacological Regulation and Functional Significance of Chromatin Binding by BET Tandem Bromodomains. 2020 , 209-248	
293	(H)stemonamine Can Enhance the Anti-Proliferative Activity of Trichostatin A Against Human Breast Cancer MDA-MB-231 Cells. 2020 , 3, 56-59	
292	Hypomethylating Agents Use in Acute Myeloid Leukemia: A Single-Center Experience. 2020 , 41, 202-208	
291	Circulating tumor DNA as specific biomarkers for early diagnosis and prognosis of pancreatic cancer. 2019 , 11, 11-17	
290	Discovery of potential epigenetic inhibitors against histone methyltransferases through molecular docking and molecular dynamics simulations.	
289	An update on genotoxic and epigenetic studies of fumonisin B1. 1-16	1
288	Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin. 2021 ,	1
287	Context Matters-Why We Need to Change From a One Size Fits all Approach to Made-to-Measure Therapies for Individual Patients With Pancreatic Cancer. 2021 , 9, 760705	1
286	Chaga and its bioactive complexes: history and perspectives. 2020 , 2, 84-93	1
285	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas.	
284	Breast Cancer Patients: Diagnostic Epigenetic Markers in Blood. 2008 , 125-140	
283	Fast detection of differential chromatin domains with SCIDDO. 2021 , 37, 1198-1205	1
282	DNA methylation-based age estimation in pediatric healthy tissues and brain tumors. 2020 , 12, 21037-21056	6
281	Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives. 2020 , 20, 2190-2206	1
280	Epigenetics and epigenetic alterations in pancreatic cancer. 2009 , 2, 310-26	51
279	Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. 2010 , 16, 828-42	21
278	DNA methylation-dependent regulation of BORIS/CTCF expression in ovarian cancer. 2007 , 7, 21	75
277	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. 2009 , 27,	4

276	Genetic and epigenetic alterations during renal carcinogenesis. 2010 , 4, 58-73	45
275	UHRF1 Links the Histone code and DNA Methylation to ensure Faithful Epigenetic Memory Inheritance. 2010 , 2009, 29-36	27
274	Next-generation sequencing for cancer diagnostics: a practical perspective. 2011 , 32, 177-95	246
273	The role of gene expression profiling in early-stage non-small cell lung cancer. 2010 , 2, 89-99	27
272	MicroRNAs in cancer treatment and prognosis. 2012 , 2, 414-33	43
271	Molecular characteristics of cancer stem-like cells derived from human breast cancer cells. 2013 , 33, 763-77	6
270	Linking DNA methylation to the onset of human tubal ectopic pregnancy. 2013 , 5, 116-25	4
269	A novel in vitro model for cancer stem cell culture using ectopically expressed piwil2 stable cell line. 2013 , 15, 250-7	15
268	SET domain-containing Protein 4 (SETD4) is a Newly Identified Cytosolic and Nuclear Lysine Methyltransferase involved in Breast Cancer Cell Proliferation. 2013 , 5, 58-65	17
267	Histone-modifying genes as biomarkers in hepatocellular carcinoma. 2014 , 7, 2496-507	30
266	Methylation status of promoter 1 region of GDNF gene in human glioma cells. 2014 , 7, 1735-40	4
265	The Study of DNA Methylation of bax Gene Promoter in Breast and Colorectal Carcinoma Cell Lines. 2013 , 6, 59-64	8
264	Epigenetic silencing of dual oxidase 1 by promoter hypermethylation in human hepatocellular carcinoma. 2014 , 4, 508-17	22
263	RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence. 2014 , 4, 725-37	10
262	Expression profiling and clinicopathological significance of DNA methyltransferase 1, 3A and 3B in sporadic human renal cell carcinoma. 2014 , 7, 7597-609	6
261	Methylation of sodium iodide symporter promoter correlated with aggressiveness and metastasis in papillary thyroid carcinoma: a meta-analysis. 2015 , 8, 10731-8	1
260	MTRR silencing inhibits growth and cisplatin resistance of ovarian carcinoma via inducing apoptosis and reducing autophagy. 2015 , 7, 1510-27	13
259	DISCOVERY OF MOLECULARLY TARGETED THERAPIES. 2016 , 21, 1-8	

258	CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. 2016 , 127, 313-327	1
257	DNMT3B modulates the expression of cancer-related genes and downregulates the expression of the gene VAV3 via methylation. 2017 , 7, 77-87	8
256	Controlling Epithelial to Mesenchymal Transition through Acetylation of Histone H2BK5. 2017 , 3,	2
255	Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in bladder cancer. 2017 , 10, 11326-11334	
254	Frequent CpG island methylation: a risk factor in the progression of traditional serrated adenoma of the colorectum. 2017 , 10, 9666-9674	
253	Association between HIC1 promoter methylation and solid tumor: A meta-analysis. 2020 , 19, 476-489	1
252	[Modification of DNA methylation in leukemia development]. 2016 , 37, 1003-1007	
251	[A Review of Epigenetic Modifications Regulate MicroRNA Expression in Lung Cancer]. 2020 , 23, 582-588	
250	HDAC inhibitors in cancer care. 2010 , 24, 180-5	22
249	Epigenetic Instability Caused by Oxidative Stress Triggers Tumorigenesis. 2021 , 1-18	
248	Epigenetics and precision medicine in bone and soft tissue sarcomas. 2022 , 147-191	
247	Misregulation of the expression and activity of DNA methyltransferases in cancer. 2021 , 3, zcab045	2
246	Epigenetic Mechanisms and Therapeutic Targets in Chemoresistant High-Grade Serous Ovarian Cancer. 2021 , 13,	2
245	Comparative Analysis of COL9A1 Genotyping in Oral Squamous Cell Carcinoma Diagnosis: A Pilot Study. 2021 , 11, 11102	0
244	A Portrait of Intratumoral Genomic and Transcriptomic Heterogeneity at Single-Cell Level in Colorectal Cancer. 2021 , 57,	
243	Epigenetic Modifications and Therapy in Uveitis. 2021 , 9, 758240	0
242	The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review. 2021 , 13,	6
241	Head and Neck Cancers Are Not Alike When Tarded with the Same Brush: An Epigenetic Perspective from the Cancerization Field to Prognosis. 2021 , 13,	1

240	At the dawn: cell-free DNA fragmentomics and gene regulation. 2021 ,	2
239	Integrative Bioinformatics approaches to therapeutic gene target selection in various cancers for Nitroglycerin. 2021 , 11, 22036	1
238	Myelodysplastic Syndromes and Modalities of Treatment: An Updated Literature Review. 2021 , 13, e20116	
237	Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. 2021 , 101030	3
236	Epigenetics of Immunoglobulin G Glycosylation. 2021 , 112, 289-301	0
235	Prognostic significance of ferroptosis-related genes and their methylation in AML. 2021 , 26, 919-930	4
234	RAP1GAP Functions as a Tumor Suppressor Gene and Is Regulated by DNA Methylation in Differentiated Thyroid Cancer. 2021 , 161, 227-235	2
233	The Yin and Yang of epigenetics in the field of nanoparticles.	1
232	Curcumin encapsulation in functional PLGA nanoparticles: A promising strategy for cancer therapies.. 2021 , 300, 102582	4
231	Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge.. 2021 , 146, 112123	1
230	Analytical and Omics Approaches in the Identification of Oxidative Stress-Induced Cancer Biomarkers. 2021 , 1-24	
229	Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity.. 2022 , 8, eabl5220	0
228	A proposed Information-Based modality for the treatment of cancer.. 2021 , 211, 104587	0
227	Epigenetic Therapies and Biomarkers in Breast Cancer.. 2022 , 14,	3
226	Analytical and Omics Approaches in the Identification of Oxidative Stress-Induced Cancer Biomarkers. 2022 , 2493-2516	
225	Identification of Prognostic Biomarkers for Bladder Cancer Based on DNA Methylation Profile.. 2021 , 9, 817086	1
224	Investigation of promoter methylation patterns association with genes expression profile of ISL1, MGMT and DMNT3b in tissue of breast cancer patients.. 2022 , 49, 847	1
223	The association of long non-coding RNA in the prognosis of oral squamous cell carcinoma.. 2022 , 44, 327	1

222	Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.. 2022,	0
221	Cancer epigenetics: Chromatin remodeling and other epigenetic mechanisms. 2022, 149-158	1
220	Epigenetic alterations induced by genotoxic occupational and environmental human chemical carcinogens: An update of a systematic literature review. 2022, 789, 108408	2
219	Cancer epigenetics: DNA methylation and histone modifications. 2022, 133-148	
218	Neurofibromin and suppression of tumorigenesis: beyond the GAP.. 2022,	0
217	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.. 2022, 13, 809761	5
216	Epigenetic Instability Caused by Oxidative Stress Triggers Tumorigenesis. 2022, 1639-1655	
215	Analysis of 5-Methylcytosine Regulators and DNA Methylation-Driven Genes in Colon Cancer.. 2021, 9, 657092	0
214	DNA methylation across the tree of life, from micro to macro-organism.. 2022, 13, 1666-1685	0
213	Physiological and Epigenetic Reaction of Barley (L.) to the Foliar Application of Silicon under Soil Salinity Conditions.. 2022, 23,	0
212	Systems Medicine Applied to Epidemiology. 2022, 181-187	
211	Epigenetic dysregulation from chromosomal transit in micronuclei.	0
210	A Slight of the Diagnostic Value of Aberrant Cell-Free DNA Methylation in Lung Cancer.. 2022, 2022, 9619357	
209	Discovered Key CpG Sites by Analyzing DNA Methylation and Gene Expression in Breast Cancer Samples.. 2022, 10, 815843	0
208	Aberrant epigenetic and transcriptional events associated with breast cancer risk.. 2022, 14, 21	1
207	Vitamin C promotes anti-leukemia of DZNep in acute myeloid leukemia.. 2022, 1868, 166357	0
206	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.. 2021, 11, 792385	0
205	Epigenetics with special reference to the human X chromosome inactivation and the enigma of DNA methylation. 2018, 97, 371-378	4

204	A review of computational algorithms for CpG islands detection. 2019 , 44,	1
203	[Progress on epigenetic regulation of iron homeostasis]. 2020 , 49, 58-70	2
202	Radiation-Induced Epigenetic Changes And Their Modulation By Epidrugs. 2022 , 1-16	
201	Epigenetic mechanisms in paediatric brain tumours: regulators lose control.. 2022 ,	0
200	Editorial: Epigenetic and Transcriptional Dysregulations in Cancer and Therapeutic Opportunities.. 2022 , 13, 857380	
199	Biotechnological Innovations from Ocean: Transpiring Role of Marine Drugs in Management of Chronic Disorders.. 2022 , 27,	1
198	The Role of Mesenchymal Stem Cells in the Induction of Cancer-Stem Cell Phenotype.. 2022 , 12, 817971	2
197	A Self-attention Graph Convolutional Network for Precision Multi-tumour Early Diagnostics with DNA Methylation Data.	
196	Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia.. 2022 ,	1
195	Multi-omic characterization of genome-wide abnormal DNA methylation reveals diagnostic and prognostic markers for esophageal squamous-cell carcinoma.. 2022 , 7, 53	1
194	Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer. 2022 , 1-12	2
193	Gene Promoter-Methylation Signature as Biomarker to Predict Cisplatin-Radiotherapy Sensitivity in Locally Advanced Cervical Cancer.. 2022 , 12, 773438	0
192	CTBP1 ve NF2 Gen Ekspresyonları Prostat Kanseri Hastalarında KDM6A/B Aracılığıyla Epigenetik Regülasyonunun İncelenmesi. 220-228	
191	Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma.. 2022 ,	
190	Short-Term Hypothermic Holding of Mouse Immature Testicular Tissue Does Not Alter the Expression of DNA Methyltransferases and Global DNA Methylation Level, Post-Organotypic Culture.. 2022 , 13, 854297	
189	Evodiamine-Inspired Topoisomerase-Histone Deacetylase Dual Inhibitors: Novel Orally Active Antitumor Agents for Leukemia Therapy.. 2022 ,	4
188	Integrating whole genome sequencing, methylation, gene expression, topological associated domain information in regulatory mutation prediction: A study of follicular lymphoma.. 2022 , 20, 1726-1742	
187	Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma.. 2022 , 10, 840759	2

186	CRMP4 CpG Hypermethylation Predicts Upgrading to Gleason Score ≥ 8 in Prostate Cancer.. 2022 , 12, 840950	0
185	Novel tryptanthrin hybrids bearing aminothiazoles as potential EGFR inhibitors: Design, synthesis, biological screening, molecular docking studies, and ADME /T predictions.	1
184	Downregulation of MiR-1538 promotes proliferation and metastasis of colorectal cancer by targeting DNMT3A.. 2022 , 609, 119-126	0
183	Promoter methylation-regulated miR-148a-3p inhibits lung adenocarcinoma (LUAD) progression by targeting MAP3K9.. 2022 ,	0
182	Methylation classifiers: brain tumors, sarcomas and what's next.. 2022 ,	0
181	Design, synthesis, and biological evaluation of β -carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.. 2022 , 128663	2
180	Immunomodulatory effect of mushrooms and their bioactive compounds in cancer: A comprehensive review. 2022 , 149, 112901	3
179	Nuclear receptors in oral cancer-emerging players in tumorigenesis.. 2022 , 215666	2
178	The Impact of EGCG and RG108 on SOCS1 Promoter DNA Methylation and Expression in U937 Leukemia Cells.. 2021 , 10, 455-461	0
177	Manipulating Histone Acetylation Leads to Adverse Effects in Hemangiosarcoma Cells.	
176	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.. 2021 , 20, 171	6
175	Recent Discoveries in Epigenetic Modifications of Polycystic Kidney Disease.. 2021 , 22,	0
174	Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells.. 2022 , 60, 100-117	4
173	Cigarette smoke-promoted increases in osteopontin expression attract mesenchymal stem cell recruitment and facilitate lung cancer metastasis. 2021 ,	
172	INTS8 is a therapeutic target for intrahepatic cholangiocarcinoma via the integration of bioinformatics analysis and experimental validation. 2021 , 11, 23649	
171	KDM6 Demethylases and Their Roles in Human Cancers.. 2021 , 11, 779918	3
170	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy.. 2021 , 13,	1
169	Predicting the possible effect of miR-203a-3p and miR-29a-3p on and genes expression.. 2021 ,	3

- 168 Emerging Role of Autophagy in the Development and Progression of Oral Squamous Cell Carcinoma.. **2021**, 13, 0
- 167 Discovery of Novel Small Molecule HDAC1, 2, 3 Inhibitors -- Combined Receptor-Based and Ligand-Based Virtual Screening Strategy. **2021**, 19,
- 166 The Human Epigenome. **2022**, 3-25
- 165 Genome-wide methylation profiling of early colorectal cancer using an Illumina Infinium Methylation EPIC BeadChip.. **2022**, 14, 935-946 0
- 164 Thorough statistical analyses of breast cancer co-methylation patterns.. **2022**, 23, 29 0
- 163 Pioneer transcription factors are associated with the modulation of DNA methylation patterns across cancers.. **2022**, 15, 13 0
- 162 Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates.. **2022**, 27, 3
- 161 Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis.. **2022**, 79, 104001 2
- 160 Epigenomic code. 113-133
- 159 CHAPTER 3. Nickel Toxicity and Carcinogenesis. 27-42
- 158 DataSheet_1.pdf. **2019**,
- 157 Data_Sheet_1.PDF. **2019**,
- 156 DataSheet_1.pdf. **2020**,
- 155 Table_1.docx. **2020**,
- 154 Table_2.docx. **2020**,
- 153 Table_3.docx. **2020**,
- 152 Table_4.docx. **2020**,
- 151 Table_5.docx. **2020**,

150 Table_6.docx. **2020**,

149 Table_7.xls. **2020**,

148 Table_8.docx. **2020**,

147 Epigenetic biomarkers in diagnosis, prognosis, and treatment of hepatocellular carcinoma. **2022**, 415-433

146 Triple-negative breast cancer - an aggressive subtype of breast cancer. **2022**, 1-28

145 Aberrant DNA Methylation of Tumor Suppressor Genes and Oncogenes as Cancer Biomarkers. **2022**, 251-271

1

144 Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth.. **2022**, 39, 86

1

143 Insulin-like growth factor 2 hypermethylation in peripheral blood leukocytes and colorectal cancer risk and prognosis: a propensity score analysis of multiple-centre populations.

142 FGFR2-BRD4 Axis Regulates Transcriptional Networks of Histone 3 Modification and Synergy Between Its Inhibitors and PD-1/PD-L1 in a TNBC Mouse Model.. **2022**, 13, 861221

141 Obesity-Associated Differentially Methylated Regions in Colon Cancer. **2022**, 12, 660

140 Rare and misincorporated DNA N-methyladenine is a hallmark of cytotoxic stresses for selectively stimulating the stemness and proliferation of glioblastoma cells.. **2022**, 8, 39

1

139 Origin Links Between Humans and Infectious Disease Agents. **2022**, 1-28

138 Induction of BRAFV600E Mutation in Thyroid Cells Leads to Frequent Hypermethylation.. **2022**,

1

137 Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer. **2022**, 13,

0

136 Methylated Septin9 has moderate diagnostic value in colorectal cancer detection in Chinese population: a multicenter study.. **2022**, 22, 232

0

135 Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.. **2022**, 237, 114407

0

134 PRKCB is relevant to prognosis of lung adenocarcinoma through methylation and immune infiltration.. **2022**,

133 Radiation-Induced Epigenetic Changes And Their Modulation By Epidrugs. **2022**, 1-16

- 132 Genome-wide promoter methylation profiling in a cellular model of melanoma progression reveals markers of malignancy and metastasis that predict melanoma survival. **2022**, 14, 0
- 131 Stroke and Etiopathogenesis: What Is Known?. **2022**, 13, 978 1
- 130 Epigenetics Regulates Antitumor Immunity in Melanoma. **2022**, 13, 1
- 129 Epigenetic Regulation in Cancer and Cancer Therapies. 0
- 128 Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk. 0
- 127 Investigating DNA methylation as a mediator of genetic risk in childhood acute lymphoblastic Leukemia. 0
- 126 Design, synthesis, and biological evaluation of novel carbazole derivatives as potent DNMT1 inhibitors with reasonable PK properties. **2022**, 37, 1537-1555 1
- 125 Computational epigenetic landscape analysis reveals association of CACNA1G-AS1, F11-AS1, NNT-AS1, and MSC-AS1 lncRNAs in prostate cancer progression through aberrant methylation. **2022**, 12, 0
- 124 Identifying the Potential Roles of PBX4 in Human Cancers Based on Integrative Analysis. **2022**, 12, 822 0
- 123 Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling. 12, 0
- 122 Obesity, the other pandemic: linking diet and carcinogenesis by epigenetic mechanisms. **2022**, 109092 0
- 121 Metabolic pathway-based molecular subtyping of colon cancer reveals clinical immunotherapy potential and prognosis. 0
- 120 A fully-convolutional residual encoder-decoder neural network to localize breast cancer on histopathology images. **2022**, 147, 105698 0
- 119 Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. **2022**, 239, 114542 4
- 118 New trend in genotoxicity research taking into account genome instability. **2022**, 157, 265-270 0
- 117 Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. 13, 0
- 116 The roles of DNA methylation on the promotor of the EpsteinBarr virus (EBV) gene and the genome in patients with EBV-associated diseases. **2022**, 106, 4413-4426 1
- 115 Structural, molecular, and functional insights into Schlafen proteins. **2022**, 54, 730-738 1

- 114 High expression of N-type calcium channel indicates a favorable prognosis in gliomas. **2022**, 101, e29782
- 113 Chromatin Methylation Abnormalities in Autosomal Dominant Polycystic Kidney Disease. **9**,
- 112 YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. **0**
- 111 Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. **2022**, 23, **1**
- 110 Epigenomics as Potential Tools for Enhancing Magnitude of Breeding Approaches for Developing Climate Resilient Chickpea. **13**, **0**
- 109 Epigenetics of Breast Cancer. **2022**, 139-170
- 108 Identification of prognostic biomarkers for suppressing tumorigenesis and metastasis of Hepatocellular carcinoma through transcriptome analysis.
- 107 Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options. **2022**, 237, 108253 **3**
- 106 Epigenomic interplay in tumor heterogeneity: Potential of epidrugs as adjunct therapy. **2022**, 157, 155967
- 105 Cancer Tumor Detection Using Genetic Mutated Data and Machine Learning Models. **2022**,
- 104 Tumor-Promoting ATAD2 and Its Preclinical Challenges. **2022**, 12, 1040 **0**
- 103 Diagnosis Biomarkers of Cholangiocarcinoma in Human Bile: An Evidence-Based Study. **2022**, 14, 3921
- 102 Identification of the Prognostic Signatures for Isocitrate Dehydrogenase Mutant Glioma. **2022**,
- 101 A Review of Medicinal Plants of the Himalayas with Anti-Proliferative Activity for the Treatment of Various Cancers. **2022**, 14, 3898 **3**
- 100 The Omnipresence of DYRK1A in Human Diseases. **2022**, 23, 9355 **1**
- 99 Differentiation-related epigenomic changes define clinically distinct keratinocyte cancer subclasses. **2022**, 18, **0**
- 98 Role of DNA De-methylation intermediate 5-hydroxymethylcytosine in ovarian cancer management: A comprehensive review. **2022**, 155, 113674 **0**
- 97 Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. **2022**, 179, 103796 **0**

96	Epigenetic therapy and DNA damage response. 2022 , 227-252	0
95	The Interface of Cancer, Their Microenvironment and Nanotechnology. 2022 , 24, 371-411	0
94	Metal oxide-based composites for magnetic hyperthermia applications. 2022 , 673-695	0
93	Epigenetic Events in Lung Cancer. 2022 ,	0
92	Radiation-Induced Epigenetic Changes and Their Modulation by Epidrugs. 2022 , 1665-1680	0
91	Recent Advance of Histone Modification in Gastric Cancer : A Review. 562-569	0
90	The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. 2022 , 13, 1555	1
89	Prognosis and Clinical features Analysis of EMT-related Signature and Tumor Immune Microenvironment in Glioma.	0
88	Biomarkers in Urological Cancers. 2022 , 37-76	0
87	Identification of key somatic oncogenic mutation based on a confounder-free causal inference model. 2022 , 18, e1010529	0
86	Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. 2022 , 166561	0
85	Food-Borne Chemical Carcinogens and the Evidence for Human Cancer Risk. 2022 , 11, 2828	4
84	In vitro anti-gastrointestinal cancer activity of Toxocara canis-derived peptide: Analyzing the expression level of factors related to cell proliferation and tumor growth. 13,	0
83	Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.	1
82	Mechanisms Controlling MicroRNA Expression in Tumor. 2022 , 11, 2852	0
81	Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. 12,	0
80	Copper-olsalazine metal-organic frameworks as a nanocatalyst and epigenetic modulator for efficient inhibition of colorectal cancer growth and metastasis. 2022 ,	1
79	Poor prognosis, hypomethylation, and immune infiltrates are associated with downregulation of INMT in head and neck squamous cell carcinoma. 13,	0

78	Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells.	o
77	Statistical inference of the rates of cell proliferation and phenotypic switching in cancer.	o
76	Celastrol inhibits lung cancer growth by triggering histone acetylation and acting synergically with HDAC inhibitors. 2022 , 106487	o
75	Robustness and Delay Margin Analysis of a Gene Regulatory Network Model. 2022 , 55, 253-258	o
74	Susceptibility of TNFAIP8, TNFAIP8L1, and TNFAIP2 Gene Polymorphisms on Cancer Risk: A Comprehensive Review and Meta-Analysis of Case-Control Studies. 2022 , 21, 153303382211231	o
73	OMICS Approaches Evaluating Keloid and Hypertrophic Scars. 2022 , 2022, 1-15	o
72	A novel prognostic model based on six methylation-driven genes predicts overall survival for patients with clear cell renal cell carcinoma. 13,	o
71	DNA methylation at birth in monozygotic twins discordant for pediatric acute lymphoblastic leukemia. 2022 , 13,	1
70	Long noncoding RNA uc.230/CUG-binding protein 1 axis sustains intestinal epithelial homeostasis and response to tissue injury. 2022 , 7,	o
69	Epigenetic Contributions to Human Cancer. 1-13	o
68	Small molecule inhibitors targeting the cancers. 2022 , 3,	o
67	A technical note on emerging combination approach involved in the onconanotherapeutics. 2022 , 29, 3197-3212	o
66	PBRM1, SETD2 and BAP1 [The trinity of 3p in clear cell renal cell carcinoma.	o
65	Construction and analysis of sample-specific driver modules for breast cancer. 2022 , 23,	o
64	DNA methylation topology differentiates between normal and malignant in cell models, resected human tissues, and exfoliated sputum cells of lung epithelium. 12,	o
63	Development of epigenetic biomarkers for the identification of sex and thermal stress in fish using DNA methylation analysis and machine learning procedures.	o
62	FOXK2 transcription factor and its roles in tumorigenesis (Review). 2022 , 24,	o
61	The Role of DNA Methylation and DNA Methyltransferases in Cancer. 2022 , 317-348	1

- 60 Nanoscale calcium oxide and its biomedical applications: A comprehensive review. **2022**, 102506 ○
- 59 Epigenetic alterations fuel brain metastasis via regulating inflammatory cascade. **2022**, ○
- 58 Chromatin Remodeling ATPases CHR12 and CHR23 Affect Apical Meristem Development and Play an Important Role during Response to Drought Stress in Arabidopsis. **2022**, 69, ○
- 57 SPOP in Cancer: Phenomena, Mechanisms and Its Role in Therapeutic Implications. **2022**, 13, 2051 ○
- 56 Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer. **2022**, 87, 48-83 1
- 55 Molecular perspectives in hypertrophic heart disease: An epigenetic approach from chromatin modification. 10, ○
- 54 DNA Methylation Analysis Reveals Distinct Patterns in Satellite Cell-Derived Myogenic Progenitor Cells of Subjects with Spastic Cerebral Palsy. **2022**, 12, 1978 ○
- 53 Gene body methylation in cancer: molecular mechanisms and clinical applications. **2022**, 14, ○
- 52 Small molecule-induced epigenomic reprogramming of APL blasts leading to antiviral-like response and c-MYC downregulation. ○
- 51 Biomarkers for the Detection and Risk Stratification of Aggressive Prostate Cancer. **2022**, 14, 6094 ○
- 50 De Novo Design of AC-P19M, a Novel Anticancer Peptide with Apoptotic Effects on Lung Cancer Cells and Anti-Angiogenic Activity. **2022**, 23, 15594 1
- 49 Epigenetics and Gut Microbiota Crosstalk: A potential Factor in Pathogenesis of Cardiovascular Disorders. **2022**, 9, 798 ○
- 48 Challenges and opportunities for omics-based precision medicine in chronic low back pain. ○
- 47 The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer. **2022**, 28, 3563-3571 ○
- 46 Differential adenine methylation analysis reveals increased variability in 6mA in the absence of methyl-directed mismatch repair. ○
- 45 Crosstalk between epigenetics and tumor promoting androgen signaling in prostate cancer. **2022**, ○
- 44 RNA-to-image multi-cancer synthesis using cascaded diffusion models. ○
- 43 CuAAC ensembled 1,2,3-triazole linked nanogels for targeted drug delivery: a review. **2023**, 13, 2912-2936 ○

- 42 Role of epigenetics in pancreatic ductal adenocarcinoma. ○
- 41 Epigenetic adaptations in drug-tolerant tumor cells. **2023**, ○
- 40 Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis. **2023**, 24, 486 ○
- 39 Cancer and Inflammation. **2015**, 1-7 ○
- 38 Nursing Informatics and Epigenetics: Methodological Considerations for Big Data Analysis. Publish Ahead of Print, ○
- 37 Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. **2023**, 201-235 ○
- 36 MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. ○
- 35 Epigenetics of radiation-induced GI damage: Role of protein modifications. **2023**, 545-563 ○
- 34 Tumour DNA Sequencing. **2023**, 81-99 ○
- 33 Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses. ○
- 32 Current perspective of transcriptional regulators in human health and diseases. **2023**, 3-16 ○
- 31 A review and comparative study of cancer detection using machine learning: SBERT and SimCSE application. **2023**, 24, ○
- 30 Nano-Strategies for Lignin Biomaterials toward Cancer Therapy. ○
- 29 EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates. **2023**, 24, ○
- 28 PROTACs in Epigenetic Cancer Therapy: Current Status and Future Opportunities. **2023**, 28, 1217 ○
- 27 Comparative Study on the Sensing Kinetics of Carbon and Nitrogen Nutrients in Cancer Tissues and Normal Tissues Based Electrochemical Biosensors. **2023**, 28, 1453 ○
- 26 Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. **2023**, 11, 448 ○
- 25 Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. **2023**, 8, ○

- 24 The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?. **2023**, 20, 3640 ○
- 23 Consequences of Glucose Enriched Diet on Oncologic Patients. **2023**, 13, 2757 ○
- 22 Epigenetics in cancer development, diagnosis and therapy. **2023**, ○
- 21 Early-onset colorectal cancer: A review of current knowledge. 29, 1289-1303 ○
- 20 Epigenetic Abnormalities in Chondrosarcoma. **2023**, 24, 4539 ○
- 19 Epigenetics and stroke: role of DNA methylation and effect of aging on bloodBrain barrier recovery. **2023**, 20, ○
- 18 Prognosis Prediction of Lung Adenocarcinoma Patients Based on Molecular Subgroups of DNA Methylation. **2023**, 31, 255-265 ○
- 17 Role of Defensins in Tumor Biology. **2023**, 24, 5268 ○
- 16 A proficient two stage model for identification of promising gene subset and accurate cancer classification. **2023**, 15, 1555-1568 ○
- 15 In silico investigation of a novel anti EGFR Scfv IL 24 fusion protein induces apoptosis in malignant cells. ○
- 14 H4-methylation regulators mediated epitranscriptome patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma. **2023**, 15, ○
- 13 MetaHMEI: meta-learning for prediction of few-shot histone modifying enzyme inhibitors. ○
- 12 Postbiotics Implication in the Microbiota-Host Intestinal Epithelial Cells Mutualism. ○
- 11 Pan-cancer analysis identifies tumor-specific antigens derived from transposable elements. **2023**, 55, 631-639 ○
- 10 The Epigenesis of Salivary Glands Carcinoma: From Field Cancerization to Carcinogenesis. **2023**, 15, 2111 ○
- 9 Pyrazole derivatives of pyridine and naphthyridine as proapoptotic agents in cervical and breast cancer cells. **2023**, 13, ○
- 8 Methylglyoxal: a novel upstream regulator of DNA methylation. **2023**, 42, ○
- 7 Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid. **2023**, 26, 106597 ○

- 6 DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. **2023**, 13, ○
- 5 Thallium-induced DNA damage, genetic, and epigenetic alterations. 14, ○
- 4 Statistical inference of the rates of cell proliferation and phenotypic switching in cancer. **2023**, 111497 ○
- 3 Systems biology tools for the identification of potential drug targets and biological markers effective for cancer therapeutics. **2023**, 259-292 ○
- 2 Zinc Finger Protein 479 Promotes Metastasis and Epithelial-Mesenchymal Transition in Gastric Cancer via MEK/ERK/DNMT1 Signaling Pathway. **2023**, 19, 36-44 ○
- 1 Epigenomic profiling at genome scale: from assays and analysis to clinical insights. **2023**, 143-174 ○